{
    "LDA_Topics": [
        [
            0,
            "0.017*\"patient\" + 0.014*\"nsclc\" + 0.012*\"cancer\" + 0.011*\"trial\" + 0.010*\"phase\""
        ],
        [
            1,
            "0.001*\"patient\" + 0.001*\"nsclc\" + 0.001*\"cancer\" + 0.001*\"trial\" + 0.001*\"j\""
        ]
    ],
    "PDF_Summary": "",
    "NER_Tags": "(S\n  Critical/JJ\n  Reviews/NNP\n  in/IN\n  Oncology/Hematology/NNP\n  82/CD\n  (/(\n  2012/CD\n  )/)\n  200\u2013212/CD\n  Challenges/NNPS\n  in/IN\n  the/DT\n  current/JJ\n  antiangiogenic/JJ\n  treatment/NN\n  paradigm/NN\n  for/IN\n  patients/NNS\n  with/IN\n  non-small/JJ\n  cell/NN\n  lung/NN\n  cancer/NN\n  (PERSON Antoinette/NNP Wozniak\u2217/NNP Department/NNP)\n  of/IN\n  Hematology-Oncology/NNP\n  ,/,\n  (PERSON Wayne/NNP State/NNP University/NNP)\n  ,/,\n  (PERSON Karmanos/NNP Cancer/NNP Institute/NNP)\n  ,/,\n  4100/CD\n  (PERSON John/NNP R/NNP)\n  ,/,\n  (GPE Detroit/NNP)\n  ,/,\n  MI/NNP\n  48201/CD\n  ,/,\n  (GPE United/NNP States/NNPS)\n  Accepted/VBD\n  13/CD\n  May/NNP\n  2011/CD\n  Contents/NNP\n  1/CD\n  ./.\n  Introduction/NN\n  ........................................................................................................./VBD\n  2/CD\n  0/CD\n  1/CD\n  2/CD\n  ./.\n  (PERSON Key/NNP)\n  angiogenic/JJ\n  pathways/NNS\n  :/:\n  rationale/NN\n  for/IN\n  therapy/NN\n  ........................................................................../NN\n  2/CD\n  0/CD\n  1/CD\n  2.1/CD\n  ./.\n  (ORGANIZATION VEGF/NNP)\n  and/CC\n  angiogenesis/NN\n  ......................................................................................../VBP\n  2/CD\n  0/CD\n  1/CD\n  2.2/CD\n  ./.\n  (ORGANIZATION PDGF/NNP)\n  and/CC\n  angiogenesis/NN\n  ......................................................................................../VBP\n  2/CD\n  0/CD\n  2/CD\n  2.3/CD\n  ./.\n  (ORGANIZATION FGF/NNP)\n  and/CC\n  angiogenesis/NN\n  ........................................................................................../VBP\n  2/CD\n  0/CD\n  2/CD\n  3/CD\n  ./.\n  (PERSON Bevacizumab/NNP)\n  ......................................................................................................../VBD\n  2/CD\n  0/CD\n  3/CD\n  3.1/CD\n  ./.\n  (PERSON Clinical/JJ)\n  trials/NNS\n  ................................................................................................../VBD\n  2/CD\n  0/CD\n  3/CD\n  3.2/CD\n  ./.\n  Current/JJ\n  treatment/NN\n  challenges/NNS\n  ..................................................................................../VBP\n  2/CD\n  0/CD\n  5/CD\n  4/CD\n  ./.\n  Antiangiogenic/JJ\n  agents/NNS\n  in/IN\n  development/NN\n  for/IN\n  (ORGANIZATION NSCLC/NNP)\n  ......................................................................./NNP\n  2/CD\n  0/CD\n  5/CD\n  4.1/CD\n  ./.\n  Antiangiogenic/JJ\n  antibodies/NNS\n  ....................................................................................../VBP\n  2/CD\n  0/CD\n  5/CD\n  4.2/CD\n  ./.\n  Multitargeted/VBN\n  antiangiogenic/JJ\n  (ORGANIZATION TKIs/NNP)\n  .............................................................................../NNP\n  2/CD\n  0/CD\n  6/CD\n  4.2.1/CD\n  ./.\n  (PERSON Sorafenib/NNP)\n  ............................................................................................../VBD\n  2/CD\n  0/CD\n  6/CD\n  4.2.2/CD\n  ./.\n  (PERSON Sunitinib/NNP)\n  ............................................................................................../VBD\n  2/CD\n  0/CD\n  6/CD\n  4.2.3/CD\n  ./.\n  BIBF/VB\n  1120/CD\n  ............................................................................................/NNP\n  2/CD\n  0/CD\n  6/CD\n  4.2.4/CD\n  ./.\n  (PERSON Cediranib/NNP)\n  ............................................................................................./VBD\n  2/CD\n  0/CD\n  7/CD\n  4.2.5/CD\n  ./.\n  (PERSON Motesanib/NNP)\n  ............................................................................................./VBD\n  2/CD\n  0/CD\n  7/CD\n  4.2.6/CD\n  ./.\n  (PERSON Axitinib/NNP)\n  .............................................................................................../VBD\n  2/CD\n  0/CD\n  7/CD\n  4.2.7/CD\n  ./.\n  (PERSON Pazopanib/NNP)\n  ............................................................................................./VBD\n  2/CD\n  0/CD\n  7/CD\n  4.2.8/CD\n  ./.\n  (PERSON Vandetanib/NNP)\n  ............................................................................................/VBD\n  2/CD\n  0/CD\n  7/CD\n  5/CD\n  ./.\n  Current/JJ\n  challenges/NNS\n  and/CC\n  individualized/JJ\n  therapy/NN\n  .........................................................................../VBD\n  2/CD\n  0/CD\n  7/CD\n  5.1/CD\n  ./.\n  VEGF/NNP\n  as/IN\n  a/DT\n  biomarker/NN\n  ........................................................................................../VBZ\n  2/CD\n  0/CD\n  8/CD\n  5.2/CD\n  ./.\n  Other/JJ\n  biomarkers/NNS\n  ............................................................................................../VBP\n  2/CD\n  0/CD\n  8/CD\n  6/CD\n  ./.\n  Conclusions/NNS\n  ........................................................................................................./VBP\n  2/CD\n  0/CD\n  8/CD\n  Con\ufb02ict/NNP\n  of/IN\n  interest/NN\n  statement/NN\n  ........................................................................................../VBD\n  2/CD\n  0/CD\n  9/CD\n  Reviewers/NNPS\n  .........................................................................................................../VBD\n  2/CD\n  0/CD\n  9/CD\n  Acknowledgments/NNS\n  ..................................................................................................../VBD\n  2/CD\n  0/CD\n  9/CD\n  References/NNS\n  ........................................................................................................../VBD\n  2/CD\n  0/CD\n  9/CD\n  (PERSON Biography/NNP)\n  .........................................................................................................../VBD\n  2/CD\n  1/CD\n  2/CD\n  Abstract/JJ\n  Patients/NNS\n  with/IN\n  non-small/JJ\n  cell/NN\n  lung/NN\n  cancer/NN\n  (/(\n  (ORGANIZATION NSCLC/NNP)\n  )/)\n  often/RB\n  present/JJ\n  with/IN\n  advanced/JJ\n  disease/NN\n  and/CC\n  cure/NN\n  rates/NNS\n  are/VBP\n  dismal/JJ\n  with/IN\n  currently/RB\n  available/JJ\n  treatment/NN\n  ./.\n  Novel/NNP\n  therapies/NNS\n  including/VBG\n  small/JJ\n  molecule/NN\n  tyrosine/NN\n  kinase/NN\n  inhibitors/NNS\n  and/CC\n  monoclonal/JJ\n  antibodies/NNS\n  are/VBP\n  being/VBG\n  developed/VBN\n  to/TO\n  targetangiogenesis/VB\n  ,/,\n  an/DT\n  essential/JJ\n  step/NN\n  in/IN\n  tumorigenesis/NN\n  and/CC\n  metastasis/NN\n  ./.\n  The/DT\n  only/JJ\n  antiangiogenic/JJ\n  agent/NN\n  currently/RB\n  approved/VBN\n  for/IN\n  treatment/NN\n  of/IN\n  (ORGANIZATION NSCLC/NNP)\n  \u2217Tel/NNP\n  ./.\n  :/:\n  +1/JJ\n  313/CD\n  576/CD\n  8751/CD\n  ;/:\n  fax/NN\n  :/:\n  +1/JJ\n  313/CD\n  576/CD\n  8699/CD\n  ./.\n  E-mail/JJ\n  address/NN\n  :/:\n  wozniakt/NN\n  @/VBZ\n  karmanos.org/JJ\n  1040-8428//JJ\n  $/$\n  \u2013/CD\n  see/VBP\n  front/JJ\n  matter/NN\n  \u00a9/NN\n  2011/CD\n  Elsevier/NNP\n  Ireland/NNP\n  Ltd./NNP\n  All/NNP\n  rights/NNS\n  reserved/VBN\n  ./.\n  doi:10.1016/j.critrevonc.2011.05.003A/NN\n  ./.\n  (PERSON Wozniak/NNP)\n  //NNP\n  Critical/NNP\n  Reviews/NNP\n  in/IN\n  Oncology/Hematology/NNP\n  82/CD\n  (/(\n  2012/CD\n  )/)\n  200\u2013212/CD\n  201/CD\n  is/VBZ\n  bevacizumab/VBN\n  ,/,\n  although/IN\n  numerous/JJ\n  other/JJ\n  antiangiogenic/JJ\n  inhibitors/NNS\n  (/(\n  e.g./NN\n  ,/,\n  sorafenib/NN\n  ,/,\n  sunitinib/NN\n  ,/,\n  cediranib/NN\n  ,/,\n  motesanib/NN\n  ,/,\n  (ORGANIZATION BIBF/NNP)\n  1120/CD\n  )/)\n  are/VBP\n  in/IN\n  clinical/JJ\n  trials/NNS\n  ./.\n  Individualized/NNP\n  treatment/NN\n  algorithms/NN\n  may/MD\n  improve/VB\n  patient/NN\n  outcomes/NNS\n  and/CC\n  new/JJ\n  evidence/NN\n  suggests/VBZ\n  that/IN\n  biomarkers/NNS\n  may/MD\n  guidetreatment/VB\n  decisions/NNS\n  ./.\n  We/PRP\n  present/VBD\n  an/DT\n  overview/NN\n  of/IN\n  the/DT\n  molecular/JJ\n  pathways/NNS\n  involved/VBN\n  in/IN\n  angiogenesis/NN\n  ,/,\n  discuss/VB\n  clinical/JJ\n  trials/NNS\n  of/IN\n  bevacizumab/NN\n  anddevelopmental/JJ\n  antiangiogenic/JJ\n  agents/NNS\n  ,/,\n  and/CC\n  address/VB\n  the/DT\n  challenges/NNS\n  of/IN\n  developing/VBG\n  individualized/JJ\n  treatment/NN\n  paradigms/NN\n  for/IN\n  (ORGANIZATION NSCLC/NNP)\n  ,/,\n  particularlythe/NN\n  use/NN\n  of/IN\n  biomarkers.\u00a9/NN\n  2011/CD\n  Elsevier/NNP\n  Ireland/NNP\n  Ltd./NNP\n  All/NNP\n  rights/NNS\n  reserved/VBN\n  ./.\n  Keywords/NNS\n  :/:\n  (PERSON Carcinoma/NNP)\n  ;/:\n  Non-small/NNP\n  cell/NN\n  lung/NN\n  ;/:\n  (GPE Angiogenesis/NNP)\n  inhibitor/NN\n  ;/:\n  Protein-tyrosine/JJ\n  kinase/NN\n  ;/:\n  (PERSON Vascular/NNP)\n  endothelial/JJ\n  growth/NN\n  factor/NN\n  ;/:\n  (GPE Receptor/NNP)\n  ;/:\n  Vascular/NNP\n  endot/VBP\n  helial/JJ\n  growth/NN\n  factor/NN\n  ;/:\n  (ORGANIZATION Biological/NNP)\n  marker/NN\n  1/CD\n  ./.\n  Introduction/NN\n  (PERSON Lung/NNP)\n  cancer/NN\n  is/VBZ\n  the/DT\n  leading/VBG\n  cause/NN\n  of/IN\n  cancer-related/JJ\n  deaths/NNS\n  in/IN\n  the/DT\n  (GPE United/NNP States/NNPS)\n  and/CC\n  worldwide/VB\n  [/$\n  1,2/CD\n  ]/NNP\n  ./.\n  The/DT\n  (ORGANIZATION American/JJ)\n  Can-/NNP\n  cer/NN\n  (PERSON Society/NNP)\n  reported/VBD\n  an/DT\n  estimated/VBN\n  222,520/CD\n  new/JJ\n  cases/NNS\n  and157,300/VBP\n  lung/JJ\n  cancer-related/JJ\n  deaths/NNS\n  for/IN\n  2010/CD\n  in/IN\n  the/DT\n  (ORGANIZATION UnitedStates/NNP)\n  alone/RB\n  [/VBD\n  2/CD\n  ]/NN\n  ./.\n  The/DT\n  5-year/JJ\n  survival/NN\n  rate/NN\n  was/VBD\n  15.2/CD\n  %/NN\n  for/IN\n  all/DT\n  stages/NNS\n  of/IN\n  lung/NN\n  cancer/NN\n  and/CC\n  2.8/CD\n  %/NN\n  for/IN\n  lung/NN\n  cancer/NN\n  patients/NNS\n  diag-nosed/JJ\n  with/IN\n  distant/JJ\n  metastases/NNS\n  [/VBP\n  3/CD\n  ]/NN\n  ./.\n  Non-small/NN\n  cell/NN\n  lung/NN\n  cancer/NN\n  (/(\n  (ORGANIZATION NSCLC/NNP)\n  )/)\n  accounts/NNS\n  for/IN\n  approximately/RB\n  85/CD\n  %/NN\n  of/IN\n  all/DT\n  lung/NN\n  cancercases/VBZ\n  [/$\n  3/CD\n  ]/NNP\n  ./.\n  While/IN\n  surgery/NN\n  is/VBZ\n  usually/RB\n  recommended/VBN\n  for/IN\n  patients/NNS\n  with/IN\n  localized/JJ\n  disease/NN\n  ,/,\n  approximately/RB\n  80/CD\n  %/NN\n  of/IN\n  patients/NNS\n  presentwith/VBP\n  locally/RB\n  advanced/JJ\n  or/CC\n  metastatic/JJ\n  (ORGANIZATION NSCLC/NNP)\n  [/NNP\n  4,5/CD\n  ]/NNP\n  and/CC\n  thus/RB\n  may/MD\n  also/RB\n  require/VB\n  radiation/NN\n  and/or/IN\n  systemic/JJ\n  chemotherapy/NN\n  [/VBD\n  5/CD\n  ]/NN\n  ./.\n  The/DT\n  use/NN\n  of/IN\n  platinum-based/JJ\n  doublets/NNS\n  (/(\n  carboplatin/NN\n  or/CC\n  cisplatinplus/VB\n  a/DT\n  cytotoxic/JJ\n  agent/NN\n  )/)\n  is/VBZ\n  common/JJ\n  in/IN\n  the/DT\n  treatment/NN\n  of/IN\n  (ORGANIZATION NSCLC/NNP)\n  [/NNP\n  5/CD\n  ]/NNP\n  ./.\n  With/IN\n  the/DT\n  exception/NN\n  of/IN\n  a/DT\n  signi\ufb01cant/JJ\n  overall/JJ\n  survival/NN\n  (/(\n  OS/NNP\n  )/)\n  bene\ufb01t/NN\n  with/IN\n  cisplatin/JJ\n  plus/CC\n  pemetrexed/JJ\n  vs/NN\n  cisplatin/NN\n  plusgemcitabine/NN\n  for/IN\n  treating/VBG\n  tumors/NNS\n  of/IN\n  nonsquamous/JJ\n  histology/NN\n  (/(\n  and/CC\n  cisplatin/pemetrexed/VBN\n  inferior/JJ\n  to/TO\n  cisplatin/gemcitabinefor/VB\n  squamous/JJ\n  histology/NN\n  )/)\n  as/IN\n  \ufb01rst-line/JJ\n  chemotherapy/NN\n  [/$\n  6/CD\n  ]/NNP\n  ,/,\n  f/JJ\n  e/NN\n  w/IN\n  particular/JJ\n  drug/NN\n  combinations/NNS\n  have/VBP\n  been/VBN\n  identi\ufb01ed/VBN\n  as/IN\n  superiorto/NN\n  others/NNS\n  [/VBP\n  7/CD\n  ]/NN\n  ./.\n  In/IN\n  general/JJ\n  ,/,\n  chemotherapy/VBZ\n  only/RB\n  provides/VBZ\n  modest/JJ\n  clinical/JJ\n  bene\ufb01t/NN\n  and/CC\n  can/MD\n  be/VB\n  associated/VBN\n  with/IN\n  signi\ufb01cant/JJ\n  toxicity/NN\n  [/VBP\n  8/CD\n  ]/NN\n  ./.\n  Recently/RB\n  ,/,\n  small/JJ\n  molecule/NN\n  tyrosine/NN\n  kinase/NN\n  inhibitors/NNS\n  (/(\n  (ORGANIZATION TKIs/NNP)\n  )/)\n  and/CC\n  monoclonal/JJ\n  antibodies/NNS\n  that/WDT\n  target/VBP\n  speci\ufb01c/JJ\n  pathwaysand/NN\n  processes/NNS\n  have/VBP\n  been/VBN\n  developed/VBN\n  and/CC\n  integrated/VBN\n  intotreatment/JJ\n  algorithms/NN\n  for/IN\n  (ORGANIZATION NSCLC/NNP)\n  [/NNP\n  5/CD\n  ]/NNP\n  ./.\n  Erlotinib/NNP\n  (/(\n  (PERSON Tarceva/NNP)\n  \u00ae/NNP\n  ,/,\n  (GPE Genentech/NNP)\n  ;/:\n  (GPE South/NNP)\n  (PERSON San/NNP Francisco/NNP)\n  ,/,\n  (ORGANIZATION CA/NNP)\n  ,/,\n  (ORGANIZATION USA/NNP)\n  )/)\n  and/CC\n  ge\ufb01-tinib/JJ\n  (/(\n  (PERSON Iressa/NNP TM/NNP)\n  ,/,\n  (ORGANIZATION AstraZeneca/NNP)\n  ;/:\n  (PERSON Wilmington/NNP)\n  ,/,\n  (ORGANIZATION DE/NNP)\n  ,/,\n  (ORGANIZATION USA/NNP)\n  )/)\n  are/VBP\n  reversible/JJ\n  TKIs/NNP\n  that/WDT\n  target/VBP\n  the/DT\n  epidermal/JJ\n  growth/NN\n  factorreceptor/NN\n  (/(\n  (ORGANIZATION EGFR/NNP)\n  )/)\n  and/CC\n  are/VBP\n  approved/VBN\n  for/IN\n  the/DT\n  treatment/NN\n  ofpatients/NNS\n  with/IN\n  (ORGANIZATION NSCLC/NNP)\n  [/NNP\n  9,10/CD\n  ]/NNP\n  ./.\n  Another/DT\n  targeted/JJ\n  agent/NN\n  is/VBZ\n  bevacizumab/VBN\n  (/(\n  (PERSON Avastin/NNP)\n  \u00ae/NNP\n  ,/,\n  (GPE Genentech/NNP)\n  ;/:\n  (GPE South/NNP)\n  (PERSON San/NNP Francisco/NNP)\n  ,/,\n  (ORGANIZATION CA/NNP)\n  ,/,\n  (ORGANIZATION USA/NNP)\n  )/)\n  ,/,\n  a/DT\n  monoclonal/JJ\n  antibody/NN\n  that/WDT\n  binds/VBZ\n  vascularendothelial/JJ\n  growth/NN\n  factor/NN\n  (/(\n  (ORGANIZATION VEGF/NNP)\n  )/)\n  ,/,\n  a/DT\n  key/JJ\n  mediator/NN\n  of/IN\n  angio-genesis/NN\n  ./.\n  Although/IN\n  bevacizumab/NN\n  is/VBZ\n  the/DT\n  only/JJ\n  antiangiogenicagent/NN\n  currently/RB\n  approved/VBN\n  for/IN\n  treatment/NN\n  of/IN\n  (ORGANIZATION NSCLC/NNP)\n  ,/,\n  manyothers/NNS\n  are/VBP\n  under/IN\n  development/NN\n  ./.\n  In/IN\n  this/DT\n  article/NN\n  ,/,\n  we/PRP\n  providean/VBP\n  overview/NN\n  of/IN\n  angiogenesis/NN\n  as/IN\n  a/DT\n  therapeutic/JJ\n  target/NN\n  (ORGANIZATION inNSCLC/NN)\n  ,/,\n  summarize/VB\n  agents/NNS\n  in/IN\n  use/NN\n  and/CC\n  in/IN\n  development/NN\n  forthe/NN\n  treatment/NN\n  of/IN\n  (ORGANIZATION NSCLC/NNP)\n  ,/,\n  and/CC\n  discuss/VB\n  current/JJ\n  challenges/NNS\n  inantiangiogenic/JJ\n  treatment/NN\n  ,/,\n  with/IN\n  a/DT\n  focus/NN\n  on/IN\n  the/DT\n  use/NN\n  of/IN\n  biomark-ers.2/NN\n  ./.\n  (PERSON Key/NNP)\n  angiogenic/JJ\n  pathways/NNS\n  :/:\n  rationale/NN\n  for/IN\n  therapy/NN\n  Because/IN\n  tumors/NNS\n  larger/JJR\n  than/IN\n  2/CD\n  mm/NN\n  in/IN\n  diameter/NN\n  can/MD\n  not/RB\n  acquire/VB\n  nutrients/NNS\n  and/CC\n  oxygen/NN\n  through/IN\n  diffusion/NN\n  alone/RB\n  ,/,\n  angio-genesis/JJ\n  ,/,\n  or/CC\n  the/DT\n  formation/NN\n  of/IN\n  vasculature/NN\n  from/IN\n  preexistingvessels/NNS\n  ,/,\n  represents/VBZ\n  a/DT\n  fundamental/JJ\n  step/NN\n  in/IN\n  tumorigenesisand/NN\n  metastasis/NN\n  [/VBD\n  11,12/CD\n  ]/NN\n  ./.\n  (PERSON Angiogenesis/NNP)\n  is/VBZ\n  a/DT\n  complex/JJ\n  pro-/JJ\n  cess/NN\n  regulated/VBN\n  by/IN\n  cellular/JJ\n  cues/NNS\n  ,/,\n  multiple/JJ\n  receptor-mediatedsignaling/JJ\n  networks/NNS\n  ,/,\n  and/CC\n  a/DT\n  number/NN\n  of/IN\n  pro-/JJ\n  and/CC\n  antiangio-genic/JJ\n  factors/NNS\n  [/VBP\n  13\u201316/CD\n  ]/NN\n  ./.\n  VEGF/NNP\n  (/(\n  also/RB\n  referred/VBN\n  to/TO\n  as/IN\n  VEGF-A/NNP\n  )/)\n  is/VBZ\n  the/DT\n  most/RBS\n  potent/JJ\n  and/CC\n  well/RB\n  studied/JJ\n  proangiogenic/JJ\n  signal-ing/JJ\n  factor/NN\n  [/VBD\n  15,16/CD\n  ]/NN\n  ,/,\n  though/IN\n  other/JJ\n  members/NNS\n  of/IN\n  the/DT\n  (ORGANIZATION VEGF/NNP)\n  family/NN\n  include/VBP\n  placental/JJ\n  growth/NN\n  factor/NN\n  (/(\n  (ORGANIZATION PlGF/NNP)\n  )/)\n  ,/,\n  VEGF-B/NNP\n  ,/,\n  VEGF-C/NNP\n  ,/,\n  and/CC\n  VEGF-D./NNP\n  VEGF/NNP\n  is/VBZ\n  produced/VBN\n  by/IN\n  tumorcells/NNS\n  and/CC\n  stromal/JJ\n  cells/NNS\n  [/VBP\n  17,18/CD\n  ]/NN\n  ./.\n  The/DT\n  (ORGANIZATION VEGF/NNP)\n  family/NN\n  of/IN\n  lig-/JJ\n  ands/NNS\n  binds/VBZ\n  3/CD\n  cognate/NN\n  receptor/NN\n  tyrosine/NN\n  kinases/NNS\n  (/(\n  (ORGANIZATION RTKs/NNP)\n  )/)\n  :/:\n  VEGFR-1/JJ\n  ,/,\n  VEGFR-2/NNP\n  ,/,\n  and/CC\n  VEGFR-3/NNP\n  ./.\n  VEGF/NNP\n  primarily/RB\n  sig-nals/NNS\n  through/IN\n  VEGFR-2/NNP\n  ,/,\n  although/IN\n  some/DT\n  other/JJ\n  family/NN\n  membersalso/NNS\n  have/VBP\n  receptor/NN\n  preferences/NNS\n  speci\ufb01c/VBP\n  to/TO\n  their/PRP$\n  particularroles/NNS\n  [/VBP\n  19/CD\n  ]/NN\n  ./.\n  As/IN\n  a/DT\n  classical/JJ\n  (ORGANIZATION RTK/NNP)\n  ,/,\n  binding/NN\n  of/IN\n  ligand/NN\n  induces/NNS\n  the/DT\n  receptor/NN\n  to/TO\n  undergo/VB\n  dimerization/NN\n  ,/,\n  autophosphorylation/NN\n  ,/,\n  and/CC\n  activation/NN\n  ./.\n  VEGFRs/NNP\n  activate/VBP\n  downstream/NN\n  signalingmolecules/NNS\n  that/WDT\n  promote/VBP\n  prosurvival/NN\n  ,/,\n  mitogenic/NN\n  ,/,\n  and/CC\n  migra-tory/JJ\n  signaling/NN\n  cascades/NNS\n  (/(\n  (ORGANIZATION Fig/NNP)\n  ./.\n  1/CD\n  )/)\n  ./.\n  These/DT\n  include/VBP\n  3/CD\n  pathways/NNS\n  :/:\n  the/DT\n  phosphatidylinositol-3-kinase/NN\n  (/(\n  (ORGANIZATION PI3K/NNP)\n  )/)\n  /protein/NNP\n  kinase/NN\n  B/NNP\n  (/(\n  Akt/NNP\n  )/)\n  pathway/NN\n  ,/,\n  the/DT\n  phospholipase/NN\n  C-/NNP\n  /H9253/NNP\n  (/(\n  PLC-/NNP\n  /H9253/NNP\n  )/)\n  /protein/VBP\n  kinase/JJ\n  C/NNP\n  (/(\n  (ORGANIZATION PKC/NNP)\n  )/)\n  pathway/NN\n  ,/,\n  and/CC\n  the/DT\n  retrovirus-associatedDNA/JJ\n  sequences/NNS\n  (/(\n  Ras/NNP\n  )/)\n  /v-raf/VBP\n  1/CD\n  murine/NN\n  leukemia/JJ\n  viral/JJ\n  onco-gene/JJ\n  homolog/NN\n  1/CD\n  (/(\n  Raf/NNP\n  )/)\n  /mitogen-activated/JJ\n  protein/NN\n  kinase/NN\n  (/(\n  (ORGANIZATION MEK/NNP)\n  )/)\n  /extracellular/VBD\n  signal-regulated/JJ\n  kinase/NN\n  (/(\n  Erk/NNP\n  )/)\n  pathway/NN\n  (/(\n  reviewed/VBN\n  in/IN\n  [/JJ\n  13/CD\n  ]/NN\n  )/)\n  ./.\n  2.1/CD\n  ./.\n  (ORGANIZATION VEGF/NNP)\n  and/CC\n  angiogenesis/NN\n  (ORGANIZATION VEGF/NNP)\n  inhibition/NN\n  has/VBZ\n  been/VBN\n  consistently/RB\n  shown/VBN\n  to/TO\n  slow/VB\n  tumor/NN\n  cell/NN\n  growth/NN\n  and/CC\n  angiogenesis/NN\n  (/(\n  reviewed/VBN\n  in/IN\n  [/JJ\n  20/CD\n  ]/NN\n  )/)\n  ./.\n  In/IN\n  mice/NN\n  ,/,\n  a/DT\n  monoclonal/JJ\n  antibody/NN\n  inhibitor/NN\n  of/IN\n  (ORGANIZATION VEGF/NNP)\n  pre-vented/JJ\n  tumor/NN\n  cell/NN\n  growth/NN\n  [/VBP\n  21/CD\n  ]/NN\n  ,/,\n  and/CC\n  in/IN\n  a/DT\n  transgenic/JJ\n  mouse/NN\n  model/NN\n  ,/,\n  absence/NN\n  of/IN\n  endogenous/JJ\n  inhibitors/NNS\n  of/IN\n  angio-genesis/NN\n  ,/,\n  such/JJ\n  as/IN\n  thrombospondin-1/NN\n  ,/,\n  led/VBN\n  to/TO\n  increasedtumor/VB\n  cell/NN\n  growth/NN\n  and/CC\n  angiogenesis/NN\n  [/VBP\n  22/CD\n  ]/NN\n  ./.\n  (ORGANIZATION VEGFRs/NNP)\n  and/CC\n  (ORGANIZATION VEGFs/NNP)\n  are/VBP\n  expressed/VBN\n  and/or/RB\n  upregulated/VBN\n  in/IN\n  most/JJS\n  solidtumors/NNS\n  ,/,\n  making/VBG\n  this/DT\n  pathway/NN\n  a/DT\n  feasible/JJ\n  target/NN\n  for/IN\n  therapy/NN\n  [/NN\n  19,23,24/CD\n  ]/NN\n  .202/NNP\n  A./NN\n  (PERSON Wozniak/NNP)\n  //NNP\n  Critical/NNP\n  Reviews/NNP\n  in/IN\n  Oncology/Hematology/NNP\n  82/CD\n  (/(\n  2012/CD\n  )/)\n  200\u2013212/CD\n  2.2/CD\n  ./.\n  (ORGANIZATION PDGF/NNP)\n  and/CC\n  angiogenesis/RB\n  More/RBR\n  recently/RB\n  ,/,\n  the/DT\n  platelet-derived/JJ\n  growth/NN\n  factor/NN\n  (/(\n  (ORGANIZATION PDGF/NNP)\n  )/)\n  and/CC\n  \ufb01broblast/JJ\n  growth/NN\n  factor/NN\n  (/(\n  (ORGANIZATION FGF/NNP)\n  )/)\n  signaling/VBG\n  pathways/NNS\n  havealso/RB\n  been/VBN\n  implicated/VBN\n  in/IN\n  angiogenesis/NN\n  ./.\n  The/DT\n  (ORGANIZATION PDGF/NNP)\n  family/NN\n  ofligands/VBZ\n  comprises/VBZ\n  5/CD\n  dimeric/NN\n  isoforms/NNS\n  (/(\n  PDGF-AA/NNP\n  ,/,\n  -BB/NNP\n  ,/,\n  -CC/NNP\n  ,/,\n  -DD/NNP\n  ,/,\n  and/CC\n  -AB/NNP\n  )/)\n  that/IN\n  bind/NN\n  and/CC\n  activate/VB\n  2/CD\n  cognate/NN\n  (ORGANIZATION RTKs/NNP)\n  ,/,\n  (ORGANIZATION PDGFreceptor/NNP)\n  /H9251/NNP\n  (/(\n  PDGFR-/NNP\n  /H9251/NNP\n  )/)\n  and/CC\n  (ORGANIZATION PDGF/NNP)\n  receptor/NN\n  /H9252/NNP\n  (/(\n  PDGFR-/NNP\n  /H9252/NNP\n  )/)\n  [/VBD\n  25,26/CD\n  ]/NN\n  ./.\n  (GPE Ligand/NNP)\n  binding/VBG\n  results/NNS\n  in/IN\n  classical/JJ\n  receptor/NN\n  dimer-/JJ\n  ization/NN\n  and/CC\n  activation/NN\n  ,/,\n  which/WDT\n  ,/,\n  in/IN\n  turn/NN\n  ,/,\n  stimulates/VBZ\n  downstreamtargets/NNS\n  including/VBG\n  (ORGANIZATION PI3K/NNP)\n  and/CC\n  (PERSON Ras/NNP)\n  [/NNP\n  27/CD\n  ]/NNP\n  (/(\n  (ORGANIZATION Fig/NNP)\n  ./.\n  1/CD\n  )/)\n  ./.\n  Enhanced/VBD\n  signaling/VBG\n  through/IN\n  (ORGANIZATION PDGFRs/NNP)\n  has/VBZ\n  been/VBN\n  implicated/VBN\n  in/IN\n  tumorige-nesis/NN\n  and/CC\n  angiogenesis/NN\n  ,/,\n  among/IN\n  other/JJ\n  processes/NNS\n  [/VBP\n  28/CD\n  ]/NN\n  ./.\n  PDGFRs/NNP\n  are/VBP\n  expressed/VBN\n  on/IN\n  vascular/JJ\n  smooth/JJ\n  muscle/NN\n  cells/NNS\n  (/(\n  (ORGANIZATION VMCs/NNP)\n  )/)\n  andon/VBP\n  pericytes/NNS\n  [/VBP\n  29\u201331/CD\n  ]/NN\n  ,/,\n  which/WDT\n  are/VBP\n  critical/JJ\n  to/TO\n  the/DT\n  integrity/NN\n  and/CC\n  function/NN\n  of/IN\n  developing/VBG\n  vasculature/NN\n  [/$\n  32/CD\n  ]/NNP\n  ./.\n  In/IN\n  paracrine/JJ\n  fash-/JJ\n  ion/NN\n  ,/,\n  (ORGANIZATION PDGF/NNP)\n  released/VBN\n  by/IN\n  endothelial/JJ\n  cells/NNS\n  recruits/NNS\n  pericytesand/VBP\n  (ORGANIZATION VMCs/NNP)\n  ,/,\n  which/WDT\n  promote/VBP\n  blood/NN\n  vessel/NN\n  stabilization/NN\n  ,/,\n  to/TO\n  the/DT\n  developing/JJ\n  vasculature/NN\n  [/VBZ\n  31\u201335/CD\n  ]/NN\n  ./.\n  In/IN\n  addition/NN\n  ,/,\n  secretion/NN\n  of/IN\n  (ORGANIZATION PDGF/NNP)\n  by/IN\n  tumors/NNS\n  may/MD\n  recruit/VB\n  stromal/JJ\n  cells/NNS\n  that/WDT\n  can/MD\n  sup-port/VB\n  angiogenesis/NN\n  through/IN\n  the/DT\n  release/NN\n  of/IN\n  (ORGANIZATION VEGF/NNP)\n  [/NNP\n  36/CD\n  ]/NNP\n  ./.\n  (ORGANIZATION PDGF/NNP)\n  signaling/NN\n  has/VBZ\n  been/VBN\n  associated/VBN\n  with/IN\n  resistance/NN\n  to/TO\n  anti-VEGFtherapy/NN\n  in/IN\n  preclinical/JJ\n  models/NNS\n  ./.\n  In/IN\n  mouse/NN\n  models/NNS\n  ,/,\n  inhibitionof/JJ\n  PDGFR/NNP\n  by/IN\n  (ORGANIZATION TKIs/NNP)\n  disrupts/NNS\n  angiogenic/JJ\n  cellular/JJ\n  associationswith/NN\n  tumor/NN\n  vasculature/NN\n  ,/,\n  and/CC\n  combined/JJ\n  inhibition/NN\n  of/IN\n  (ORGANIZATION VEGFRand/NNP)\n  PDGFR/NNP\n  is/VBZ\n  more/RBR\n  effective/JJ\n  than/IN\n  (ORGANIZATION VEGFR/NNP)\n  inhibition/NN\n  alone/RB\n  [/VBZ\n  37\u201339/CD\n  ]/NN\n  ./.\n  These/DT\n  \ufb01ndings/NNS\n  suggest/VBP\n  that/IN\n  combined/JJ\n  inhibition/NN\n  of/IN\n  (ORGANIZATION VEGF/NNP)\n  and/CC\n  (ORGANIZATION PDGF/NNP)\n  pathways/NNS\n  may/MD\n  be/VB\n  a/DT\n  rational/JJ\n  approach/NN\n  toantiangiogenic/JJ\n  therapy/NN\n  ./.\n  2.3/CD\n  ./.\n  (ORGANIZATION FGF/NNP)\n  and/CC\n  angiogenesis/VB\n  The/DT\n  (ORGANIZATION FGF/NNP)\n  family/NN\n  of/IN\n  ligands/NNS\n  has/VBZ\n  22/CD\n  known/VBN\n  members/NNS\n  and/CC\n  is/VBZ\n  involved/VBN\n  in/IN\n  diverse/JJ\n  processes/NNS\n  including/VBG\n  embryonic/JJ\n  develop-/JJ\n  Fig/NNP\n  ./.\n  1/CD\n  ./.\n  (PERSON Key/NNP)\n  angiogenic/JJ\n  pathways/NNS\n  ./.\n  (GPE Ligand/NNP)\n  binding/VBG\n  induces/NNS\n  activation/NN\n  of/IN\n  (ORGANIZATION RTKs/NNP)\n  (/(\n  e.g./NN\n  ,/,\n  (ORGANIZATION VEGFRs/NNP)\n  ,/,\n  (ORGANIZATION PDGFRs/NNP)\n  ,/,\n  (ORGANIZATION FGFRs/NNP)\n  )/)\n  which/WDT\n  ,/,\n  in/IN\n  turn/NN\n  ,/,\n  promote/VBP\n  angiogenesis/NN\n  throu/NN\n  gh/NN\n  cellular/JJ\n  processes/NNS\n  stimulated/VBN\n  by/IN\n  downstream/NN\n  pathways/NNS\n  ./.\n  Signaling/VBG\n  cascades/NNS\n  activated/VBN\n  by/IN\n  these/DT\n  RTKs/NNP\n  include/VBP\n  the/DT\n  Ras/Raf/MEK/Erk/NNP\n  ,/,\n  PI3K/Akt/NNP\n  ,/,\n  and/CC\n  the/DT\n  P/NNP\n  LC-/NNP\n  /H9253/PKC/NNP\n  pathways/NNS\n  ./.\n  (PERSON Key/NNP)\n  angiogenic/JJ\n  pathways/NNS\n  ./.\n  (PERSON Akt/NNP)\n  ,/,\n  protein/NN\n  kinase/NN\n  B/NNP\n  ;/:\n  (ORGANIZATION ERK/NNP)\n  ,/,\n  extracellular/JJ\n  signal-regulated/JJ\n  kinase/NN\n  ;/:\n  (ORGANIZATION FGF/NNP)\n  ,/,\n  \ufb01broblast/NNP\n  growth/NN\n  factor/NN\n  ;/:\n  (ORGANIZATION FGFR/NNP)\n  ,/,\n  \ufb01b/NNP\n  roblast/VBD\n  growth/NN\n  factor/NN\n  receptor/NN\n  ;/:\n  (ORGANIZATION MEK/NNP)\n  ,/,\n  mitogen-activated/JJ\n  protein/NN\n  kinase/NN\n  ;/:\n  (ORGANIZATION PDGF/NNP)\n  ,/,\n  platelet-derived/JJ\n  growth/NN\n  factor/NN\n  ;/:\n  (ORGANIZATION PDGFR/NNP)\n  ,/,\n  platelet-derived/JJ\n  growth/NN\n  factor/NN\n  rec/NN\n  eptor/NN\n  ;/:\n  (ORGANIZATION PI3K/NNP)\n  ,/,\n  phosphatidylinositol-3-kinase/NN\n  ;/:\n  (ORGANIZATION PlGF/NNP)\n  ,/,\n  placental/JJ\n  growth/NN\n  factor/NN\n  ;/:\n  (ORGANIZATION PKC/NNP)\n  ,/,\n  protein/NN\n  kinase/NN\n  C/NNP\n  ;/:\n  PLC-/NNP\n  /H9253/NNP\n  ,/,\n  phospholipase/VBD\n  C-/NNP\n  /H9253/NNP\n  ;/:\n  (PERSON Raf/NNP)\n  ,/,\n  v-raf/JJ\n  1/CD\n  murine/NN\n  leukemia/NN\n  viral/JJ\n  oncogene/NN\n  homolog/NN\n  1/CD\n  ;/:\n  (PERSON Ras/NNP)\n  ,/,\n  retrovirus-associated/JJ\n  (ORGANIZATION DNA/NNP)\n  sequences/NNS\n  ;/:\n  (ORGANIZATION RTK/NNP)\n  ,/,\n  receptor/NN\n  tyrosine/JJ\n  kinase/NN\n  ;/:\n  (ORGANIZATION VEGF/NNP)\n  ,/,\n  vascular/JJ\n  endothelial/JJ\n  growth/NN\n  factor/NN\n  ;/:\n  (ORGANIZATION VEGFR/NNP)\n  ,/,\n  vascular/JJ\n  en/FW\n  dothelial/JJ\n  growth/NN\n  factor/NN\n  receptor.A/NN\n  ./.\n  (PERSON Wozniak/NNP)\n  //NNP\n  Critical/NNP\n  Reviews/NNP\n  in/IN\n  Oncology/Hematology/NNP\n  82/CD\n  (/(\n  2012/CD\n  )/)\n  200\u2013212/CD\n  203/CD\n  ment/NN\n  ,/,\n  tissue/NN\n  regeneration/NN\n  ,/,\n  and/CC\n  wound/IN\n  healing/VBG\n  [/$\n  40/CD\n  ]/NNP\n  ./.\n  FGF-1/NNP\n  ,/,\n  FGF-2/NNP\n  ,/,\n  FGF-4/NNP\n  ,/,\n  FGF-5/NNP\n  ,/,\n  and/CC\n  FGF-8/NNP\n  are/VBP\n  known/VBN\n  to/TO\n  stimulateangiogenesis/VB\n  [/JJ\n  41/CD\n  ]/NN\n  ./.\n  Of/IN\n  the/DT\n  4/CD\n  FGF/NNP\n  receptor/NN\n  family/NN\n  members/NNS\n  (/(\n  FGFR-1/NNP\n  through/IN\n  -4/NNP\n  )/)\n  ,/,\n  FGFR-1/NNP\n  and/CC\n  -2/NNP\n  are/VBP\n  known/VBN\n  to/TO\n  beexpressed/VBN\n  on/IN\n  endothelial/JJ\n  cells/NNS\n  [/VBP\n  41/CD\n  ]/NNPS\n  ./.\n  Like/IN\n  other/JJ\n  (ORGANIZATION RTKs/NNP)\n  ,/,\n  (ORGANIZATION FGFRs/NNP)\n  are/VBP\n  activated/VBN\n  by/IN\n  ligand/NN\n  binding/NN\n  ./.\n  Downstream/NNP\n  targets/NNS\n  includePI3K/VBP\n  and/CC\n  the/DT\n  Ras-Raf/NNP\n  pathways/NNS\n  (/(\n  (ORGANIZATION Fig/NNP)\n  ./.\n  1/CD\n  )/)\n  [/VBD\n  41/CD\n  ]/NN\n  ./.\n  The/DT\n  angio-/JJ\n  genic/JJ\n  activity/NN\n  of/IN\n  (ORGANIZATION FGF/NNP)\n  is/VBZ\n  mainly/RB\n  mediated/VBN\n  through/IN\n  endothelialcell/NN\n  activation/NN\n  and/CC\n  pericyte/NN\n  ,/,\n  (ORGANIZATION VMC/NNP)\n  ,/,\n  and/CC\n  monocyte/JJ\n  recruit-ment/JJ\n  [/NN\n  40/CD\n  ]/NN\n  ./.\n  (ORGANIZATION FGF/NNP)\n  also/RB\n  plays/VBZ\n  a/DT\n  key/JJ\n  role/NN\n  in/IN\n  regulating/VBG\n  vascular/JJ\n  integrity/NN\n  ./.\n  Speci\ufb01cally/RB\n  ,/,\n  FGF-mediated/JJ\n  effects/NNS\n  on/IN\n  componentsof/NN\n  cell\u2013cell/NN\n  junctions/NNS\n  and/CC\n  enzymes/NNS\n  that/WDT\n  regulate/VBP\n  them/PRP\n  con-tribute/NN\n  to/TO\n  the/DT\n  degradation/NN\n  of/IN\n  the/DT\n  extracellular/JJ\n  matrix/NN\n  ,/,\n  whichfacilitates/VBZ\n  endothelial/JJ\n  cell/NN\n  migration/NN\n  [/VBZ\n  42/CD\n  ]/NN\n  ./.\n  Like/IN\n  (ORGANIZATION PDGF/NNP)\n  ,/,\n  (ORGANIZATION FGF/NNP)\n  signaling/NN\n  has/VBZ\n  been/VBN\n  implicated/VBN\n  in/IN\n  the/DT\n  development/NN\n  of/IN\n  resis-tance/NN\n  to/TO\n  (ORGANIZATION VEGF/NNP)\n  inhibition/NN\n  ./.\n  In/IN\n  a/DT\n  pancreatic/JJ\n  cancer/NN\n  animalmodel/NN\n  of/IN\n  (ORGANIZATION VEGF/NNP)\n  resistance/NN\n  ,/,\n  increased/VBD\n  FGF-2/NNP\n  was/VBD\n  detectedafter/JJ\n  relapse/NN\n  and/CC\n  was/VBD\n  associated/VBN\n  with/IN\n  tumor/NN\n  revasculariza-tion/NN\n  ./.\n  Combined/VBN\n  inhibition/NN\n  of/IN\n  (ORGANIZATION VEGFR/NNP)\n  and/CC\n  (ORGANIZATION FGFR/NNP)\n  attenuatedthis/VBP\n  revascularization/NN\n  and/CC\n  slowed/VBD\n  tumor/NN\n  growth/NN\n  [/VBP\n  43/CD\n  ]/NN\n  ./.\n  (ORGANIZATION FGF/NNP)\n  ,/,\n  (ORGANIZATION VEGF/NNP)\n  ,/,\n  and/CC\n  (ORGANIZATION PDGF/NNP)\n  pathways/NNS\n  are/VBP\n  highly/RB\n  integrated/JJ\n  ,/,\n  and/CC\n  syn-ergism/NN\n  among/IN\n  them/PRP\n  in/IN\n  the/DT\n  induction/NN\n  of/IN\n  angiogenesis/NN\n  has/VBZ\n  beenobserved/VBN\n  [/RB\n  44,45/CD\n  ]/NN\n  ./.\n  3/CD\n  ./.\n  (PERSON Bevacizumab/NNP Bevacizumab/NNP)\n  is/VBZ\n  a/DT\n  monoclonal/JJ\n  antibody/NN\n  targeting/VBG\n  (ORGANIZATION VEGF/NNP)\n  and/CC\n  is/VBZ\n  currently/RB\n  approved/VBN\n  for/IN\n  the/DT\n  treatment/NN\n  of/IN\n  severalmalignancies/NNS\n  [/VBP\n  46/CD\n  ]/NN\n  ./.\n  It/PRP\n  is/VBZ\n  labeled/VBN\n  for/IN\n  \ufb01rst-line/JJ\n  treatment/NN\n  in/IN\n  com-/JJ\n  bination/NN\n  with/IN\n  carboplatin/paclitaxel/NN\n  for/IN\n  unresected/JJ\n  ,/,\n  locallyadvanced/VBD\n  ,/,\n  recurrent/NN\n  or/CC\n  metastatic/JJ\n  nonsquamous/JJ\n  (ORGANIZATION NSCLC/NNP)\n  ./.\n  It/PRP\n  isalso/VBZ\n  approved/VBN\n  for/IN\n  \ufb01rst-/JJ\n  or/CC\n  second-line/JJ\n  treatment/NN\n  of/IN\n  metastaticcolorectal/JJ\n  cancer/NN\n  in/IN\n  combination/NN\n  with/IN\n  5-\ufb02uorouracil-basedchemotherapy/JJ\n  ./.\n  In/IN\n  addition/NN\n  ,/,\n  it/PRP\n  received/VBD\n  fast/JJ\n  track/NN\n  approvalin/NN\n  combination/NN\n  with/IN\n  paclitaxel/NN\n  for/IN\n  patients/NNS\n  with/IN\n  metastaticbreast/JJ\n  cancer/NN\n  that/WDT\n  is/VBZ\n  negative/JJ\n  for/IN\n  human/JJ\n  epidermal/JJ\n  growthfactor/NN\n  receptor/NN\n  2/CD\n  (/(\n  (ORGANIZATION HER2/NNP)\n  )/)\n  ,/,\n  who/WP\n  have/VBP\n  not/RB\n  progressed/VBN\n  follow-ing/JJ\n  anthracycline/NN\n  and/CC\n  taxane/NN\n  chemotherapy/NN\n  ./.\n  However/RB\n  ,/,\n  (ORGANIZATION theOncology/NN Drugs/NNP Advisory/NNP Committee/NNP)\n  of/IN\n  the/DT\n  (ORGANIZATION Food/NNP)\n  and/CC\n  (ORGANIZATION DrugAdministration/NNP)\n  (/(\n  (ORGANIZATION FDA/NNP)\n  )/)\n  recently/RB\n  recommended/VBD\n  removal/NN\n  of/IN\n  thebevacizumab/JJ\n  indication/NN\n  for/IN\n  breast/NN\n  cancer/NN\n  based/VBN\n  on/IN\n  the/DT\n  lackof/NN\n  signi\ufb01cant/JJ\n  clinical/JJ\n  bene\ufb01t/NN\n  in/IN\n  2/CD\n  breast/NN\n  cancer/NN\n  trials/NNS\n  [/VBP\n  47/CD\n  ]/NN\n  and/CC\n  the/DT\n  (ORGANIZATION FDA/NNP)\n  concurred/VBD\n  with/IN\n  this/DT\n  decision/NN\n  [/VBZ\n  48/CD\n  ]/NN\n  ./.\n  (PERSON Bevacizumab/NNP)\n  is/VBZ\n  also/RB\n  used/VBN\n  as/IN\n  a/DT\n  single/JJ\n  agent/NN\n  for/IN\n  patients/NNS\n  with/IN\n  glioblastomawho/NNS\n  have/VBP\n  progressive/JJ\n  disease/NN\n  following/VBG\n  prior/JJ\n  therapy/NN\n  ,/,\n  andin/JJ\n  combination/NN\n  with/IN\n  interferon-/JJ\n  /H9251for/NNP\n  metastatic/JJ\n  renal/NN\n  cell/NN\n  carcinoma/NN\n  ./.\n  3.1/CD\n  ./.\n  (PERSON Clinical/JJ)\n  trials/NNS\n  In/IN\n  a/DT\n  phase/NN\n  II/NNP\n  trial/NN\n  of/IN\n  99/CD\n  patients/NNS\n  with/IN\n  advanced/JJ\n  (ORGANIZATION NSCLC/NNP)\n  of/IN\n  all/DT\n  histologies/NNS\n  ,/,\n  patients/NNS\n  were/VBD\n  given/VBN\n  paclitaxel/NNS\n  and/CC\n  carbo-platin/NN\n  with/IN\n  or/CC\n  without/IN\n  bevacizumab/JJ\n  7.5/CD\n  or/CC\n  15/CD\n  mg/kg/NNS\n  [/VBD\n  49/CD\n  ]/NN\n  ./.\n  The/DT\n  results/NNS\n  of/IN\n  this/DT\n  study/NN\n  suggested/VBD\n  improved/JJ\n  ef\ufb01cacy/NN\n  fordoses/NNS\n  of/IN\n  15/CD\n  mg/kg/NNS\n  and/CC\n  7.5/CD\n  mg/kg/NN\n  bevacizumab/NN\n  combinedwith/NN\n  paclitaxel/NN\n  and/CC\n  carboplatin/NN\n  compared/VBN\n  with/IN\n  paclitaxel/NN\n  and/CC\n  carboplatin/NN\n  alone/RB\n  ,/,\n  including/VBG\n  a/DT\n  longer/JJR\n  time/NN\n  to/TO\n  progres-sion/NN\n  (/(\n  7.4/CD\n  months/NNS\n  vs/RB\n  4.2/CD\n  months/NNS\n  ;/:\n  P=/NNP\n  0.023/CD\n  )/)\n  and/CC\n  increase/VB\n  in/IN\n  (GPE OS/NNP)\n  (/(\n  17.7/CD\n  months/NNS\n  vs/RB\n  14.9/CD\n  months/NNS\n  ;/:\n  P=/NNP\n  0.63/CD\n  )/)\n  ./.\n  However/RB\n  ,/,\n  fatal/JJ\n  hemoptysis/NN\n  occurred/VBD\n  in/IN\n  4/CD\n  of/IN\n  the/DT\n  66/CD\n  patients/NNS\n  in/IN\n  thebevacizumab/JJ\n  arms/NNS\n  ./.\n  Analysis/NN\n  of/IN\n  these/DT\n  events/NNS\n  revealed/VBD\n  thatsquamous/JJ\n  histology/NN\n  was/VBD\n  associated/VBN\n  with/IN\n  the/DT\n  increased/VBN\n  riskof/NN\n  serious/JJ\n  pulmonary/JJ\n  hemorrhage/NN\n  [/VBD\n  49/CD\n  ]/NN\n  ,/,\n  resulting/VBG\n  in/IN\n  the/DT\n  exclusion/NN\n  of/IN\n  such/JJ\n  patients/NNS\n  from/IN\n  many/JJ\n  subsequent/JJ\n  trials/NNS\n  ofbevacizumab/VBP\n  ./.\n  Two/CD\n  phase/NN\n  (ORGANIZATION III/NNP)\n  trials/NNS\n  have/VBP\n  reported/VBN\n  signi\ufb01cantlyimproved/JJ\n  progression-free/JJ\n  survival/NN\n  (/(\n  (ORGANIZATION PFS/NNP)\n  )/)\n  and/CC\n  response/NN\n  rates/NNS\n  (/(\n  RR/NNP\n  )/)\n  with/IN\n  bevacizumab/NN\n  in/IN\n  combination/NN\n  with/IN\n  chemotherapyvs/JJ\n  chemotherapy/NN\n  alone/RB\n  as/IN\n  \ufb01rst-line/JJ\n  treatment/NN\n  of/IN\n  patients/NNS\n  withNSCLC/WDT\n  ./.\n  The/DT\n  phase/NN\n  (ORGANIZATION III/NNP E4599/NNP)\n  trial/NN\n  (/(\n  N=/NNP\n  878/CD\n  )/)\n  evaluated/VBD\n  the/DT\n  addition/NN\n  of/IN\n  bevacizumab/NN\n  15/CD\n  mg/kg/NN\n  to/TO\n  carboplatin/paclitaxelin/VB\n  chemonaive/JJ\n  patients/NNS\n  with/IN\n  advanced/JJ\n  (ORGANIZATION NSCLC/NNP)\n  of/IN\n  non-squamous/JJ\n  histology/NN\n  [/VBZ\n  50/CD\n  ]/NN\n  ./.\n  Signi\ufb01cant/JJ\n  improvements/NNS\n  in/IN\n  (GPE RR/NNP)\n  (/(\n  35/CD\n  %/NN\n  vs/JJ\n  15/CD\n  %/NN\n  ;/:\n  (PERSON P/NNP)\n  </NNP\n  0.001/CD\n  )/)\n  ,/,\n  (ORGANIZATION PFS/NNP)\n  (/(\n  6.2/CD\n  months/NNS\n  vs/RB\n  4.5/CD\n  months/NNS\n  ;/:\n  HR/NNP\n  ,/,\n  0.66/CD\n  ;/:\n  (PERSON P/NNP)\n  </NNP\n  0.001/CD\n  )/)\n  ,/,\n  and/CC\n  (ORGANIZATION OS/NNP)\n  (/(\n  12.3/CD\n  months/NNS\n  vs/RB\n  10.3/CD\n  months/NNS\n  ;/:\n  HR/NNP\n  ,/,\n  0.80/CD\n  ;/:\n  P=/NNP\n  0.003/CD\n  )/)\n  ,/,\n  were/VBD\n  observed/VBN\n  in/IN\n  the/DT\n  bevacizumab/NN\n  arm/NN\n  of/IN\n  this/DT\n  study/NN\n  ./.\n  Bevacizumab-related/JJ\n  toxicities/NNS\n  includedhematologic/JJ\n  events/NNS\n  ,/,\n  febrile/JJ\n  neutropenia/NN\n  ,/,\n  hypertension/NN\n  ,/,\n  andhemorrhage/NN\n  ./.\n  There/EX\n  were/VBD\n  15/CD\n  treatment-related/JJ\n  deaths/NNS\n  in/IN\n  thebevacizumab/JJ\n  arm/NN\n  ,/,\n  5/CD\n  of/IN\n  which/WDT\n  were/VBD\n  due/JJ\n  to/TO\n  hemorrhage/VB\n  ./.\n  Therewas/NNP\n  1/CD\n  death/NN\n  due/JJ\n  to/TO\n  gastrointestinal/JJ\n  hemorrhage/NN\n  and/CC\n  1/CD\n  deathdue/NN\n  to/TO\n  febrile/VB\n  neutropenia/NN\n  in/IN\n  the/DT\n  carboplatin/paclitaxel/NN\n  arm.The/JJ\n  phase/NN\n  (ORGANIZATION III/NNP)\n  A/NNP\n  V/NNP\n  AiL/NNP\n  trial/NN\n  (/(\n  N=/NNP\n  1043/CD\n  )/)\n  evaluated/VBD\n  the/DT\n  addi-/JJ\n  tion/NN\n  of/IN\n  bevacizumab/NN\n  (/(\n  7.5/CD\n  mg/kg/NN\n  or/CC\n  15/CD\n  mg/kg/NN\n  )/)\n  in/IN\n  combinationwith/NN\n  cisplatin/gemcitabine/NN\n  as/IN\n  \ufb01rst-line/JJ\n  therapy/NN\n  in/IN\n  patientswith/NN\n  advanced/VBD\n  nonsquamous/JJ\n  (ORGANIZATION NSCLC/NNP)\n  [/NNP\n  51/CD\n  ]/NNP\n  ./.\n  A/DT\n  very/RB\n  mod-/JJ\n  est/NN\n  but/CC\n  signi\ufb01cant/JJ\n  improvement/NN\n  in/IN\n  (ORGANIZATION PFS/NNP)\n  was/VBD\n  observed/VBN\n  withboth/RB\n  7.5/CD\n  mg/kg/NN\n  (/(\n  (ORGANIZATION HR/NNP)\n  ,/,\n  0.75/CD\n  ;/:\n  P=/NNP\n  0.0003/CD\n  )/)\n  and/CC\n  15/CD\n  mg/kg/NN\n  (/(\n  (ORGANIZATION HR/NNP)\n  ,/,\n  0.85/CD\n  ;/:\n  P=/NNP\n  0.0456/CD\n  )/)\n  doses/NNS\n  of/IN\n  bevacizumab/NN\n  ./.\n  RRs/NNP\n  were/VBD\n  also/RB\n  sig-/JJ\n  ni\ufb01cantly/RB\n  improved/VBN\n  with/IN\n  both/DT\n  7.5/CD\n  mg/kg/NN\n  (/(\n  37.8/CD\n  %/NN\n  vs/JJ\n  21.6/CD\n  %/NN\n  ;/:\n  (PERSON P/NNP)\n  </NNP\n  0.0001/CD\n  )/)\n  and/CC\n  15/CD\n  mg/kg/NN\n  (/(\n  34.6/CD\n  %/NN\n  vs/JJ\n  21.6/CD\n  %/NN\n  ;/:\n  P=/NNP\n  0.0002/CD\n  )/)\n  doses/NNS\n  of/IN\n  bevacizumab/NNS\n  compared/VBN\n  with/IN\n  placebo/NN\n  ;/:\n  however/RB\n  ,/,\n  therewas/VBZ\n  no/DT\n  statistically/RB\n  signi\ufb01cant/JJ\n  improvement/NN\n  in/IN\n  (ORGANIZATION OS/NNP)\n  [/NNP\n  51/CD\n  ]/NNP\n  ./.\n  The/DT\n  study/NN\n  did/VBD\n  not/RB\n  demonstrate/VB\n  a/DT\n  signi\ufb01cant/JJ\n  improvement/NN\n  in/IN\n  (GPE OS/NNP)\n  ,/,\n  and/CC\n  potential/JJ\n  explanations/NNS\n  could/MD\n  be/VB\n  the/DT\n  choice/NN\n  of/IN\n  chemother-apy/NN\n  that/WDT\n  was/VBD\n  administered/VBN\n  with/IN\n  bevacizumab/NN\n  and/CC\n  subsequenttreatment/NN\n  that/WDT\n  could/MD\n  have/VB\n  confounded/VBN\n  OS/NNP\n  [/$\n  51/CD\n  ]/NN\n  ./.\n  It/PRP\n  is/VBZ\n  notewor-/JJ\n  thy/NN\n  that/WDT\n  median/JJ\n  OS/NNP\n  in/IN\n  the/DT\n  control/NN\n  group/NN\n  of/IN\n  the/DT\n  A/NNP\n  V/NNP\n  AiL/NNP\n  trialwas/NN\n  markedly/RB\n  longer/RBR\n  than/IN\n  was/VBD\n  observed/VBN\n  in/IN\n  the/DT\n  (GPE E4599/NNP)\n  trial/NN\n  (/(\n  13.1/CD\n  months/NNS\n  vs/RB\n  10.3/CD\n  months/NNS\n  ,/,\n  respectively/RB\n  )/)\n  [/VBZ\n  50,51/CD\n  ]/NN\n  ./.\n  Many/JJ\n  factors/NNS\n  are/VBP\n  considered/VBN\n  during/IN\n  patient/JJ\n  selection/NN\n  in/IN\n  (GPE NSCLC/NNP)\n  ,/,\n  including/VBG\n  histology/NN\n  ,/,\n  appearance/NN\n  at/IN\n  bronchoscopy/NN\n  ,/,\n  history/NN\n  of/IN\n  hemoptysis/NN\n  ,/,\n  age/NN\n  ,/,\n  and/CC\n  comorbidities/NNS\n  ./.\n  Patient/JJ\n  selec-tion/NN\n  by/IN\n  tumor/NN\n  histology/NN\n  has/VBZ\n  greatly/RB\n  reduced/VBN\n  the/DT\n  incidenceof/JJ\n  adverse/JJ\n  events/NNS\n  ,/,\n  including/VBG\n  pulmonary/JJ\n  hemorrhage/NN\n  ,/,\n  asso-ciated/JJ\n  with/IN\n  bevacizumab/NN\n  in/IN\n  (GPE NSCLC/NNP)\n  clinical/JJ\n  trials/NNS\n  ./.\n  (PERSON Basedon/NNP)\n  safety/NN\n  data/NNS\n  from/IN\n  the/DT\n  phase/NN\n  II/NNP\n  trial/NN\n  [/VBD\n  49/CD\n  ]/NNS\n  ,/,\n  patients/NNS\n  with/IN\n  squamous/JJ\n  histology/NN\n  were/VBD\n  excluded/VBN\n  from/IN\n  the/DT\n  (GPE E4599/NNP)\n  phase/NN\n  (ORGANIZATION III/NNP)\n  trial/NN\n  ,/,\n  and/CC\n  the/DT\n  incidence/NN\n  of/IN\n  grade/NN\n  4/CD\n  or/CC\n  5/CD\n  bleeding/NN\n  eventsin/NN\n  the/DT\n  bevacizumab/NN\n  arm/NN\n  was/VBD\n  2.3/CD\n  %/NN\n  [/CC\n  50/CD\n  ]/NN\n  ./.\n  In/IN\n  the/DT\n  A/NNP\n  V/NNP\n  AiL/NNP\n  trial/NN\n  ,/,\n  which/WDT\n  adopted/VBD\n  an/DT\n  additional/JJ\n  exclusion/NN\n  of/IN\n  patients/NNS\n  withtumors/NNS\n  invading/VBG\n  or/CC\n  against/IN\n  blood/NN\n  vessels/NNS\n  ,/,\n  pulmonary/JJ\n  hemor-204/JJ\n  A./NN\n  (PERSON Wozniak/NNP)\n  //NNP\n  Critical/NNP\n  Reviews/NNP\n  in/IN\n  Oncology/Hematology/NNP\n  82/CD\n  (/(\n  2012/CD\n  )/)\n  200\u2013212/CD\n  Table/JJ\n  1/CD\n  Overview/NNP\n  of/IN\n  current/JJ\n  phase/NN\n  (ORGANIZATION III/NNP)\n  trials/NNS\n  of/IN\n  antiangiogenic/JJ\n  agents/NNS\n  for/IN\n  (ORGANIZATION NSCLC/NNP)\n  ./.\n  (PERSON Agent/NNP Patient/NNP)\n  selection/NN\n  Setting/VBG\n  (PERSON Trial/NNP)\n  identi\ufb01era/NN\n  (PERSON Antibodies/NNP A\ufb02ibercept/NNP Locally/NNP)\n  advanced/metastatic/JJ\n  nonsquamous/JJ\n  (ORGANIZATION NSCLC/NNP)\n  Second-line/NNP\n  combination/NN\n  with/IN\n  docetaxel/JJ\n  (ORGANIZATION NCT00532155Bevacizumab/NNP)\n  Stage/NNP\n  IIIB/IV/NNP\n  nonsquamous/JJ\n  (ORGANIZATION NSCLC/NNP)\n  ;/:\n  elderly/JJ\n  First-line/JJ\n  combination/NN\n  with/IN\n  pemetrexed/JJ\n  with/IN\n  or/CC\n  without/IN\n  (ORGANIZATION carboplatinNCT00976456/NNS Locally/NNP)\n  advanced/metastatic/JJ\n  nonsquamous/JJ\n  (ORGANIZATION NSCLC/NNP)\n  First-line/NNP\n  combination/NN\n  with/IN\n  gemcitabine/cisplatin/JJ\n  (ORGANIZATION NCT00806923/NNP Advanced/NNP)\n  ,/,\n  recurrent/NN\n  ,/,\n  or/CC\n  metastatic/JJ\n  (ORGANIZATION NSCLC/NNP Maintenance/NNP)\n  therapy/NN\n  combination/NN\n  with/IN\n  erlotinib/NN\n  (ORGANIZATION NCT00257608Advanced/NNP)\n  nonsquamous/JJ\n  (ORGANIZATION NSCLC/NNP)\n  Second-line/NNP\n  combination/NN\n  with/IN\n  erlotinib/JJ\n  (ORGANIZATION NCT00130728Stage/NNP)\n  IIIB/IV/NNP\n  nonsquamous/JJ\n  (ORGANIZATION NSCLC/NNP Maintenance/NNP)\n  therapy/NN\n  (ORGANIZATION NCT01107626Locally/NNP)\n  advanced/metastatic/JJ\n  nonsquamous/JJ\n  (ORGANIZATION NSCLC/NNP)\n  First-line/NNP\n  induction/NN\n  and/CC\n  maintenance/NN\n  therapy/NN\n  (ORGANIZATION NCT00961415Stage/NNP)\n  IIIB/IV/NNP\n  nonsquamous/JJ\n  (ORGANIZATION NSCLC/NNP)\n  First-line/NNP\n  induction/NN\n  and/CC\n  maintenance/NN\n  therapy/NN\n  (ORGANIZATION NCT00762034Stage/NNP)\n  IV/NNP\n  nonsquamous/JJ\n  (ORGANIZATION NSCLC/NNP)\n  First-line/NNP\n  induction/NN\n  and/CC\n  maintenance/NN\n  therapy/NN\n  (ORGANIZATION NCT00948675Stage/NNP)\n  IV/NNP\n  or/CC\n  recurrent/JJ\n  (ORGANIZATION NSCLC/NNP)\n  First-line/NNP\n  combination/NN\n  with/IN\n  carboplatin/paclitaxel/NN\n  and/CC\n  (ORGANIZATION cetuximabNCT00946712/JJ Stage/NNP)\n  IB-IIIA/NNP\n  NSCLC/NNP\n  Adjuvant/NNP\n  therapy/NN\n  following/VBG\n  surgical/JJ\n  resection/NN\n  (ORGANIZATION NCT00324805/NNP)\n  TKIs/NNP\n  BIBF/NNP\n  1120/CD\n  Stage/NNP\n  IIIB/IV/NNP\n  or/CC\n  recurrent/JJ\n  (ORGANIZATION NSCLC/NNP)\n  Second-line/NNP\n  combination/NN\n  with/IN\n  docetaxel/JJ\n  (ORGANIZATION NCT00805194/NNP)\n  Stage/NNP\n  IIIB/IV/NNP\n  or/CC\n  recurrent/NN\n  nonsquamous/JJ\n  (ORGANIZATION NSCLC/NNP)\n  Second-line/NNP\n  combination/NN\n  with/IN\n  pemetrexed/JJ\n  (ORGANIZATION NCT00806819/NNP Cediranib/NNP)\n  Stage/NNP\n  IIIB/IV/NNP\n  NSCLC/NNP\n  First-line/NNP\n  combination/NN\n  with/IN\n  paclitaxel/carboplatin/JJ\n  (ORGANIZATION NCT00795340/NNP)\n  Stage/NNP\n  IIIB/IV/NNP\n  NSCLC/NNP\n  First-line/NNP\n  combination/NN\n  with/IN\n  paclitaxel/carboplatin/JJ\n  (ORGANIZATION NCT00245154/NNP Motesanib/NNP)\n  Stage/NNP\n  IIIB/IV/NNP\n  nonsquamous/JJ\n  (ORGANIZATION NSCLC/NNP)\n  First-line/NNP\n  combination/NN\n  with/IN\n  paclitaxel/carboplatin/JJ\n  (ORGANIZATION NCT00460317Pazopanib/NNP)\n  Stage/NNP\n  I/PRP\n  (ORGANIZATION NSCLC/NNP Adjuvant/NNP)\n  therapy/NN\n  following/VBG\n  surgical/JJ\n  resection/NN\n  (ORGANIZATION NCT00775307Sorafenib/NNP)\n  Relapsed/VBD\n  or/CC\n  refractory/NN\n  advanced/VBN\n  predominantly/RB\n  nonsquamous/JJ\n  NSCLCThird-/NNP\n  or/CC\n  fourth-line/JJ\n  monotherapy/NN\n  (ORGANIZATION NCT00863746/NNP)\n  Stage/NNP\n  IIIB/IV/NNP\n  nonsquamous/JJ\n  (ORGANIZATION NSCLC/NNP)\n  First-line/NNP\n  combination/NN\n  with/IN\n  cisplatin/gemcitabine/JJ\n  (ORGANIZATION NCT00449033/NNP Sunitinib/NNP)\n  Stage/NNP\n  IIIB/IV/NNP\n  NSCLC/NNP\n  Maintenance/NNP\n  therapy/NN\n  (ORGANIZATION NCT00693992/NNP Locally/NNP)\n  advanced/metastatic/JJ\n  (ORGANIZATION NSCLC/NNP)\n  Second-/NNP\n  or/CC\n  third-line/JJ\n  combination/NN\n  with/IN\n  erlotinib/JJ\n  (ORGANIZATION NCT00457392/NNP)\n  NSCLC/NNP\n  ,/,\n  non-small/JJ\n  cell/NN\n  lung/NN\n  cancer/NN\n  ;/:\n  (ORGANIZATION TKI/NNP)\n  ,/,\n  tyrosine/JJ\n  kinase/NN\n  inhibitor/NN\n  ./.\n  (ORGANIZATION aAll/JJ)\n  trials/NNS\n  listed/VBN\n  have/VBP\n  been/VBN\n  initiated/VBN\n  and/CC\n  are/VBP\n  recruiting/VBG\n  patients/NNS\n  or/CC\n  ongoing/VBG\n  (/(\n  as/IN\n  of/IN\n  February/NNP\n  28/CD\n  ,/,\n  2011/CD\n  )/)\n  ./.\n  rhage/NN\n  occurred/VBD\n  in/IN\n  only/RB\n  1.5/CD\n  %/NN\n  of/IN\n  patients/NNS\n  in/IN\n  all/DT\n  arms/NNS\n  ,/,\n  despite/IN\n  an/DT\n  allowance/NN\n  for/IN\n  therapeutic/JJ\n  anticoagulation/NN\n  on-study/JJ\n  totreat/NN\n  venous/JJ\n  thrombosis/NN\n  [/VBD\n  51,52/CD\n  ]/NNP\n  ./.\n  Alternative/NNP\n  dosing/NN\n  of/IN\n  beva-/JJ\n  cizumab/NN\n  in/IN\n  combination/NN\n  with/IN\n  chemotherapy/NN\n  is/VBZ\n  currentlybeing/VBG\n  investigated/VBN\n  in/IN\n  patients/NNS\n  with/IN\n  (ORGANIZATION NSCLC/NNP)\n  of/IN\n  squamoushistology/NN\n  ,/,\n  who/WP\n  were/VBD\n  previously/RB\n  excluded/VBN\n  from/IN\n  treatment.The/NN\n  BRIDGE/NNP\n  trial/NN\n  evaluated/VBD\n  whether/IN\n  delayed/JJ\n  administrationof/NN\n  bevacizumab/NN\n  in/IN\n  combination/NN\n  with/IN\n  carboplatin/paclitaxelcould/JJ\n  improve/VB\n  safety/NN\n  in/IN\n  patients/NNS\n  with/IN\n  (ORGANIZATION NSCLC/NNP)\n  of/IN\n  squamoushistology/NN\n  [/$\n  53/CD\n  ]/NNP\n  ./.\n  Of/IN\n  31/CD\n  bevacizumab-treated/JJ\n  patients/NNS\n  ,/,\n  1/CD\n  (/(\n  3.2/CD\n  %/NN\n  )/)\n  had/VBD\n  a/DT\n  grade/NN\n  \u22653/NN\n  pulmonary/JJ\n  hemorrhage/NN\n  event/NN\n  ./.\n  Trials/NNS\n  to/TO\n  evaluate/VB\n  the/DT\n  feasibility/NN\n  of/IN\n  bevacizumab/NN\n  treatment/NN\n  in/IN\n  otherpatient/JJ\n  populations/NNS\n  excluded/VBD\n  from/IN\n  the/DT\n  (ORGANIZATION E4599/NNP)\n  and/CC\n  A/NNP\n  V/NNP\n  AiLtrials/NNP\n  ,/,\n  such/JJ\n  as/IN\n  those/DT\n  with/IN\n  brain/NN\n  metastases/NNS\n  ,/,\n  have/VBP\n  also/RB\n  beenperformed/VBN\n  ./.\n  In/IN\n  the/DT\n  phase/NN\n  II/NNP\n  PASSPORT/NNP\n  trial/NN\n  ,/,\n  of/IN\n  106/CD\n  safety-evaluable/JJ\n  patients/NNS\n  ,/,\n  no/DT\n  episodes/NNS\n  of/IN\n  grade/NN\n  \u22652/JJ\n  central/JJ\n  nervous/JJ\n  system/NN\n  hemorrhage/NN\n  were/VBD\n  reported/VBN\n  with/IN\n  bevacizumab/NN\n  [/$\n  54/CD\n  ]/NNP\n  ./.\n  Hypertension/NNP\n  ,/,\n  risk/NN\n  of/IN\n  bleeding/VBG\n  events/NNS\n  ,/,\n  and/CC\n  proteinuria/NNS\n  havealso/VBP\n  been/VBN\n  associated/VBN\n  with/IN\n  bevacizumab/NN\n  in/IN\n  (ORGANIZATION NSCLC/NNP)\n  [/NNP\n  55/CD\n  ]/NNP\n  ./.\n  The/DT\n  ongoing/JJ\n  phase/NN\n  (ORGANIZATION III/NNP)\n  ARIES/NNP\n  observational/JJ\n  cohort/NN\n  studyis/NN\n  evaluating/VBG\n  the/DT\n  safety/NN\n  of/IN\n  bevacizumab/NN\n  as/IN\n  \ufb01rst-line/JJ\n  treat-ment/NN\n  for/IN\n  (ORGANIZATION NSCLC/NNP)\n  in/IN\n  populations/NNS\n  that/WDT\n  include/VBP\n  patients/NNS\n  whoare/JJ\n  elderly/RB\n  ,/,\n  have/VBP\n  (ORGANIZATION ECOG/NNP)\n  PS/NNP\n  \u22652/NNP\n  ,/,\n  have/VBP\n  brain/NN\n  metastases/NNS\n  ,/,\n  or/CC\n  are/VBP\n  on/IN\n  therapeutic/JJ\n  anticoagulants/NNS\n  ./.\n  Preliminary/JJ\n  results/NNS\n  sug-gest/JJ\n  that/IN\n  rates/NNS\n  of/IN\n  targeted/JJ\n  adverse/JJ\n  events/NNS\n  and/CC\n  serious/JJ\n  adverseevents/NNS\n  were/VBD\n  similar/JJ\n  between/IN\n  the/DT\n  overall/JJ\n  population/NN\n  and/CC\n  thesecohorts/NNS\n  [/VBP\n  56,57/CD\n  ]/NN\n  ./.\n  The/DT\n  ef\ufb01cacy/NN\n  and/CC\n  tolerability/NN\n  of/IN\n  bevacizumab/NN\n  in/IN\n  the/DT\n  elderly/JJ\n  population/NN\n  were/VBD\n  retrospectively/RB\n  evaluated/VBN\n  insubset/NN\n  analyses/NNS\n  of/IN\n  the/DT\n  aforementioned/JJ\n  E4599/NNP\n  and/CC\n  A/NNP\n  V/NNP\n  AiL/NNP\n  tri-/JJ\n  als/NNS\n  ./.\n  Among/IN\n  elderly/JJ\n  patients/NNS\n  (/(\n  N=/NNP\n  224/CD\n  )/)\n  in/IN\n  the/DT\n  (GPE E4599/NNP)\n  study/NN\n  ,/,\n  addition/NN\n  of/IN\n  bevacizumab/NN\n  to/TO\n  \ufb01rst-line/VB\n  carboplatin/paclitaxeldid/NN\n  not/RB\n  signi\ufb01cantly/RB\n  improve/VB\n  outcomes/NNS\n  (/(\n  (ORGANIZATION RR/NNP)\n  ,/,\n  (ORGANIZATION PFS/NNP)\n  ,/,\n  or/CC\n  OS/NNP\n  )/)\n  but/CC\n  was/VBD\n  associated/VBN\n  with/IN\n  a/DT\n  signi\ufb01cantly/RB\n  higher/JJR\n  incidence/NN\n  ofgrade/VBD\n  \u22653/JJ\n  toxicities/NNS\n  vs/VBP\n  chemotherapy/NN\n  alone/RB\n  (/(\n  87/CD\n  %/NN\n  vs/JJ\n  61/CD\n  %/NN\n  ,/,\n  respectively/RB\n  ;/:\n  (PERSON P/NNP)\n  </NNP\n  0.001/CD\n  )/)\n  [/VBD\n  58/CD\n  ]/NN\n  ./.\n  In/IN\n  contrast/NN\n  ,/,\n  bevacizumab-based/JJ\n  therapy/NN\n  (/(\n  7.5/CD\n  mg/kg/NN\n  dose/NN\n  only/RB\n  )/)\n  was/VBD\n  associated/VBN\n  with/IN\n  (ORGANIZATION PFS/NNP)\n  bene-\ufb01t/NN\n  in/IN\n  the/DT\n  elderly/JJ\n  subpopulation/NN\n  of/IN\n  the/DT\n  A/NNP\n  V/NNP\n  AiL/NNP\n  study/NN\n  (/(\n  N=/NNP\n  304/CD\n  )/)\n  vs/NN\n  chemotherapy/NN\n  alone/RB\n  ,/,\n  with/IN\n  no/DT\n  particular/JJ\n  safety/NN\n  concernswith/NN\n  either/DT\n  bevacizumab/NN\n  dose/VBD\n  [/JJ\n  59/CD\n  ]/NN\n  ./.\n  Recent/JJ\n  research/NN\n  with/IN\n  bevacizumab/NN\n  in/IN\n  (GPE NSCLC/NNP)\n  has/VBZ\n  focused/VBN\n  on/IN\n  evaluating/VBG\n  variables/NNS\n  of/IN\n  treatment/NN\n  with/IN\n  chemotherapy/NN\n  (/(\n  e.g./JJ\n  ,/,\n  dose/NN\n  of/IN\n  bevacizumab/NN\n  ,/,\n  choice/NN\n  of/IN\n  chemotherapy/NN\n  ,/,\n  whether/IN\n  and/CC\n  how/WRB\n  bevacizumab/NN\n  is/VBZ\n  bene\ufb01cial/JJ\n  as/IN\n  maintenancetherapy/NN\n  )/)\n  and/CC\n  the/DT\n  combination/NN\n  of/IN\n  bevacizumab/NN\n  with/IN\n  (ORGANIZATION EGFRinhibitors/NNS)\n  (/(\n  Table/JJ\n  1/CD\n  )/)\n  ./.\n  The/DT\n  (ORGANIZATION ATLAS/NNP)\n  trial/NN\n  (/(\n  (ORGANIZATION NCT00257608/NNP)\n  )/)\n  is/VBZ\n  evaluating/VBG\n  erlotinib/NN\n  or/CC\n  placebo/NN\n  in/IN\n  combination/NN\n  withbevacizumab/NN\n  as/IN\n  maintenance/NN\n  therapy/NN\n  in/IN\n  patients/NNS\n  withadvanced/JJ\n  NSCLC/NNP\n  who/WP\n  did/VBD\n  not/RB\n  have/VB\n  disease/NN\n  progressionfollowing/VBG\n  treatment/NN\n  with/IN\n  bevacizumab/NN\n  and/CC\n  chemotherapy.Preliminary/JJ\n  results/NNS\n  from/IN\n  768/CD\n  evaluable/JJ\n  patients/NNS\n  reported/VBD\n  asigni\ufb01cant/JJ\n  improvement/NN\n  in/IN\n  median/JJ\n  (ORGANIZATION PFS/NNP)\n  with/IN\n  bevacizumaband/NN\n  erlotinib/NN\n  vs/NN\n  bevacizumab/NN\n  and/CC\n  placebo/NN\n  (/(\n  4.8/CD\n  monthsvs/RB\n  3.7/CD\n  months/NNS\n  ;/:\n  HR/NNP\n  ,/,\n  0.722/CD\n  ;/:\n  P=/NNP\n  0.0012/CD\n  )/)\n  ,/,\n  but/CC\n  no/DT\n  improve-/JJ\n  ment/NN\n  in/IN\n  (GPE OS/NNP)\n  (/(\n  15.9/CD\n  vs/RB\n  13.9/CD\n  months/NNS\n  ;/:\n  HR/NNP\n  ,/,\n  0.90/CD\n  ;/:\n  P=/NNP\n  0.2686/CD\n  )/)\n  [/VBD\n  60,61/CD\n  ]/NN\n  ./.\n  The/DT\n  (ORGANIZATION BeTa/NNP)\n  phase/NN\n  (ORGANIZATION III/NNP)\n  trial/NN\n  evaluated/VBD\n  the/DT\n  addition/NN\n  of/IN\n  bevacizumab/NN\n  to/TO\n  erlotinib/VB\n  as/IN\n  second-line/JJ\n  therapy/NN\n  (ORGANIZATION inA/NN)\n  ./.\n  (PERSON Wozniak/NNP)\n  //NNP\n  Critical/NNP\n  Reviews/NNP\n  in/IN\n  Oncology/Hematology/NNP\n  82/CD\n  (/(\n  2012/CD\n  )/)\n  200\u2013212/CD\n  205/CD\n  patients/NNS\n  with/IN\n  (ORGANIZATION NSCLC/NNP)\n  ./.\n  Although/IN\n  (ORGANIZATION OS/NNP)\n  was/VBD\n  not/RB\n  signi\ufb01cantly/RB\n  different/JJ\n  with/IN\n  the/DT\n  addition/NN\n  of/IN\n  bevacizumab/NN\n  vs/NN\n  placebo/NN\n  (/(\n  9.3/CD\n  months/NNS\n  vs/RB\n  9.2/CD\n  months/NNS\n  ;/:\n  HR/NNP\n  ,/,\n  0.97/CD\n  ;/:\n  95/CD\n  %/NN\n  con\ufb01denceinterval/NN\n  [/NNP\n  CI/NNP\n  ]/NNP\n  ,/,\n  0.80\u20131.18/CD\n  ;/:\n  P=/NNP\n  0.75/CD\n  )/)\n  ,/,\n  signi\ufb01cant/JJ\n  improvements/NNS\n  were/VBD\n  observed/VBN\n  in/IN\n  (GPE PFS/NNP)\n  (/(\n  3.4/CD\n  months/NNS\n  vs/RB\n  1.7/CD\n  months/NNS\n  ;/:\n  HR/NNP\n  ,/,\n  0.62/CD\n  ;/:\n  95/CD\n  %/NN\n  CI/NNP\n  ,/,\n  0.52\u20130.75/CD\n  ;/:\n  (PERSON P/NNP)\n  </NNP\n  0.0001/CD\n  )/)\n  and/CC\n  overall/JJ\n  RR/NNP\n  (/(\n  12.6/CD\n  %/NN\n  vs/JJ\n  6.2/CD\n  %/NN\n  ;/:\n  P=/NNP\n  0.006/CD\n  )/)\n  [/VBD\n  62/CD\n  ]/NN\n  ./.\n  The/DT\n  effectiveness/NN\n  of/IN\n  bevacizumab/NN\n  combined/VBN\n  with/IN\n  erlotinib/NN\n  is/VBZ\n  being/VBG\n  evaluated/VBN\n  in/IN\n  phase/NN\n  IItrials/NNS\n  as/IN\n  \ufb01rst-line/JJ\n  therapy/NN\n  (/(\n  (ORGANIZATION NCT00585377/NNP)\n  ,/,\n  (ORGANIZATION NCT00976677/NNP)\n  ,/,\n  (ORGANIZATION NCT01116219/NNP)\n  ,/,\n  and/CC\n  (ORGANIZATION NCT00531960/NNP)\n  )/)\n  ,/,\n  as/IN\n  second-line/JJ\n  ther-apy/NN\n  (/(\n  (ORGANIZATION NCT00553800/NNP)\n  ,/,\n  (ORGANIZATION NCT00749567/NNP)\n  ,/,\n  (ORGANIZATION NCT00280150/NNP)\n  ,/,\n  (ORGANIZATION NCT00445848/NNP)\n  ,/,\n  (ORGANIZATION NCT00800202/NNP)\n  ,/,\n  (ORGANIZATION NCT00436332/NNP)\n  ,/,\n  (ORGANIZATION andNCT00585377/NN)\n  )/)\n  ,/,\n  as/IN\n  adjuvant/JJ\n  therapy/NN\n  after/IN\n  resection/NN\n  forearly/RB\n  stage/JJ\n  disease/NN\n  (/(\n  (ORGANIZATION NCT00675597/NNP)\n  )/)\n  ,/,\n  and/CC\n  as/IN\n  maintenancetherapy/NN\n  (/(\n  (ORGANIZATION NCT00621049/NNP)\n  )/)\n  in/IN\n  patients/NNS\n  with/IN\n  (ORGANIZATION NSCLC/NNP)\n  ./.\n  Thephase/NNP\n  III/NNP\n  A/NNP\n  V/NNP\n  APERL1/NNP\n  trial/NN\n  (/(\n  (ORGANIZATION NCT00961415/NNP)\n  )/)\n  is/VBZ\n  evaluatingbevacizumab/JJ\n  with/IN\n  or/CC\n  without/IN\n  pemetrexed/JJ\n  as/IN\n  mainte-nance/NN\n  therapy/NN\n  in/IN\n  patients/NNS\n  with/IN\n  advanced/JJ\n  nonsquamousNSCLC/NNS\n  who/WP\n  responded/VBD\n  to/TO\n  treatment/NN\n  with/IN\n  bevacizumabin/JJ\n  combination/NN\n  with/IN\n  cisplatin/pemetrexed/JJ\n  ./.\n  Estimatedenrollment/NN\n  is/VBZ\n  362/CD\n  and/CC\n  the/DT\n  trial/NN\n  is/VBZ\n  expected/VBN\n  to/TO\n  be/VB\n  completein/JJ\n  December/NNP\n  2011/CD\n  ./.\n  The/DT\n  phase/NN\n  (ORGANIZATION III/NNP)\n  POINTBREAK/NNP\n  trial/NN\n  ,/,\n  which/WDT\n  recently/RB\n  completed/VBD\n  accrual/JJ\n  ,/,\n  randomized/VBN\n  patientswith/NN\n  advanced/VBD\n  nonsquamous/JJ\n  NSCLC/NNP\n  to/TO\n  receive/VB\n  carbo-platin/paclitaxel/bevacizumab/NN\n  followed/VBN\n  by/IN\n  bevacizumab/NN\n  orcarboplatin/pemetrexed/bevacizumab/NN\n  followed/VBN\n  by/IN\n  peme-trexed/bevacizumab/JJ\n  [/NN\n  63/CD\n  ]/NN\n  ./.\n  In/IN\n  another/DT\n  phase/NN\n  (ORGANIZATION III/NNP)\n  trial/NN\n  by/IN\n  the/DT\n  (LOCATION Eastern/NNP Cooperative/NNP)\n  (ORGANIZATION Oncology/NNP Group/NNP)\n  ,/,\n  patients/NNS\n  will/MD\n  receivecarboplatin/paclitaxel/bevacizumab/VB\n  as/IN\n  an/DT\n  induction/NN\n  therapyfor/VBZ\n  up/IN\n  to/TO\n  4/CD\n  treatment/NN\n  cycles/NNS\n  of/IN\n  21/CD\n  days/NNS\n  ,/,\n  followed/VBN\n  by/IN\n  amaintenance/NN\n  therapy/NN\n  of/IN\n  either/DT\n  pemetrexed/NN\n  or/CC\n  bevacizumab/NN\n  ,/,\n  or/CC\n  bevacizumab/pemetrexed/NN\n  (/(\n  (ORGANIZATION NCT01107626/NNP)\n  )/)\n  ./.\n  Trials/NNS\n  ofantiangiogenic/JJ\n  agents/NNS\n  in/IN\n  other/JJ\n  patient/JJ\n  populations/NNS\n  ,/,\n  such/JJ\n  asthe/JJ\n  elderly/JJ\n  and/CC\n  those/DT\n  with/IN\n  poor/JJ\n  PS/NNP\n  ,/,\n  are/VBP\n  also/RB\n  being/VBG\n  conducted/VBN\n  (/(\n  (ORGANIZATION NCT00976456/NNP)\n  and/CC\n  (ORGANIZATION NCT00892710/NNP)\n  )/)\n  ./.\n  Ongoing/VBG\n  phase/NN\n  IIItrials/NNS\n  of/IN\n  bevacizumab/NN\n  and/CC\n  other/JJ\n  antiangiogenic/JJ\n  agents/NNS\n  indevelopment/NN\n  for/IN\n  (ORGANIZATION NSCLC/NNP)\n  are/VBP\n  summarized/VBN\n  in/IN\n  Table/JJ\n  1/CD\n  ./.\n  3.2/CD\n  ./.\n  Current/JJ\n  treatment/NN\n  challenges/NNS\n  Although/IN\n  the/DT\n  potential/NN\n  for/IN\n  using/VBG\n  bevacizumab/NN\n  in/IN\n  previ-/JJ\n  ously/RB\n  excluded/VBN\n  patient/JJ\n  populations/NNS\n  is/VBZ\n  being/VBG\n  investigated/VBN\n  inclinical/JJ\n  trials/NNS\n  (/(\n  Section/NNP\n  3.1/CD\n  )/)\n  ,/,\n  currently/RB\n  ,/,\n  only/RB\n  a/DT\n  select/JJ\n  number/NN\n  of/IN\n  patients/NNS\n  are/VBP\n  eligible/JJ\n  for/IN\n  treatment/NN\n  ./.\n  For/IN\n  example/NN\n  ,/,\n  bevacizumabis/VBZ\n  not/RB\n  indicated/VBN\n  for/IN\n  patients/NNS\n  with/IN\n  hemorrhage/NN\n  or/CC\n  recenthemoptysis/NN\n  [/VBP\n  46/CD\n  ]/NN\n  ./.\n  In/IN\n  addition/NN\n  ,/,\n  while/IN\n  the/DT\n  development/NN\n  and/CC\n  approval/NN\n  of/IN\n  bevacizumab/NN\n  for/IN\n  (ORGANIZATION NSCLC/NNP)\n  has/VBZ\n  been/VBN\n  an/DT\n  achieve-ment/NN\n  of/IN\n  targeted/JJ\n  therapy/NN\n  and/CC\n  antiangiogenic/JJ\n  therapy/NN\n  ,/,\n  whencombined/VBN\n  with/IN\n  chemotherapy/NN\n  ,/,\n  bevacizumab/NN\n  resulted/VBD\n  in/IN\n  onlya/JJ\n  modest/JJ\n  improvement/NN\n  in/IN\n  (GPE OS/NNP)\n  (/(\n  12.3/CD\n  months/NNS\n  vs/RB\n  10.3/CD\n  months/NNS\n  ;/:\n  HR/NNP\n  ,/,\n  0.79/CD\n  ;/:\n  P=/NNP\n  0.003/CD\n  )/)\n  in/IN\n  1/CD\n  phase/NN\n  (ORGANIZATION III/NNP)\n  trial/NN\n  [/VBD\n  50/CD\n  ]/NN\n  ./.\n  In/IN\n  another/DT\n  trial/NN\n  ,/,\n  while/IN\n  (ORGANIZATION PFS/NNP)\n  was/VBD\n  signi\ufb01cantly/RB\n  longer/RBR\n  with/IN\n  bevacizumab/NN\n  ,/,\n  (ORGANIZATION OSwas/NNP)\n  not/RB\n  improved/VBD\n  [/JJ\n  51/CD\n  ]/NN\n  ./.\n  Resistance/NN\n  to/TO\n  (ORGANIZATION VEGF/NNP)\n  therapy/NN\n  has/VBZ\n  been/VBN\n  reported/VBN\n  in/IN\n  preclinical/JJ\n  models/NNS\n  [/VBP\n  43,64,65/CD\n  ]/NNS\n  and/CC\n  may/MD\n  explain/VB\n  these/DT\n  modest/JJ\n  bene\ufb01ts/NN\n  ./.\n  A/DT\n  better/JJR\n  understanding/NN\n  of/IN\n  the/DT\n  mech-anisms/NNS\n  of/IN\n  (ORGANIZATION VEGF/NNP)\n  therapy/NN\n  resistance/NN\n  will/MD\n  assist/VB\n  in/IN\n  predictingTable/JJ\n  2/CD\n  Targets/NNS\n  of/IN\n  antiangiogenic/JJ\n  agents/NNS\n  currently/RB\n  in/IN\n  development/NN\n  for/IN\n  (ORGANIZATION NSCLC/NNP)\n  ./.\n  (PERSON Agent/NNP Targeta/NNP Antibodies/NNP)\n  IMC-1121B/NNP\n  VEGFR-2A\ufb02ibercept/NNP\n  VEGF-A/NNP\n  ,/,\n  (ORGANIZATION PlGFBevacizumab/NNP)\n  VEGF/NNP\n  TKIs/NNP\n  Axitinib/NNP\n  VEGFR/NNP\n  ,/,\n  (ORGANIZATION PDGFR/NNP)\n  ,/,\n  c-kitBIBF/JJ\n  1120/CD\n  VEGFR/NNP\n  ,/,\n  FLT-3/NNP\n  ,/,\n  (ORGANIZATION PDGFR/NNP)\n  ,/,\n  (ORGANIZATION FGFR/NNP)\n  ,/,\n  (PERSON Src/NNP)\n  ,/,\n  (ORGANIZATION LynCediranib/NNP)\n  VEGFR/NNP\n  ,/,\n  c-kit/NN\n  ,/,\n  (ORGANIZATION PDGFR/NNP)\n  ,/,\n  FLT-3Motesanib/NNP\n  VEGFR/NNP\n  ,/,\n  c-kit/NN\n  ,/,\n  (ORGANIZATION RET/NNP)\n  ,/,\n  (ORGANIZATION PDGFRPazopanib/NNP)\n  VEGFR/NNP\n  ,/,\n  (ORGANIZATION PDGFR/NNP)\n  ,/,\n  c-kit/NN\n  ,/,\n  (ORGANIZATION FGFRSorafenib/NNP Raf/NNP)\n  ,/,\n  (ORGANIZATION VEGFR/NNP)\n  ,/,\n  (ORGANIZATION PDGFR/NNP)\n  ,/,\n  (ORGANIZATION FLT3/NNP)\n  ,/,\n  c-kit/JJ\n  (ORGANIZATION Sunitinib/NNP)\n  VEGFR/NNP\n  ,/,\n  (ORGANIZATION PDGFR/NNP)\n  ,/,\n  c-kit/JJ\n  ,/,\n  FLT-3/NNP\n  ,/,\n  (ORGANIZATION RET/NNP)\n  ,/,\n  CSF-1R/NNP\n  b/NN\n  (PERSON Vandetanib/NNP VEGFR-2/NNP)\n  ,/,\n  VEGFR-3/NNP\n  ,/,\n  (ORGANIZATION RET/NNP)\n  ,/,\n  (ORGANIZATION EGFR/NNP)\n  c-kit/NN\n  ,/,\n  stem/NN\n  cell/NN\n  factor/NN\n  receptor/NN\n  ;/:\n  CSF-1R/NNP\n  ,/,\n  colony/NN\n  stimulating/VBG\n  factor/NN\n  1/CD\n  receptor/NN\n  ;/:\n  (ORGANIZATION FGFR/NNP)\n  ,/,\n  \ufb01broblast/NNP\n  growth/NN\n  factor/NN\n  receptor/NN\n  ;/:\n  FLT-3/NNP\n  ,/,\n  fms-like/JJ\n  tyrosine/JJ\n  kinase-3/NN\n  ;/:\n  (ORGANIZATION NSCLC/NNP)\n  ,/,\n  non-small/JJ\n  cell/NN\n  lung/NN\n  cancer/NN\n  ;/:\n  (ORGANIZATION PDGFR/NNP)\n  ,/,\n  platelet-derived/JJ\n  growth/NN\n  fac-tor/JJ\n  receptor/NN\n  ;/:\n  (ORGANIZATION PlGF/NNP)\n  ,/,\n  placental/JJ\n  growth/NN\n  factor/NN\n  ;/:\n  (PERSON Raf/NNP)\n  ,/,\n  v-raf/JJ\n  1/CD\n  murine/JJ\n  leukemiaviral/JJ\n  oncogene/NN\n  homolog/NN\n  1/CD\n  ;/:\n  (ORGANIZATION RET/NNP)\n  ,/,\n  rearranged/VBD\n  during/IN\n  transfection/NN\n  ;/:\n  (ORGANIZATION TKI/NNP)\n  ,/,\n  tyro-sine/JJ\n  kinase/NN\n  inhibitor/NN\n  ;/:\n  (ORGANIZATION VEGF/NNP)\n  ,/,\n  vascular/JJ\n  endothelial/JJ\n  growth/NN\n  factor/NN\n  ;/:\n  (ORGANIZATION VEGFR/NNP)\n  ,/,\n  vascular/JJ\n  endothelial/JJ\n  growth/NN\n  factor/NN\n  receptor/NN\n  ./.\n  aTargets/NNS\n  are/VBP\n  listed/VBN\n  in/IN\n  order/NN\n  of/IN\n  potency/NN\n  ./.\n  (ORGANIZATION bTarget/NN)\n  for/IN\n  which/WDT\n  potency/NN\n  is/VBZ\n  not/RB\n  available/JJ\n  ./.\n  which/WDT\n  patients/NNS\n  are/VBP\n  most/RBS\n  likely/JJ\n  to/TO\n  bene\ufb01t/VB\n  from/IN\n  bevacizumab/JJ\n  treatment/NN\n  [/VBD\n  65/CD\n  ]/NN\n  ./.\n  Because/IN\n  single-target/JJ\n  antiangiogenic/JJ\n  agents/NNS\n  are/VBP\n  currently/RB\n  selected/VBN\n  by/IN\n  exclusion/NN\n  only/RB\n  ,/,\n  predictive/JJ\n  biomark-ers/NNS\n  are/VBP\n  needed/VBN\n  to/TO\n  guide/VB\n  the/DT\n  personalized/JJ\n  use/NN\n  of/IN\n  these/DT\n  agentsfor/JJ\n  treatment/NN\n  of/IN\n  (ORGANIZATION NSCLC/NNP)\n  ./.\n  Multitargeted/NNP\n  antiangiogenic/JJ\n  agentsinhibit/NN\n  multiple/JJ\n  members/NNS\n  of/IN\n  the/DT\n  (ORGANIZATION VEGFR/NNP)\n  family/NN\n  and/or/NN\n  othermediators/NNS\n  of/IN\n  angiogenesis/NN\n  ,/,\n  such/JJ\n  as/IN\n  (ORGANIZATION FGFRs/NNP)\n  and/CC\n  (ORGANIZATION PDGFRs/NNP)\n  ;/:\n  itis/NN\n  hoped/VBD\n  that/IN\n  targeting/VBG\n  multiple/JJ\n  pathways/NNS\n  will/MD\n  result/VB\n  in/IN\n  moredurable/JJ\n  clinical/JJ\n  bene\ufb01t/NN\n  as/IN\n  they/PRP\n  target/VBP\n  multiple/JJ\n  angiogenicpathways/NNS\n  ./.\n  Some/DT\n  of/IN\n  these/DT\n  agents/NNS\n  are/VBP\n  being/VBG\n  investigated/VBN\n  (ORGANIZATION inNSCLC/NN)\n  and/CC\n  they/PRP\n  are/VBP\n  listed/VBN\n  along/IN\n  with/IN\n  their/PRP$\n  targets/NNS\n  in/IN\n  Table/JJ\n  2/CD\n  ;/:\n  however/RB\n  ,/,\n  initial/JJ\n  results/NNS\n  have/VBP\n  not/RB\n  been/VBN\n  that/IN\n  encouraging/VBG\n  ./.\n  4/CD\n  ./.\n  Antiangiogenic/JJ\n  agents/NNS\n  in/IN\n  development/NN\n  for/IN\n  (ORGANIZATION NSCLC/NNP)\n  4.1/CD\n  ./.\n  Antiangiogenic/JJ\n  antibodies/NNS\n  A\ufb02ibercept/NNP\n  or/CC\n  A/NNP\n  V0005/NNP\n  (/(\n  (ORGANIZATION VEGF/NNP Trap/NNP)\n  ,/,\n  (GPE Regeneron/NNP)\n  ;/:\n  Tarry-/NNP\n  town/NN\n  ,/,\n  (ORGANIZATION NY/NNP)\n  ,/,\n  (ORGANIZATION USA/NNP)\n  )/)\n  is/VBZ\n  an/DT\n  antiangiogenic/JJ\n  peptide-antibody/NN\n  fusionthat/WP\n  contains/VBZ\n  portions/NNS\n  of/IN\n  human/JJ\n  VEGFR-1/NNP\n  and/CC\n  -2/NNP\n  [/NNP\n  66/CD\n  ]/NNP\n  .I/NNP\n  ti/NN\n  s/NN\n  in/IN\n  phase/NN\n  (ORGANIZATION III/NNP)\n  clinical/JJ\n  development/NN\n  for/IN\n  several/JJ\n  malignancies/NNS\n  ,/,\n  including/VBG\n  colorectal/NN\n  ,/,\n  pancreatic/JJ\n  ,/,\n  prostate/NN\n  ,/,\n  and/CC\n  ovarian/JJ\n  can-cer/NN\n  ,/,\n  in/IN\n  addition/NN\n  to/TO\n  (ORGANIZATION NSCLC/NNP)\n  ./.\n  Phase/NNP\n  I/PRP\n  studies/NNS\n  in/IN\n  solid/JJ\n  tumorswere/RB\n  well/RB\n  tolerated/VBN\n  and/CC\n  showed/VBD\n  evidence/NN\n  of/IN\n  (ORGANIZATION VEGF/NNP)\n  blockade/VBD\n  [/$\n  66/CD\n  ]/NNP\n  ./.\n  A/NNP\n  phase/NN\n  II/NNP\n  trial/NN\n  of/IN\n  single-agent/JJ\n  a\ufb02ibercept/NN\n  in/IN\n  98/CD\n  patients/NNS\n  with/IN\n  platinum-/JJ\n  and/CC\n  erlotinib-resistant/JJ\n  lung/NN\n  adenocarcinomashowed/VBD\n  overall/JJ\n  RR/NNP\n  of/IN\n  2/CD\n  %/NN\n  (/(\n  95/CD\n  %/NN\n  CI/NNP\n  ,/,\n  0.2\u20137.2/CD\n  )/)\n  ,/,\n  median/JJ\n  (ORGANIZATION PFS/NNP)\n  of2.7/MD\n  months/NNS\n  (/(\n  95/CD\n  %/NN\n  CI/NNP\n  ,/,\n  2.2\u20133.4/CD\n  )/)\n  ,/,\n  and/CC\n  median/JJ\n  OS/NNP\n  of/IN\n  6.2/CD\n  months/NNS\n  (/(\n  95/CD\n  %/NN\n  CI/NNP\n  ,/,\n  4.8\u201311.4/CD\n  )/)\n  [/VBD\n  67/CD\n  ]/NN\n  ./.\n  The/DT\n  most/RBS\n  common/JJ\n  grade/NN\n  3/CD\n  and/CC\n  4/CD\n  adverse/JJ\n  events/NNS\n  included/VBD\n  proteinuria/NN\n  ,/,\n  hypertension/NN\n  ,/,\n  and/CC\n  dys-pnea/NN\n  ./.\n  There/EX\n  were/VBD\n  2/CD\n  treatment-related/JJ\n  fatalities/NNS\n  ,/,\n  both/DT\n  weregrade/VBP\n  5/CD\n  hemoptysis/NN\n  [/VBD\n  67/CD\n  ]/NNP\n  ./.\n  A/DT\n  phase/NN\n  (ORGANIZATION III/NNP)\n  trial/NN\n  (/(\n  (ORGANIZATION NCT00532155/NNP)\n  )/)\n  206/CD\n  A./NN\n  (PERSON Wozniak/NNP)\n  //NNP\n  Critical/NNP\n  Reviews/NNP\n  in/IN\n  Oncology/Hematology/NNP\n  82/CD\n  (/(\n  2012/CD\n  )/)\n  200\u2013212/CD\n  of/IN\n  a\ufb02ibercept/NN\n  in/IN\n  combination/NN\n  with/IN\n  docetaxel/NN\n  as/IN\n  second-line/JJ\n  therapy/NN\n  in/IN\n  patients/NNS\n  with/IN\n  advanced/JJ\n  (ORGANIZATION NSCLC/NNP)\n  is/VBZ\n  ongoing/VBG\n  ./.\n  Another/DT\n  anti-VEGFR-2/JJ\n  monoclonal/NN\n  antibody/NN\n  ,/,\n  1MC-/JJ\n  1121B/CD\n  (/(\n  (ORGANIZATION ImClone/NNP Systems/NNP)\n  ,/,\n  (GPE Inc./NNP)\n  ;/:\n  (GPE New/NNP York/NNP)\n  ,/,\n  (ORGANIZATION NY/NNP)\n  ,/,\n  (ORGANIZATION USA/NNP)\n  )/)\n  ,/,\n  isin/JJ\n  phase/NN\n  (ORGANIZATION III/NNP)\n  clinical/JJ\n  development/NN\n  for/IN\n  breast/NN\n  and/CC\n  gastric/JJ\n  can-cer/NN\n  ./.\n  IMC-1121B/NNP\n  is/VBZ\n  also/RB\n  being/VBG\n  evaluated/VBN\n  in/IN\n  a/DT\n  phase/NN\n  II/NNP\n  trial/NN\n  (/(\n  (ORGANIZATION NCT00735696/NNP)\n  )/)\n  in/IN\n  combination/NN\n  with/IN\n  carboplatin/paclitaxelas/JJ\n  \ufb01rst-line/JJ\n  therapy/NN\n  in/IN\n  patients/NNS\n  with/IN\n  advanced/JJ\n  (ORGANIZATION NSCLC/NNP)\n  ./.\n  4.2/CD\n  ./.\n  Multitargeted/VBN\n  antiangiogenic/JJ\n  TKIs/NNP\n  4.2.1/CD\n  ./.\n  (PERSON Sorafenib/NNP Sorafenib/NNP)\n  ,/,\n  or/CC\n  (ORGANIZATION Bay/NNP)\n  43-9006/JJ\n  (/(\n  (ORGANIZATION Nexavar/NNP)\n  \u00ae/NNP\n  ,/,\n  (GPE Bayer/NNP)\n  ;/:\n  Lev-/NNP\n  erkusen/NN\n  ,/,\n  (GPE Germany/NNP)\n  )/)\n  ,/,\n  is/VBZ\n  a/DT\n  small/JJ\n  molecule/NN\n  that/IN\n  targetsproliferation/NN\n  by/IN\n  inhibiting/VBG\n  (PERSON Raf/NNP)\n  ,/,\n  stem/NN\n  cell/NN\n  factor/NN\n  receptor/NN\n  (/(\n  c-kit/NN\n  )/)\n  ,/,\n  and/CC\n  fms-like/JJ\n  tyrosine/NN\n  kinase-3/NN\n  (/(\n  FLT-3/NNP\n  )/)\n  ./.\n  It/PRP\n  also/RB\n  targetsangiogenesis/NN\n  by/IN\n  inhibiting/VBG\n  VEGFR-2/NNP\n  and/CC\n  -3/NNP\n  and/CC\n  PDGFR-/H9252/NNP\n  [/NNP\n  68/CD\n  ]/NNP\n  ./.\n  (PERSON Sorafenib/NNP)\n  is/VBZ\n  approved/VBN\n  by/IN\n  the/DT\n  (ORGANIZATION FDA/NNP)\n  for/IN\n  treatment/NN\n  of/IN\n  patients/NNS\n  with/IN\n  hepatocellular/JJ\n  carcinoma/NN\n  and/CC\n  for/IN\n  those/DT\n  withadvanced/JJ\n  renal/JJ\n  cell/NN\n  carcinoma/NN\n  [/VBZ\n  69/CD\n  ]/NN\n  ./.\n  In/IN\n  a/DT\n  phase/NN\n  II/NNP\n  discontin-/JJ\n  uation/NN\n  trial/NN\n  of/IN\n  heavily/RB\n  pretreated/VBN\n  patients/NNS\n  with/IN\n  (ORGANIZATION NSCLC/NNP)\n  whowere/RB\n  selected/VBN\n  for/IN\n  slow-growing/JJ\n  disease/NN\n  ,/,\n  signi\ufb01cantly/RB\n  (ORGANIZATION longerPFS/NN)\n  was/VBD\n  reported/VBN\n  with/IN\n  sorafenib/JJ\n  vs/NN\n  placebo/NN\n  (/(\n  3.6/CD\n  months/NNS\n  vs1.9/JJ\n  months/NNS\n  ;/:\n  P=/NNP\n  0.01/CD\n  )/)\n  ./.\n  (PERSON Patients/NNS)\n  also/RB\n  had/VBD\n  a/DT\n  higher/JJR\n  rate/NN\n  of/IN\n  sta-/JJ\n  ble/JJ\n  disease/NN\n  (/(\n  SD/NNP\n  )/)\n  with/IN\n  sorafenib/NN\n  (/(\n  29/CD\n  %/NN\n  vs/JJ\n  5/CD\n  %/NN\n  ;/:\n  P=/NNP\n  0.002/CD\n  )/)\n  [/VBD\n  70/CD\n  ]/NN\n  ./.\n  The/DT\n  most/RBS\n  common/JJ\n  grade/NN\n  3/CD\n  and/CC\n  4/CD\n  adverse/JJ\n  events/NNS\n  in/IN\n  patientsreceiving/VBG\n  sorafenib/NN\n  were/VBD\n  rash/hand-foot/JJ\n  syndrome/NN\n  (/(\n  15/CD\n  %/NN\n  )/)\n  andfatigue/NN\n  (/(\n  11/CD\n  %/NN\n  )/)\n  ./.\n  Two/CD\n  hemoptysis-related/JJ\n  deaths/NNS\n  and/CC\n  1/CD\n  case/NN\n  ofgrade/VBD\n  3/CD\n  hemoptysis/NN\n  were/VBD\n  observed/VBN\n  ./.\n  The/DT\n  phase/NN\n  (ORGANIZATION III/NNP)\n  ESCAPEtrial/NNP\n  (/(\n  N=/NNP\n  926/CD\n  )/)\n  was/VBD\n  initiated/VBN\n  to/TO\n  evaluate/VB\n  carboplatin/paclitaxel/NN\n  with/IN\n  or/CC\n  without/IN\n  sorafenib/NN\n  in/IN\n  chemonaive/JJ\n  patients/NNS\n  withadvanced/VBD\n  (ORGANIZATION NSCLC/NNP)\n  ;/:\n  however/RB\n  ,/,\n  the/DT\n  trial/NN\n  was/VBD\n  suspended/VBN\n  forfutility/NN\n  and/CC\n  did/VBD\n  not/RB\n  meet/VB\n  its/PRP$\n  OS/NNP\n  endpoint/NN\n  [/VBD\n  71/CD\n  ]/NNP\n  ./.\n  Patients/NNS\n  with/IN\n  squamous/JJ\n  histology/NN\n  had/VBD\n  a/DT\n  lower/JJR\n  OS/NNP\n  compared/VBN\n  withpatients/NNS\n  receiving/VBG\n  carboplatin/paclitaxel/NN\n  alone/RB\n  (/(\n  8.9/CD\n  months/NNS\n  vs13.6/JJ\n  months/NNS\n  ;/:\n  HR/NNP\n  1.85/CD\n  ;/:\n  95/CD\n  %/NN\n  CI/NNP\n  ,/,\n  1.22\u20132.81/CD\n  )/)\n  ,/,\n  and/CC\n  patients/NNS\n  withsquamous/JJ\n  histology/NN\n  had/VBD\n  a/DT\n  higher/JJR\n  incidence/NN\n  of/IN\n  clinically/RB\n  sig-ni\ufb01cant/JJ\n  hemorrhagic/NN\n  episodes/NNS\n  compared/VBN\n  with/IN\n  patients/NNS\n  withnonsquamous/JJ\n  histology/NN\n  receiving/VBG\n  sorafenib/NN\n  (/(\n  1.8/CD\n  %/NN\n  vs/JJ\n  0.3/CD\n  %/NN\n  )/)\n  .These/JJ\n  results/NNS\n  led/VBD\n  to/TO\n  the/DT\n  subsequent/JJ\n  exclusion/NN\n  of/IN\n  patients/NNS\n  withsquamous/JJ\n  histology/NN\n  in/IN\n  the/DT\n  ongoing/JJ\n  phase/NN\n  (ORGANIZATION III/NNP)\n  NExUS/NNP\n  trial/NN\n  (/(\n  (ORGANIZATION NCT00449033/NNP)\n  )/)\n  ,/,\n  undertaken/JJ\n  to/TO\n  evaluate/VB\n  sorafenib/NN\n  in/IN\n  com-bination/NN\n  with/IN\n  gemcitabine/cisplatin/NN\n  in/IN\n  chemonaive/JJ\n  patientswith/NN\n  advanced/VBD\n  nonsquamous/JJ\n  (ORGANIZATION NSCLC/NNP)\n  ./.\n  This/DT\n  study/NN\n  enrolledapproximately/RB\n  900/CD\n  treatment-naive/JJ\n  (ORGANIZATION NSCLC/NNP)\n  patients/NNS\n  ./.\n  Thesepatients/NNS\n  were/VBD\n  treated/VBN\n  with/IN\n  gemcitabine/NN\n  and/CC\n  cisplatin/NN\n  withor/NN\n  without/IN\n  sorafenib/JJ\n  400/CD\n  mg/NNS\n  bid/NN\n  for/IN\n  6/CD\n  cycles/NNS\n  ,/,\n  followed/VBD\n  bymaintenance/NN\n  with/IN\n  sorafenib/NN\n  or/CC\n  placebo/NN\n  ./.\n  This/DT\n  study/NN\n  failed/VBD\n  tomeet/NN\n  its/PRP$\n  primary/JJ\n  endpoint/NN\n  of/IN\n  improved/JJ\n  OS/NNP\n  ,/,\n  but/CC\n  did/VBD\n  showimproved/VBN\n  (ORGANIZATION PFS/NNP)\n  without/IN\n  unexpected/JJ\n  toxicities/NNS\n  [/VBP\n  72/CD\n  ]/NN\n  ./.\n  A/DT\n  phase/NN\n  (ORGANIZATION III/NNP)\n  trial/NN\n  (/(\n  (ORGANIZATION NCT00863746/NNP)\n  )/)\n  evaluating/VBG\n  single-agent/JJ\n  sorafenib/NN\n  inthe/JJ\n  third-/JJ\n  or/CC\n  fourth-line/JJ\n  setting/NN\n  in/IN\n  patients/NNS\n  with/IN\n  (ORGANIZATION NSCLC/NNP)\n  iscurrently/RB\n  recruiting/VBG\n  patients/NNS\n  ./.\n  Other/JJ\n  phase/NN\n  II/NNP\n  trials/NNS\n  in/IN\n  NSCLCevaluating/VBG\n  sorafenib/NN\n  in/IN\n  combination/NN\n  with/IN\n  chemotherapy/NN\n  orerlotinib/NN\n  are/VBP\n  also/RB\n  recruiting/VBG\n  patients.4.2.2/NN\n  ./.\n  (PERSON Sunitinib/NNP Sunitinib/NNP)\n  ,/,\n  or/CC\n  (ORGANIZATION SU11248/NNP)\n  (/(\n  (ORGANIZATION Sutent/NNP)\n  \u00ae/NNP\n  ,/,\n  (GPE P\ufb01zer/NNP)\n  ;/:\n  (GPE New/NNP London/NNP)\n  ,/,\n  (ORGANIZATION CT/NNP)\n  ,/,\n  (ORGANIZATION USA/NNP)\n  )/)\n  ,/,\n  is/VBZ\n  a/DT\n  small/JJ\n  molecule/NN\n  inhibitor/NN\n  of/IN\n  VEGFR-1/NNP\n  ,/,\n  -2/NNP\n  ,/,\n  and-3/JJ\n  ,/,\n  PDGFR-/JJ\n  /H9251and/NN\n  -/H9252/NNP\n  ,/,\n  c-kit/JJ\n  ,/,\n  FLT-3/NNP\n  ,/,\n  and/CC\n  the/DT\n  rearranged/NN\n  during/IN\n  transfection/NN\n  (/(\n  (ORGANIZATION RET/NNP)\n  )/)\n  receptor/NN\n  [/$\n  73/CD\n  ]/NNP\n  ./.\n  (PERSON Sunitinib/NNP)\n  is/VBZ\n  currently/RB\n  approved/VBN\n  by/IN\n  the/DT\n  (ORGANIZATION FDA/NNP)\n  for/IN\n  patients/NNS\n  with/IN\n  gastrointestinal/JJ\n  stro-mal/JJ\n  tumors/NNS\n  and/CC\n  for/IN\n  those/DT\n  with/IN\n  advanced/JJ\n  renal/JJ\n  cell/NN\n  carcinoma/NN\n  [/VBZ\n  74/CD\n  ]/NN\n  ./.\n  A/DT\n  phase/NN\n  II/NNP\n  study/NN\n  of/IN\n  63/CD\n  patients/NNS\n  with/IN\n  advanced/JJ\n  (ORGANIZATION NSCLC/NNP)\n  ,/,\n  excluding/VBG\n  those/DT\n  with/IN\n  higher/JJR\n  bleeding/NN\n  risk/NN\n  ,/,\n  was/VBD\n  conductedto/JJ\n  evaluate/JJ\n  single-agent/JJ\n  sunitinib/NN\n  as/IN\n  a/DT\n  second-/JJ\n  or/CC\n  third-linetherapy/JJ\n  [/JJ\n  75/CD\n  ]/NN\n  ./.\n  Seven/JJ\n  patients/NNS\n  had/VBD\n  con\ufb01rmed/VBN\n  partial/JJ\n  responses/NNS\n  (/(\n  (ORGANIZATION PRs/NNP)\n  )/)\n  for/IN\n  an/DT\n  overall/JJ\n  RR/NNP\n  of/IN\n  11.1/CD\n  %/NN\n  ./.\n  An/DT\n  additional/JJ\n  18/CD\n  patients/NNS\n  (/(\n  28.6/CD\n  %/NN\n  )/)\n  experienced/VBD\n  SD/NNP\n  of/IN\n  \u22658/NNP\n  weeks/NNS\n  ./.\n  (PERSON Median/JJ PFS/NNP)\n  was/VBD\n  12.0/CD\n  weeks/NNS\n  and/CC\n  median/JJ\n  OS/NNP\n  was/VBD\n  23.4/CD\n  weeks/NNS\n  ./.\n  (PERSON Major/NNP)\n  toxicitieswere/RB\n  observed/VBD\n  in/IN\n  >/JJ\n  10/CD\n  %/NN\n  of/IN\n  patients/NNS\n  ,/,\n  and/CC\n  fatigue/asthenia/NN\n  (/(\n  29/CD\n  %/NN\n  )/)\n  ,/,\n  lymphopenia/NN\n  (/(\n  25/CD\n  %/NN\n  )/)\n  ,/,\n  and/CC\n  pain/myalgia/NN\n  (/(\n  17/CD\n  %/NN\n  )/)\n  werethe/VBZ\n  most/RBS\n  common/JJ\n  grade/NN\n  3/CD\n  and/CC\n  4/CD\n  adverse/JJ\n  events/NNS\n  in/IN\n  this/DT\n  study.A/NN\n  similar/JJ\n  phase/NN\n  II/NNP\n  study/NN\n  was/VBD\n  conducted/VBN\n  in/IN\n  47/CD\n  patients/NNS\n  withadvanced/VBD\n  pretreated/JJ\n  (ORGANIZATION NSCLC/NNP)\n  [/NNP\n  76/CD\n  ]/NNP\n  ./.\n  One/CD\n  patient/NN\n  achieved/VBD\n  a/DT\n  con\ufb01rmed/JJ\n  PR/NNP\n  ,/,\n  for/IN\n  an/DT\n  overall/JJ\n  RR/NNP\n  of/IN\n  2.1/CD\n  %/NN\n  ,/,\n  and/CC\n  11/CD\n  (/(\n  23.4/CD\n  %/NN\n  )/)\n  hadSD\u22658/NN\n  weeks/NNS\n  ./.\n  Five/CD\n  patients/NNS\n  had/VBD\n  (ORGANIZATION SD/NNP)\n  fo/JJ\n  r/NN\n  >/$\n  6/CD\n  months/NNS\n  ./.\n  (PERSON Median/JJ PFS/NNP)\n  was/VBD\n  11.9/CD\n  weeks/NNS\n  and/CC\n  median/JJ\n  OS/NNP\n  was/VBD\n  37.1/CD\n  weeks/NNS\n  ,/,\n  with/IN\n  a1-year/JJ\n  survival/JJ\n  probability/NN\n  of/IN\n  38.4/CD\n  %/NN\n  ./.\n  (GPE Fatigue/NNP)\n  (/(\n  17/CD\n  %/NN\n  )/)\n  was/VBD\n  themost/JJ\n  common/JJ\n  adverse/JJ\n  event/NN\n  in/IN\n  this/DT\n  study/NN\n  ;/:\n  other/JJ\n  commonadverse/NN\n  events/NNS\n  included/VBD\n  neutropenia/NN\n  (/(\n  9/CD\n  %/NN\n  )/)\n  and/CC\n  hypertension/NN\n  (/(\n  9/CD\n  %/NN\n  )/)\n  ./.\n  The/DT\n  phase/NN\n  (ORGANIZATION III/NNP)\n  CALGB/NNP\n  30607/CD\n  trial/NN\n  is/VBZ\n  currentlyevaluating/VBG\n  sunitinib/RB\n  as/IN\n  maintenance/NN\n  therapy/NN\n  in/IN\n  patients/NNS\n  withadvanced/JJ\n  (ORGANIZATION NSCLC/NNP)\n  and/CC\n  the/DT\n  ongoing/JJ\n  phase/NN\n  II/NNP\n  CALGB/NNP\n  30704is/CD\n  evaluating/VBG\n  the/DT\n  addition/NN\n  of/IN\n  sunitinib/NN\n  to/TO\n  pemetrexed/VB\n  assecond-line/JJ\n  therapy/NN\n  ./.\n  A/DT\n  phase/NN\n  II/NNP\n  trial/NN\n  (/(\n  (ORGANIZATION NCT00265317/NNP)\n  )/)\n  and/CC\n  aphase/JJ\n  (ORGANIZATION III/NNP)\n  trial/NN\n  (/(\n  (ORGANIZATION NCT00457392/NNP)\n  )/)\n  are/VBP\n  evaluating/VBG\n  the/DT\n  addition/NN\n  ofsunitinib/NN\n  to/TO\n  erlotinib/VB\n  as/IN\n  second-line/JJ\n  therapy/NN\n  in/IN\n  patients/NNS\n  withadvanced/JJ\n  (ORGANIZATION NSCLC/NNP)\n  ./.\n  4.2.3/CD\n  ./.\n  BIBF/VB\n  1120/CD\n  BIBF/NNP\n  1120/CD\n  (/(\n  (ORGANIZATION Boehringer/NNP Ingelheim/NNP)\n  ;/:\n  (GPE Ingelheim/NNP)\n  ,/,\n  (GPE Germany/NNP)\n  )/)\n  is/VBZ\n  an/DT\n  oral/JJ\n  small/JJ\n  molecule/NN\n  inhibitor/NN\n  of/IN\n  VEGFR-1/NNP\n  ,/,\n  -2/NNP\n  ,/,\n  and/CC\n  -3/NNP\n  ,/,\n  PDGFR-/NNP\n  /H9251and/NNP\n  -/H9252/NNP\n  ,/,\n  FGFR-1/NNP\n  ,/,\n  -2/NNP\n  ,/,\n  and/CC\n  -3/NNP\n  ,/,\n  FLT-3/NNP\n  ,/,\n  v-src/JJ\n  sarcoma/NN\n  viral/JJ\n  oncogene/NN\n  homolog/NN\n  (/(\n  Src/NNP\n  )/)\n  ,/,\n  and/CC\n  v-yes-1/JJ\n  Yamaguchisarcoma/NNP\n  viral/NN\n  related/VBN\n  oncogene/JJ\n  homolog/NN\n  (/(\n  Lyn/NNP\n  )/)\n  [/VBD\n  77,78/CD\n  ]/NNP\n  .I/NNP\n  n/VBZ\n  a/DT\n  phase/NN\n  I/PRP\n  trial/NN\n  of/IN\n  (ORGANIZATION BIBF/NNP)\n  1120/CD\n  plus/CC\n  pemetrexed/JJ\n  in/IN\n  patientswith/JJ\n  NSCLC/NNP\n  who/WP\n  had/VBD\n  received/VBN\n  1/CD\n  \ufb01rst-line/JJ\n  ,/,\n  platinum-basedchemotherapy/JJ\n  regimen/NNS\n  ,/,\n  of/IN\n  26/CD\n  treated/JJ\n  patients/NNS\n  ,/,\n  13/CD\n  (/(\n  50/CD\n  %/NN\n  )/)\n  patients/NNS\n  had/VBD\n  (ORGANIZATION SD/NNP)\n  and/CC\n  the/DT\n  median/JJ\n  (ORGANIZATION PFS/NNP)\n  was/VBD\n  5.4/CD\n  months/NNS\n  ./.\n  (PERSON Onepatient/NNP)\n  achieved/VBD\n  a/DT\n  complete/JJ\n  response/NN\n  ./.\n  The/DT\n  most/RBS\n  commongrade/JJ\n  3/CD\n  toxicities/NNS\n  observed/VBN\n  were/VBD\n  fatigue/JJ\n  (/(\n  23.1/CD\n  %/NN\n  )/)\n  andreversible/JJ\n  alanine/JJ\n  transaminase/NN\n  elevations/NNS\n  (/(\n  11.5/CD\n  %/NN\n  )/)\n  [/VBZ\n  79/CD\n  ]/NN\n  ./.\n  BIBF/NNP\n  1120/CD\n  was/VBD\n  evaluated/VBN\n  in/IN\n  a/DT\n  phase/NN\n  II/NNP\n  study/NN\n  (/(\n  N=/NNP\n  73/CD\n  )/)\n  of/IN\n  patients/NNS\n  with/IN\n  locally/RB\n  advanced/JJ\n  or/CC\n  metastatic/JJ\n  (ORGANIZATION relapsedNSCLC/NN)\n  and/CC\n  an/DT\n  (ORGANIZATION ECOG/NNP)\n  PS/NNP\n  of/IN\n  0\u20132/CD\n  [/JJ\n  80/CD\n  ]/NN\n  ./.\n  The/DT\n  median/JJ\n  (ORGANIZATION PFS/NNP)\n  and/CC\n  (ORGANIZATION OS/NNP)\n  of/IN\n  all/DT\n  patients/NNS\n  (/(\n  N=/NNP\n  73/CD\n  )/)\n  was/VBD\n  6.9/CD\n  weeks/NNS\n  and/CC\n  21.9/CD\n  weeks/NNS\n  ,/,\n  respectively/RB\n  ./.\n  Those/DT\n  with/IN\n  an/DT\n  (ORGANIZATION ECOG/NNP)\n  PS/NNP\n  of/IN\n  0/CD\n  or1/NN\n  (/(\n  N=/NNP\n  56/CD\n  )/)\n  had/VBD\n  a/DT\n  median/JJ\n  (ORGANIZATION PFS/NNP)\n  of/IN\n  11.6/CD\n  weeks/NNS\n  and/CC\n  median/JJ\n  OS/NNP\n  of/IN\n  37.7/CD\n  weeks/NNS\n  ./.\n  SD/NNP\n  was/VBD\n  observed/VBN\n  in/IN\n  48/CD\n  %/NN\n  of/IN\n  all/DT\n  patients.Grade/NN\n  3/CD\n  and/CC\n  4/CD\n  toxicities/NNS\n  included/VBD\n  nausea/NN\n  (/(\n  7/CD\n  %/NN\n  )/)\n  ,/,\n  diarrhea/NN\n  (/(\n  8/CD\n  %/NN\n  )/)\n  ,/,\n  vomiting/VBG\n  (/(\n  3/CD\n  %/NN\n  )/)\n  ,/,\n  abdominal/JJ\n  pain/NN\n  (/(\n  3/CD\n  %/NN\n  )/)\n  ,/,\n  and/CC\n  (ORGANIZATION reversibleA/NN)\n  ./.\n  (PERSON Wozniak/NNP)\n  //NNP\n  Critical/NNP\n  Reviews/NNP\n  in/IN\n  Oncology/Hematology/NNP\n  82/CD\n  (/(\n  2012/CD\n  )/)\n  200\u2013212/CD\n  207/CD\n  elevation/NN\n  of/IN\n  alanine/JJ\n  aminotransferase/NN\n  levels/NNS\n  (/(\n  10/CD\n  %/NN\n  )/)\n  [/VBZ\n  80/CD\n  ]/NN\n  ./.\n  Notably/RB\n  ,/,\n  although/IN\n  grade/JJ\n  \u22653/NNP\n  hypertension/NN\n  has/VBZ\n  been/VBN\n  reported/VBN\n  in/IN\n  2\u20135/CD\n  %/NN\n  of/IN\n  patients/NNS\n  treated/VBN\n  with/IN\n  bevacizumab/NN\n  ,/,\n  vandetanib/NN\n  ,/,\n  sunitinib/NN\n  ,/,\n  cediranib/NN\n  ,/,\n  axitinib/NN\n  ,/,\n  and/CC\n  sorafenib/VBD\n  [/$\n  55,81,82/CD\n  ]/NNP\n  ,/,\n  grade/VBD\n  \u22653/JJ\n  hypertension/NN\n  has/VBZ\n  not/RB\n  been/VBN\n  reported/VBN\n  with/IN\n  (ORGANIZATION BIBF/NNP)\n  1120/CD\n  in/IN\n  patients/NNS\n  with/IN\n  (ORGANIZATION NSCLC/NNP)\n  [/NNP\n  80/CD\n  ]/NNP\n  ./.\n  Two/CD\n  randomized/JJ\n  phase/NN\n  (ORGANIZATION III/NNP)\n  studies/NNS\n  are/VBP\n  underway/JJ\n  to/TO\n  evaluate/VB\n  (ORGANIZATION BIBF/NNP)\n  1120/CD\n  in/IN\n  combinationwith/NN\n  docetaxel/NN\n  (/(\n  LUME-Lung/JJ\n  1/CD\n  ;/:\n  (ORGANIZATION NCT00805194/NNP)\n  )/)\n  or/CC\n  peme-trexed/JJ\n  (/(\n  LUME-Lung/JJ\n  2/CD\n  ;/:\n  (ORGANIZATION NCT00806819/NNP)\n  )/)\n  for/IN\n  the/DT\n  second-linetreatment/NN\n  of/IN\n  patients/NNS\n  with/IN\n  advanced/JJ\n  NSCLC/NNP\n  after/IN\n  failure/NN\n  of/IN\n  1prior/CD\n  chemotherapy/NN\n  regimen/NNS\n  ,/,\n  with/IN\n  or/CC\n  without/IN\n  bevacizumab/NN\n  ./.\n  4.2.4/CD\n  ./.\n  (PERSON Cediranib/NNP Cediranib/NNP)\n  ,/,\n  or/CC\n  (ORGANIZATION AZD2171/NNP)\n  (/(\n  (ORGANIZATION Recentin/NNP)\n  TM/NNP\n  ,/,\n  (ORGANIZATION AstraZeneca/NNP)\n  ;/:\n  (PERSON Wilmington/NNP)\n  ,/,\n  (ORGANIZATION DE/NNP)\n  ,/,\n  (ORGANIZATION USA/NNP)\n  )/)\n  ,/,\n  is/VBZ\n  an/DT\n  inhibitor/NN\n  of/IN\n  VEGFR-1/NNP\n  ,/,\n  -2/NNP\n  ,/,\n  and-3/JJ\n  ,/,\n  c-kit/JJ\n  ,/,\n  FGFR-1/NNP\n  ,/,\n  and/CC\n  PDGFR-/NNP\n  /H9251and/NNP\n  -/H9252/NNP\n  [/VBD\n  83/CD\n  ]/NN\n  ./.\n  In/IN\n  a/DT\n  phase/NN\n  II/III/NNP\n  trial/NN\n  (/(\n  (ORGANIZATION BR24/NNP)\n  )/)\n  evaluating/VBG\n  cediranib/NN\n  with/IN\n  carboplatin/paclitaxelas/JJ\n  \ufb01rst-line/JJ\n  therapy/NN\n  in/IN\n  251/CD\n  patients/NNS\n  with/IN\n  advanced/JJ\n  (ORGANIZATION NSCLC/NNP)\n  ,/,\n  aninterim/JJ\n  analysis/NN\n  demonstrated/VBD\n  a/DT\n  signi\ufb01cantly/RB\n  higher/JJR\n  RR/NNP\n  withcediranib/NN\n  (/(\n  38/CD\n  %/NN\n  )/)\n  vs/NN\n  placebo/NN\n  (/(\n  16/CD\n  %/NN\n  ,/,\n  (PERSON P/NNP)\n  </NNP\n  0.0001/CD\n  )/)\n  but/CC\n  the/DT\n  study/NN\n  was/VBD\n  halted/VBN\n  due/JJ\n  to/TO\n  excessive/JJ\n  toxicities/NNS\n  at/IN\n  the/DT\n  30/CD\n  mg/NN\n  dose/NN\n  ./.\n  Tenmonths/NNS\n  after/IN\n  the/DT\n  end/NN\n  of/IN\n  the/DT\n  study/NN\n  ,/,\n  median/JJ\n  survival/NN\n  was/VBD\n  longerfor/JJ\n  cediranib/NN\n  than/IN\n  for/IN\n  placebo/NN\n  (/(\n  10.5/CD\n  months/NNS\n  vs/RB\n  10.1/CD\n  months/NNS\n  ;/:\n  (ORGANIZATION HR/NNP)\n  =/VBZ\n  0.78/CD\n  ;/:\n  95/CD\n  %/NN\n  CI/NNP\n  ,/,\n  0.57\u20131.06/CD\n  ;/:\n  P=/NNP\n  0.11/CD\n  )/)\n  ./.\n  (ORGANIZATION Common/JJ)\n  toxici-/JJ\n  ties/NNS\n  reported/VBN\n  in/IN\n  the/DT\n  cediranib/NN\n  group/NN\n  included/VBD\n  hypertension/NN\n  (/(\n  grade/JJ\n  3/CD\n  ,/,\n  19/CD\n  %/NN\n  )/)\n  ,/,\n  diarrhea/FW\n  (/(\n  grade/VB\n  3/CD\n  ,/,\n  15/CD\n  %/NN\n  )/)\n  ,/,\n  anorexia/FW\n  (/(\n  grade/VB\n  3,6/CD\n  %/NN\n  )/)\n  ,/,\n  fatigue/NN\n  (/(\n  grade/JJ\n  3/CD\n  ,/,\n  29/CD\n  %/NN\n  )/)\n  ,/,\n  stomatitis/NN\n  (/(\n  grade/JJ\n  3/CD\n  ,/,\n  6/CD\n  %/NN\n  )/)\n  ,/,\n  dysp-nea/JJ\n  (/(\n  grade/JJ\n  3/CD\n  ,/,\n  10/CD\n  %/NN\n  )/)\n  ,/,\n  and/CC\n  sensory/JJ\n  neuropathy/NN\n  (/(\n  grade/JJ\n  3/CD\n  ,/,\n  3/CD\n  %/NN\n  )/)\n  ;/:\n  10fatal/CD\n  adverse/JJ\n  events/NNS\n  were/VBD\n  reported/VBN\n  in/IN\n  this/DT\n  group/NN\n  [/VBZ\n  82/CD\n  ]/NN\n  ./.\n  Based/VBN\n  on/IN\n  these/DT\n  results/NNS\n  ,/,\n  a/DT\n  similar/JJ\n  phase/NN\n  (ORGANIZATION III/NNP)\n  trial/NN\n  (/(\n  (ORGANIZATION BR29/NNP)\n  ;/:\n  (ORGANIZATION NCT00795340/NNP)\n  )/)\n  evaluating/VBG\n  cediranib/NN\n  at/IN\n  a/DT\n  lower/JJR\n  dose/NN\n  (/(\n  20/CD\n  mg/NN\n  )/)\n  in/IN\n  combina-tion/NN\n  with/IN\n  carboplatin/paclitaxel/NN\n  is/VBZ\n  recruiting/VBG\n  patients/NNS\n  ./.\n  Othertrials/NNS\n  in/IN\n  (GPE NSCLC/NNP)\n  are/VBP\n  ongoing/VBG\n  ,/,\n  including/VBG\n  a/DT\n  phase/NN\n  II/NNP\n  trial/NN\n  (/(\n  (ORGANIZATION NCT00410904/NNP)\n  )/)\n  of/IN\n  cediranib/NN\n  in/IN\n  combination/NN\n  with/IN\n  peme-trexed/JJ\n  as/IN\n  second-line/JJ\n  therapy/NN\n  ./.\n  4.2.5/CD\n  ./.\n  (PERSON Motesanib/NNP Motesanib/NNP)\n  ,/,\n  or/CC\n  AMG/$\n  706/CD\n  (/(\n  (GPE Amgen/NNP)\n  ;/:\n  (GPE Thousand/NNP Oaks/NNP)\n  ,/,\n  (ORGANIZATION CA/NNP)\n  ,/,\n  (ORGANIZATION USA/NNP)\n  )/)\n  ,/,\n  is/VBZ\n  an/DT\n  oral/JJ\n  ,/,\n  small/JJ\n  molecule/NN\n  inhibitor/NN\n  of/IN\n  VEGFR-1/NNP\n  ,/,\n  -2/NNP\n  ,/,\n  and/CC\n  -3/NNP\n  ,/,\n  (ORGANIZATION PDGFR/NNP)\n  ,/,\n  c-kit/NN\n  ,/,\n  and/CC\n  (ORGANIZATION RET/NNP)\n  signaling/VBG\n  [/RB\n  84/CD\n  ]/NN\n  ./.\n  The/DT\n  phase/NN\n  (ORGANIZATION III/NNP)\n  MONET1/NNP\n  trial/NN\n  evaluating/VBG\n  motesanib/NN\n  in/IN\n  combination/NN\n  withcarboplatin/paclitaxel/NN\n  in/IN\n  patients/NNS\n  with/IN\n  advanced/JJ\n  (ORGANIZATION NSCLC/NNP)\n  wastemporarily/RB\n  suspended/VBD\n  because/IN\n  of/IN\n  higher/JJR\n  incidence/NN\n  of/IN\n  mor-tality/NN\n  and/CC\n  hemoptysis/NN\n  in/IN\n  patients/NNS\n  with/IN\n  squamous/JJ\n  histology/NN\n  [/VBZ\n  85/CD\n  ]/NN\n  ;/:\n  following/VBG\n  the/DT\n  3-month/JJ\n  enrollment/NN\n  suspension/NN\n  ,/,\n  the/DT\n  trial/NN\n  (/(\n  (ORGANIZATION NCT00460317/NNP)\n  )/)\n  has/VBZ\n  resumed/VBN\n  recruitment/NN\n  of/IN\n  patients/NNS\n  withnonsquamous/JJ\n  histology/NN\n  ./.\n  Enrollment/NN\n  is/VBZ\n  estimated/VBN\n  at/IN\n  1400patients/CD\n  and/CC\n  results/NNS\n  are/VBP\n  expected/VBN\n  in/IN\n  2011/CD\n  ./.\n  4.2.6/CD\n  ./.\n  (PERSON Axitinib/NNP Axitinib/NNP)\n  ,/,\n  or/CC\n  AG-013736/NNP\n  (/(\n  (GPE P\ufb01zer/NNP)\n  ;/:\n  (GPE New/NNP London/NNP)\n  ,/,\n  (ORGANIZATION CT/NNP)\n  ,/,\n  (ORGANIZATION USA/NNP)\n  )/)\n  ,/,\n  is/VBZ\n  a/DT\n  (ORGANIZATION TKI/NNP)\n  of/IN\n  VEGFR-1/NNP\n  ,/,\n  -2/NNP\n  ,/,\n  and/CC\n  -3/NNP\n  ,/,\n  PDGFR-/NNP\n  /H9252/NNP\n  ,/,\n  and/CC\n  c-kit/JJ\n  [/NN\n  86/CD\n  ]/NN\n  ./.\n  In/IN\n  a/DT\n  phase/NN\n  II/NNP\n  trial/NN\n  (/(\n  N=/NNP\n  32/CD\n  )/)\n  of/IN\n  single-agent/JJ\n  axitinib/NN\n  in/IN\n  patients/NNS\n  with/IN\n  advanced/JJ\n  (ORGANIZATION NSCLC/NNP)\n  ,/,\n  of/IN\n  whom/WP\n  73/CD\n  %/NN\n  had/VBD\n  received/VBN\n  \u22651/JJ\n  prior/JJ\n  chemotherapy/NN\n  regimen/NNS\n  ,/,\n  3/CD\n  (/(\n  9/CD\n  %/NN\n  )/)\n  achieved/VBD\n  a/DT\n  PR/NNP\n  and/CC\n  41/CD\n  %/NN\n  hadSD/NN\n  ./.\n  The/DT\n  median/JJ\n  (ORGANIZATION PFS/NNP)\n  was/VBD\n  4.9/CD\n  months/NNS\n  and/CC\n  median/JJ\n  OS/NNP\n  was14.8/JJ\n  months/NNS\n  in/IN\n  all/DT\n  patients/NNS\n  and/CC\n  in/IN\n  the/DT\n  subgroup/NN\n  who/WP\n  received/VBD\n  axitinib/RB\n  as/IN\n  \ufb01rst-line/JJ\n  therapy/NN\n  ./.\n  The/DT\n  most/RBS\n  common/JJ\n  grade/NN\n  3/CD\n  toxic-ities/NNS\n  were/VBD\n  fatigue/JJ\n  (/(\n  22/CD\n  %/NN\n  )/)\n  and/CC\n  hypertension/NN\n  (/(\n  9/CD\n  %/NN\n  )/)\n  [/VBZ\n  81/CD\n  ]/NN\n  ./.\n  (PERSON Axitinib/NNP)\n  will/MD\n  be/VB\n  tested/VBN\n  in/IN\n  combination/NN\n  with/IN\n  chemotherapy/NN\n  in/IN\n  2/CD\n  trials:1/JJ\n  phase/NN\n  I/II/NNP\n  trial/NN\n  in/IN\n  nonsquamous/JJ\n  (ORGANIZATION NSCLC/NNP)\n  (/(\n  (ORGANIZATION NCT00768755/NNP)\n  )/)\n  and/CC\n  1/CD\n  phase/NN\n  II/NNP\n  trial/NN\n  in/IN\n  squamous/JJ\n  (ORGANIZATION NSCLC/NNP)\n  (/(\n  (ORGANIZATION NCT00735904/NNP)\n  )/)\n  ./.\n  4.2.7/CD\n  ./.\n  (PERSON Pazopanib/NNP Pazopanib/NNP)\n  ,/,\n  or/CC\n  (ORGANIZATION GW786034/NNP)\n  (/(\n  (ORGANIZATION GlaxoSmithKline/NNP)\n  ;/:\n  (GPE London/NNP)\n  ,/,\n  (ORGANIZATION UK/NNP)\n  )/)\n  ,/,\n  is/VBZ\n  a/DT\n  TKI/JJ\n  targeting/VBG\n  VEGFR-1/NNP\n  ,/,\n  -2/NNP\n  ,/,\n  and/CC\n  -3/NNP\n  ,/,\n  PDGFR-/H9251and/NNP\n  -/H9252/NNP\n  ,/,\n  FGFR-1/NNP\n  and/CC\n  -3/NNP\n  ,/,\n  and/CC\n  c-kit/JJ\n  [/NN\n  87,88/CD\n  ]/NN\n  ./.\n  In/IN\n  a/DT\n  phase/NN\n  II/NNP\n  trial/NN\n  of/IN\n  35/CD\n  patients/NNS\n  with/IN\n  stage/NN\n  I/II/NNP\n  resectable/JJ\n  NSCLC,3/NNP\n  (/(\n  9/CD\n  %/NN\n  )/)\n  patients/NNS\n  achieved/VBD\n  a/DT\n  PR/NNP\n  ./.\n  The/DT\n  most/RBS\n  common/JJ\n  grade\u22653/NN\n  adverse/JJ\n  event/NN\n  was/VBD\n  an/DT\n  increase/NN\n  in/IN\n  alanine/JJ\n  transaminase/NN\n  levels/NNS\n  (/(\n  6/CD\n  %/NN\n  )/)\n  [/VBZ\n  89/CD\n  ]/NN\n  ./.\n  (PERSON Pazopanib/NNP)\n  is/VBZ\n  currently/RB\n  being/VBG\n  evaluated/VBN\n  alone/RB\n  (/(\n  (ORGANIZATION NCT01049776/NNP)\n  )/)\n  and/CC\n  in/IN\n  combination/NN\n  with/IN\n  chemother-apy/NN\n  (/(\n  (ORGANIZATION NCT00866528/NNP)\n  )/)\n  or/CC\n  an/DT\n  (ORGANIZATION EGFR/NNP)\n  inhibitor/NN\n  (/(\n  (ORGANIZATION NCT01027598/NNP)\n  )/)\n  in/IN\n  phase/NN\n  II/NNP\n  trials/NNS\n  in/IN\n  (GPE NSCLC/NNP)\n  ,/,\n  and/CC\n  as/IN\n  adjuvant/JJ\n  therapy/NN\n  in/IN\n  aphase/NN\n  II/III/NNP\n  trial/NN\n  (/(\n  (ORGANIZATION NCT00775307/NNP)\n  )/)\n  in/IN\n  patients/NNS\n  with/IN\n  surgicallyresected/JJ\n  (ORGANIZATION NSCLC/NNP)\n  ./.\n  4.2.8/CD\n  ./.\n  V/NNP\n  andetanib/JJ\n  (ORGANIZATION Vandetanib/NNP)\n  ,/,\n  or/CC\n  (ORGANIZATION AZD6474/NNP)\n  (/(\n  (PERSON Zactima/NNP)\n  ,/,\n  (ORGANIZATION AstraZeneca/NNP)\n  ;/:\n  (PERSON Wilmington/NNP)\n  ,/,\n  (ORGANIZATION DE/NNP)\n  )/)\n  ,/,\n  is/VBZ\n  a/DT\n  (ORGANIZATION TKI/NNP)\n  of/IN\n  VEGFR-2/NNP\n  ,/,\n  VEGFR-3/NNP\n  ,/,\n  andRET/RB\n  ,/,\n  as/RB\n  well/RB\n  as/IN\n  a/DT\n  weaker/JJR\n  inhibitor/NN\n  of/IN\n  (ORGANIZATION EGFR/NNP)\n  [/NNP\n  90/CD\n  ]/NNP\n  ./.\n  (PERSON Phase/NNP III/NNP)\n  trials/NNS\n  demonstrated/VBD\n  no/DT\n  prolongation/NN\n  in/IN\n  (ORGANIZATION PFS/NNP)\n  for/IN\n  vandetanibcompared/VBN\n  with/IN\n  erlotinib/NN\n  in/IN\n  patients/NNS\n  with/IN\n  advanced/JJ\n  ,/,\n  previ-ously/RB\n  treated/VBN\n  (ORGANIZATION NSCLC/NNP)\n  (/(\n  (ORGANIZATION ZEST/NNP)\n  ;/:\n  N=/NNP\n  1240/CD\n  )/)\n  [/VBD\n  91/CD\n  ]/NN\n  ./.\n  Vandetanib/NNP\n  in/IN\n  combination/NN\n  with/IN\n  pemetrexed/JJ\n  resulted/VBN\n  in/IN\n  prolonged/JJ\n  PFScompared/NNP\n  with/IN\n  pemetrexed/JJ\n  alone/RB\n  (/(\n  (ORGANIZATION ZEAL/NNP)\n  ;/:\n  N=/NNP\n  534/CD\n  )/)\n  ,/,\n  but/CC\n  this/DT\n  did/VBD\n  not/RB\n  reach/VB\n  statistical/JJ\n  signi\ufb01cance/NN\n  (/(\n  P=/NNP\n  0.108/CD\n  )/)\n  ,/,\n  possibly/RB\n  due/JJ\n  to/TO\n  the/DT\n  smaller/JJR\n  size/NN\n  of/IN\n  the/DT\n  study/NN\n  population/NN\n  [/VBD\n  92/CD\n  ]/NNP\n  .I/NNP\n  na/RB\n  larger/JJR\n  phase/NN\n  (ORGANIZATION III/NNP)\n  trial/NN\n  of/IN\n  vandetanib/NN\n  combined/VBN\n  with/IN\n  docetaxelfor/JJ\n  second-line/JJ\n  treatment/NN\n  of/IN\n  (GPE NSCLC/NNP)\n  (/(\n  (ORGANIZATION ZODIAC/NNP)\n  ;/:\n  N=/NNP\n  1391/CD\n  )/)\n  ,/,\n  vandetanib/NN\n  was/VBD\n  associated/VBN\n  with/IN\n  statistically/RB\n  prolonged/VBN\n  (ORGANIZATION PFS/NNP)\n  (/(\n  4.0/CD\n  months/NNS\n  for/IN\n  vandetanib/JJ\n  plus/CC\n  docetaxel/JJ\n  vs/NN\n  3.2/CD\n  for/IN\n  placeboplus/JJ\n  docetaxel/NN\n  ;/:\n  HR/NNP\n  0.79/CD\n  ;/:\n  97.58/CD\n  %/NN\n  CI/NNP\n  ,/,\n  0.70\u20130.90/CD\n  ;/:\n  (PERSON P/NNP)\n  </NNP\n  0.0001/CD\n  )/)\n  ,/,\n  but/CC\n  showed/VBD\n  no/DT\n  signi\ufb01cant/JJ\n  increase/NN\n  in/IN\n  (GPE OS/NNP)\n  (/(\n  P=/NNP\n  0.196/CD\n  )/)\n  [/VBD\n  93/CD\n  ]/NN\n  ./.\n  After/IN\n  another/DT\n  phase/NN\n  (ORGANIZATION III/NNP)\n  study/NN\n  of/IN\n  vandetanib/NN\n  in/IN\n  patientswho/NN\n  previously/RB\n  experienced/JJ\n  failure/NN\n  of/IN\n  (ORGANIZATION EGFR/NNP)\n  TKI/NNP\n  therapy/NN\n  (/(\n  (ORGANIZATION ZEPHYR/NNP)\n  )/)\n  failed/VBD\n  to/TO\n  meet/VB\n  its/PRP$\n  primary/JJ\n  objective/NN\n  of/IN\n  (ORGANIZATION improvedOS/JJ)\n  [/FW\n  94/CD\n  ]/NN\n  ,/,\n  vandetanib/NN\n  was/VBD\n  removed/VBN\n  from/IN\n  clinical/JJ\n  development/NN\n  for/IN\n  (ORGANIZATION NSCLC/NNP)\n  ./.\n  A/NNP\n  few/JJ\n  phase/NN\n  II/NNP\n  trials/NNS\n  of/IN\n  vandetanib/NN\n  in/IN\n  (GPE NSCLC/NNP)\n  arestill/NN\n  recruiting/VBG\n  patients/NNS\n  (/(\n  (ORGANIZATION NCT00093392/NNP)\n  and/CC\n  (ORGANIZATION NCT00745732/NNP)\n  )/)\n  ./.\n  5/CD\n  ./.\n  Current/JJ\n  challenges/NNS\n  and/CC\n  individualized/JJ\n  therapy/NN\n  (PERSON Currently/NNP)\n  ,/,\n  no/DT\n  tools/NNS\n  are/VBP\n  available/JJ\n  to/TO\n  guide/VB\n  the/DT\n  use/NN\n  of/IN\n  tar-/NN\n  geted/VBN\n  antiangiogenic/JJ\n  agents/NNS\n  in/IN\n  the/DT\n  treatment/NN\n  of/IN\n  (ORGANIZATION NSCLC/NNP)\n  ,/,\n  andas/VBZ\n  a/DT\n  result/NN\n  ,/,\n  these/DT\n  therapies/NNS\n  are/VBP\n  used/VBN\n  by/IN\n  exclusion/NN\n  only/RB\n  ./.\n  Identi-\ufb01cation/NN\n  and/CC\n  validation/NN\n  of/IN\n  predictive/JJ\n  biomarkers/NNS\n  may/MD\n  providemore/VB\n  effective/JJ\n  targeted/VBN\n  treatment/NN\n  for/IN\n  (ORGANIZATION NSCLC/NNP)\n  patients/NNS\n  by/IN\n  tai-loring/JJ\n  antiangiogenic/JJ\n  treatment/NN\n  strategies/NNS\n  on/IN\n  an/DT\n  individualpatient/JJ\n  basis/NN\n  ./.\n  Candidate/NNP\n  biomarkers/NNS\n  have/VBP\n  been/VBN\n  investigatedin/JJ\n  NSCLC/NNP\n  as/IN\n  predictive/JJ\n  indicators/NNS\n  of/IN\n  response/NN\n  to/TO\n  antiangio-208/JJ\n  A./NNP\n  Wozniak/NNP\n  //NNP\n  Critical/NNP\n  Reviews/NNP\n  in/IN\n  Oncology/Hematology/NNP\n  82/CD\n  (/(\n  2012/CD\n  )/)\n  200\u2013212/CD\n  genic/JJ\n  therapy/NN\n  ./.\n  Some/DT\n  of/IN\n  these/DT\n  biomarkers/NNS\n  include/VBP\n  measures/NNS\n  of/IN\n  angiogenesis/NN\n  itself/PRP\n  ,/,\n  such/JJ\n  as/IN\n  visual/JJ\n  quanti\ufb01cation/NN\n  of/IN\n  microves-sel/JJ\n  density/NN\n  ,/,\n  and/CC\n  more/RBR\n  recently/RB\n  ,/,\n  evaluation/NN\n  of/IN\n  gene/NN\n  signaturesor/JJ\n  expression/NN\n  levels/NNS\n  at/IN\n  the/DT\n  messenger/NN\n  (ORGANIZATION RNA/NNP)\n  or/CC\n  protein/JJ\n  level/NN\n  ./.\n  5.1/CD\n  ./.\n  VEGF/NNP\n  as/IN\n  a/DT\n  biomarker/NN\n  The/DT\n  most/RBS\n  broadly/RB\n  studied/JJ\n  candidate/NN\n  biomarker/NN\n  in/IN\n  antian-/JJ\n  giogenic/JJ\n  therapy/NN\n  has/VBZ\n  been/VBN\n  (ORGANIZATION VEGF/NNP)\n  ./.\n  In/IN\n  a/DT\n  prospective/JJ\n  biomarkerstudy/NN\n  of/IN\n  the/DT\n  (GPE E4599/NNP)\n  trial/NN\n  of/IN\n  carboplatin/paclitaxel/NN\n  in/IN\n  combi-nation/NN\n  with/IN\n  bevacizumab/NN\n  ,/,\n  patients/NNS\n  with/IN\n  high/JJ\n  plasma/NN\n  levels/NNS\n  ofVEGF/VBP\n  had/VBD\n  a/DT\n  higher/JJR\n  probability/NN\n  of/IN\n  response/NN\n  with/IN\n  bevacizumabvs/JJ\n  carboplatin/paclitaxel/NN\n  alone/RB\n  (/(\n  33/CD\n  %/NN\n  vs/JJ\n  7/CD\n  %/NN\n  ,/,\n  P=/NNP\n  0.01/CD\n  )/)\n  [/VBD\n  95/CD\n  ]/NN\n  ./.\n  However/RB\n  ,/,\n  (ORGANIZATION VEGF/NNP)\n  levels/NNS\n  were/VBD\n  not/RB\n  predictive/JJ\n  of/IN\n  the/DT\n  survivalbene\ufb01t/NN\n  observed/VBD\n  in/IN\n  the/DT\n  bevacizumab/NN\n  arm/NN\n  [/NN\n  95/CD\n  ]/NN\n  ./.\n  (ORGANIZATION VEGF/NNP)\n  has/VBZ\n  also/RB\n  been/VBN\n  investigated/VBN\n  as/IN\n  a/DT\n  predictive/JJ\n  marker/NN\n  of/IN\n  response/NN\n  tovandetanib/NN\n  [/VBD\n  96/CD\n  ]/NN\n  ./.\n  In/IN\n  an/DT\n  analysis/NN\n  of/IN\n  multiple/JJ\n  trials/NNS\n  of/IN\n  previously/RB\n  treated/VBN\n  patients/NNS\n  with/IN\n  (ORGANIZATION NSCLC/NNP)\n  ,/,\n  those/DT\n  with/IN\n  low/JJ\n  baseline/NN\n  (ORGANIZATION plasmaVEGF/NN)\n  levels/NNS\n  had/VBD\n  superior/JJ\n  (ORGANIZATION PFS/NNP)\n  with/IN\n  vandetanib/JJ\n  vs/NN\n  ge\ufb01tinib/NN\n  (/(\n  (ORGANIZATION HR/NNP)\n  ,/,\n  0.55/CD\n  ;/:\n  P=/NNP\n  0.01/CD\n  )/)\n  [/VBD\n  96/CD\n  ]/NNP\n  ./.\n  Patients/NNS\n  with/IN\n  low/JJ\n  baseline/NN\n  (ORGANIZATION VEGF/NNP)\n  also/RB\n  had/VBD\n  superior/JJ\n  (ORGANIZATION PFS/NNP)\n  with/IN\n  docetaxel/JJ\n  plus/CC\n  vandetanib/JJ\n  100/CD\n  mgvs/NN\n  placebo/NN\n  (/(\n  (ORGANIZATION HR/NNP)\n  ,/,\n  0.25/CD\n  ;/:\n  P=/NNP\n  0.01/CD\n  )/)\n  ,/,\n  but/CC\n  there/EX\n  was/VBD\n  no/DT\n  signi\ufb01cant/JJ\n  correlation/NN\n  with/IN\n  docetaxel/JJ\n  plus/CC\n  vandetanib/JJ\n  300/CD\n  mg/NN\n  vs/NN\n  placebo/NN\n  [/VBD\n  96/CD\n  ]/NN\n  ./.\n  In/IN\n  another/DT\n  study/NN\n  ,/,\n  (PERSON Hanrahan/NNP)\n  et/VBZ\n  al/NN\n  ./.\n  analyzed/VBD\n  whether/IN\n  35/CD\n  different/JJ\n  cytokines/NNS\n  and/CC\n  angiogenic/JJ\n  factors/NNS\n  ,/,\n  including/VBG\n  (ORGANIZATION VEGFand/NNP)\n  VEGFR-2/NNP\n  ,/,\n  were/VBD\n  affected/VBN\n  by/IN\n  antiangiogenic/JJ\n  treatmentamong/JJ\n  123/CD\n  patients/NNS\n  with/IN\n  NSCLC/NNP\n  who/WP\n  were/VBD\n  enrolled/VBN\n  ina/RB\n  randomized/VBN\n  phase/NN\n  II/NNP\n  trial/NN\n  of/IN\n  patients/NNS\n  receiving/VBG\n  vande-tanib/JJ\n  alone/NN\n  or/CC\n  in/IN\n  combination/NN\n  with/IN\n  carboplatin/paclitaxel/JJ\n  orcarboplatin/paclitaxel/NN\n  alone/RB\n  [/VBZ\n  97/CD\n  ]/NN\n  ./.\n  With/IN\n  vandetanib/JJ\n  monother-/JJ\n  apy/NN\n  ,/,\n  (ORGANIZATION VEGF/NNP)\n  levels/NNS\n  were/VBD\n  signi\ufb01cantly/RB\n  elevated/VBN\n  at/IN\n  Day/NNP\n  43/CD\n  (/(\n  P=/NNP\n  0.048/CD\n  )/)\n  ./.\n  In/IN\n  addition/NN\n  ,/,\n  VEGFR-2/NNP\n  serum/NN\n  levels/NNS\n  were/VBD\n  signi\ufb01-/JJ\n  cantly/RB\n  lowered/VBD\n  8/CD\n  days/NNS\n  after/IN\n  treatment/NN\n  with/IN\n  vandetanib/JJ\n  amongall/JJ\n  treatment/NN\n  arms/NNS\n  (/(\n  P=/NNP\n  0.001/CD\n  )/)\n  and/CC\n  at/IN\n  Day/NNP\n  43/CD\n  in/IN\n  the/DT\n  vande-/JJ\n  tanib/NN\n  monotherapy/NN\n  arm/NN\n  (/(\n  (PERSON P/NNP)\n  </NNP\n  0.001/CD\n  )/)\n  [/VBD\n  97/CD\n  ]/NN\n  ./.\n  (ORGANIZATION VEGF/NNP)\n  elevations/NNS\n  have/VBP\n  been/VBN\n  observed/VBN\n  in/IN\n  several/JJ\n  tumor/NN\n  types/NNS\n  after/IN\n  treatmentwith/NN\n  sunitinib/NN\n  [/VBD\n  98,99/CD\n  ]/NN\n  ,/,\n  and/CC\n  reductions/NNS\n  in/IN\n  VEGFR-2/NNP\n  levels/NNS\n  with/IN\n  antiangiogenic/JJ\n  treatment/NN\n  have/VBP\n  also/RB\n  been/VBN\n  observed/VBN\n  in/IN\n  apreclinical/JJ\n  model/NN\n  following/VBG\n  sunitinib/JJ\n  treatment/NN\n  [/VBD\n  100/CD\n  ]/NNP\n  ./.\n  5.2/CD\n  ./.\n  Other/JJ\n  biomarkers/NNS\n  Results/NNS\n  from/IN\n  the/DT\n  (ORGANIZATION BATTLE/NNP)\n  (/(\n  Biomarker-integrated/JJ\n  Approaches/NNP\n  of/IN\n  (ORGANIZATION Targeted/NNP)\n  Therapy/NNP\n  for/IN\n  (PERSON Lung/NNP Cancer/NNP)\n  Elimina-tion/NNP\n  )/)\n  program/NN\n  ,/,\n  1/CD\n  of/IN\n  the/DT\n  \ufb01rst/NNP\n  large/JJ\n  prospective/JJ\n  studies/NNS\n  to/TO\n  assesscandidate/VB\n  potential/JJ\n  predictive/JJ\n  biomarkers/NNS\n  to/TO\n  guide/VB\n  treatmentselection/NN\n  in/IN\n  heavily/RB\n  pretreated/VBN\n  patients/NNS\n  with/IN\n  (ORGANIZATION advancedNSCLC/NNS)\n  ,/,\n  were/VBD\n  recently/RB\n  presented/VBN\n  [/NN\n  101/CD\n  ]/NN\n  ./.\n  Patients/NNS\n  were/VBD\n  \ufb01rst/NNP\n  enrolled/VBN\n  in/IN\n  an/DT\n  umbrella/NN\n  study/NN\n  ,/,\n  where/WRB\n  core/NN\n  biopsy/NN\n  specimenswere/RB\n  screened/VBN\n  for/IN\n  11/CD\n  individual/JJ\n  biomarkers/NNS\n  related/VBN\n  to/TO\n  4molecular/CD\n  pathways/NNS\n  in/IN\n  (GPE NSCLC/NNP)\n  (/(\n  ranked/VBN\n  in/IN\n  order/NN\n  of/IN\n  deemedimportance/NN\n  in/IN\n  (GPE NSCLC/NNP)\n  )/)\n  :/:\n  (/(\n  1/CD\n  )/)\n  (ORGANIZATION EGFR/NN)\n  ,/,\n  (/(\n  2/CD\n  )/)\n  KRAS/BRAF/NNP\n  ,/,\n  (/(\n  3/CD\n  )/)\n  (ORGANIZATION VEGF/NNP)\n  ,/,\n  and/CC\n  (/(\n  4/CD\n  )/)\n  RXR/cyclin/NNP\n  D1/NNP\n  ./.\n  Patients/NNS\n  with/IN\n  inadequatetissue/NN\n  or/CC\n  no/DT\n  biomarkers/NNS\n  present/VBP\n  were/VBD\n  assigned/VBN\n  to/TO\n  a/DT\n  \ufb01fthgroup/NN\n  ,/,\n  and/CC\n  patients/NNS\n  with/IN\n  multiple/JJ\n  markers/NNS\n  were/VBD\n  assigned/VBN\n  to/TO\n  1group/CD\n  based/VBN\n  on/IN\n  the/DT\n  highest/JJS\n  ranked/JJ\n  marker/NN\n  that/WDT\n  was/VBD\n  positive.Based/VBN\n  on/IN\n  the/DT\n  biomarker/NN\n  group/NN\n  assignments/NNS\n  ,/,\n  patients/NNS\n  were/VBD\n  \ufb01rst/NNP\n  equally/RB\n  randomized/VBD\n  and/CC\n  then/RB\n  adaptively/RB\n  randomizedto/JJ\n  1/CD\n  of/IN\n  4/CD\n  treatment/NN\n  regimens/NNS\n  :/:\n  sorafenib/NN\n  (/(\n  (ORGANIZATION NCT00411671/NNP)\n  )/)\n  ,/,\n  vandetanib/FW\n  (/(\n  (ORGANIZATION NCT00410189/NNP)\n  )/)\n  ,/,\n  erlotinib/FW\n  (/(\n  (ORGANIZATION NCT00410059/NNP)\n  )/)\n  ,/,\n  orerlotinib/bexarotene/FW\n  (/(\n  (ORGANIZATION NCT00411632/NNP)\n  )/)\n  [/VBD\n  101/CD\n  ]/NN\n  ./.\n  The/DT\n  primary/JJ\n  endpoint/NN\n  ,/,\n  disease/NN\n  control/NN\n  (/(\n  DC/NNP\n  )/)\n  at/IN\n  8/CD\n  weeks/NNS\n  ,/,\n  was/VBD\n  46/CD\n  %/NN\n  acrossall/JJ\n  treatment/NN\n  groups/NNS\n  ./.\n  Among/IN\n  patients/NNS\n  treated/VBN\n  with/IN\n  erlotinib/NN\n  (/(\n  N=/NNP\n  58/CD\n  )/)\n  ,/,\n  vandetanib/FW\n  (/(\n  N=/NNP\n  52/CD\n  )/)\n  ,/,\n  erlotinib/bexarotene/FW\n  (/(\n  N=/NNP\n  36/CD\n  )/)\n  ,/,\n  and/CC\n  sorafenib/NN\n  (/(\n  N=/NNP\n  98/CD\n  )/)\n  ,/,\n  (ORGANIZATION DC/NNP)\n  at/IN\n  8/CD\n  weeks/NNS\n  was/VBD\n  34/CD\n  %/NN\n  ,/,\n  33/CD\n  %/NN\n  ,/,\n  50/CD\n  %/NN\n  ,/,\n  and/CC\n  58/CD\n  %/NN\n  ,/,\n  respectively/RB\n  [/JJ\n  101/CD\n  ]/NN\n  ./.\n  In/IN\n  a/DT\n  subset/JJ\n  analysis/NN\n  of/IN\n  patients/NNS\n  who/WP\n  received/VBD\n  sorafenib/NN\n  (/(\n  N=/NNP\n  98/CD\n  )/)\n  ,/,\n  (ORGANIZATION DC/NNP)\n  rate/NN\n  at/IN\n  8/CD\n  weeks/NNS\n  was/VBD\n  sig-/JJ\n  ni\ufb01cantly/RB\n  lower/JJR\n  in/IN\n  patients/NNS\n  whose/WP$\n  tumors/NNS\n  had/VBD\n  an/DT\n  (ORGANIZATION activatingEGFR/NN)\n  mutation/NN\n  than/IN\n  for/IN\n  those/DT\n  without/IN\n  the/DT\n  mutation/NN\n  (/(\n  23/CD\n  %/NN\n  vs/JJ\n  64/CD\n  %/NN\n  ;/:\n  P=/NNP\n  0.012/CD\n  )/)\n  and/CC\n  in/IN\n  patients/NNS\n  with/IN\n  a/DT\n  high/JJ\n  (ORGANIZATION EGFR/NNP)\n  polysomy/NN\n  than/IN\n  in/IN\n  those/DT\n  without/IN\n  (/(\n  27/CD\n  %/NN\n  vs/JJ\n  62/CD\n  %/NN\n  ;/:\n  P=/NNP\n  0.048/CD\n  )/)\n  [/VBD\n  102/CD\n  ]/NNP\n  .I/NNP\n  n/JJ\n  patients/NNS\n  with/IN\n  (ORGANIZATION KRAS/NNP)\n  mutation/NN\n  (/(\n  (ORGANIZATION KRAS/NNP)\n  is/VBZ\n  a/DT\n  downstream/JJ\n  mediator/NN\n  of/IN\n  (ORGANIZATION EGFR/NNP)\n  signaling/VBG\n  )/)\n  ,/,\n  the/DT\n  (ORGANIZATION DC/NNP)\n  rate/NN\n  at/IN\n  8/CD\n  weeks/NNS\n  was61/CD\n  %/NN\n  with/IN\n  sorafenib/NN\n  (/(\n  11/CD\n  of/IN\n  18/CD\n  )/)\n  compared/VBN\n  with/IN\n  31/CD\n  %/NN\n  (/(\n  4/CD\n  of/IN\n  13/CD\n  )/)\n  with/IN\n  erlotinib/NN\n  ./.\n  These/DT\n  results/NNS\n  suggest/VBP\n  that/IN\n  genetic/JJ\n  (ORGANIZATION mutationsinKRAS/NN)\n  may/MD\n  be/VB\n  a/DT\n  potential/JJ\n  biomarker/NN\n  for/IN\n  predicting/VBG\n  treatment/NN\n  success/NN\n  with/IN\n  antiangiogenic/JJ\n  agents/NNS\n  (/(\n  sorafenibinhibits/NNS\n  angiogenic/RB\n  and/CC\n  proliferation/JJ\n  targets/NNS\n  )/)\n  [/VBP\n  102/CD\n  ]/NNP\n  ./.\n  Another/DT\n  example/NN\n  of/IN\n  a/DT\n  potential/JJ\n  biomarker/NN\n  to/TO\n  aid/NN\n  in/IN\n  treatment/NN\n  decisions/NNS\n  involving/VBG\n  antiangiogenic/JJ\n  therapy/NN\n  issoluble/JJ\n  intercellular/JJ\n  adhesion/NN\n  molecule/NN\n  (/(\n  (ORGANIZATION ICAM/NNP)\n  )/)\n  ./.\n  In/IN\n  asubsequent/JJ\n  analysis/NN\n  of/IN\n  the/DT\n  aforementioned/JJ\n  E4599/NNP\n  phase/NN\n  (ORGANIZATION IIItrial/NNP)\n  of/IN\n  carboplatin/paclitaxel/NN\n  with/IN\n  or/CC\n  without/IN\n  bevacizumabin/JJ\n  (ORGANIZATION NSCLC/NNP)\n  patients/NNS\n  ,/,\n  response/NN\n  was/VBD\n  correlated/VBN\n  with/IN\n  baselinebiomarker/NN\n  levels/NNS\n  [/VBP\n  95/CD\n  ]/NN\n  ./.\n  For/IN\n  either/DT\n  treatment/NN\n  group/NN\n  ,/,\n  patients/NNS\n  with/IN\n  lower/JJR\n  baseline/NN\n  levels/NNS\n  of/IN\n  (ORGANIZATION ICAM/NNP)\n  had/VBD\n  improved/VBN\n  RR/NNP\n  (/(\n  32/CD\n  %/NN\n  vs/JJ\n  14/CD\n  %/NN\n  ;/:\n  P=/NNP\n  0.02/CD\n  )/)\n  ,/,\n  (GPE OS/NNP)\n  (/(\n  62/75/CD\n  deaths/NNS\n  vs/RB\n  70/75/CD\n  deaths/NNS\n  ;/:\n  P=/NNP\n  0.00005/CD\n  )/)\n  ,/,\n  and/CC\n  1-year/JJ\n  survival/NN\n  (/(\n  65/CD\n  %/NN\n  vs/JJ\n  25/CD\n  %/NN\n  )/)\n  than/IN\n  patients/NNS\n  with/IN\n  high/JJ\n  (ORGANIZATION ICAM/NNP)\n  levels/NNS\n  ./.\n  (PERSON Baseline/NNP)\n  E-selectin/JJ\n  levels/NNS\n  ,/,\n  however/RB\n  ,/,\n  did/VBD\n  not/RB\n  have/VB\n  signi\ufb01cant/JJ\n  effects/NNS\n  on/IN\n  RR/NNP\n  ,/,\n  (ORGANIZATION PFS/NNP)\n  ,/,\n  or/CC\n  OS/NNP\n  ./.\n  Theseresults/NNP\n  suggest/VBP\n  that/IN\n  (ORGANIZATION ICAM/NNP)\n  level/NN\n  is/VBZ\n  prognostic/JJ\n  for/IN\n  survivaland/NN\n  predictive/NN\n  of/IN\n  response/NN\n  to/TO\n  chemotherapy/VB\n  with/IN\n  or/CC\n  withoutbevacizumab/VB\n  ./.\n  Hypertension/NN\n  that/IN\n  begins/VBZ\n  during/IN\n  antiangio-genic/JJ\n  treatment/NN\n  has/VBZ\n  been/VBN\n  suggested/VBN\n  as/IN\n  another/DT\n  predictorof/NN\n  clinical/JJ\n  outcomes/NNS\n  ./.\n  For/IN\n  example/NN\n  ,/,\n  in/IN\n  a/DT\n  study/NN\n  of/IN\n  patientswith/NN\n  nonsquamous/JJ\n  NSCLC/NNP\n  from/IN\n  the/DT\n  (GPE E4599/NNP)\n  study/NN\n  who/WP\n  weretreated/VBD\n  with/IN\n  bevacizumab/JJ\n  plus/CC\n  carboplatin/paclitaxel/JJ\n  vscarboplatin/paclitaxel/NN\n  alone/RB\n  ,/,\n  hypertension/NN\n  that/WDT\n  began/VBD\n  soonafter/JJR\n  the/DT\n  start/NN\n  of/IN\n  treatment/NN\n  in/IN\n  the/DT\n  bevacizumab/NN\n  arm/NN\n  wasassociated/VBD\n  with/IN\n  increased/JJ\n  median/JJ\n  OS/NNP\n  (/(\n  15.9/CD\n  months/NNS\n  ;/:\n  95/CD\n  %/NN\n  CI,13.4\u201320.3/NNP\n  )/)\n  compared/VBN\n  with/IN\n  patients/NNS\n  who/WP\n  did/VBD\n  not/RB\n  experiencehypertension/NN\n  (/(\n  11.5/CD\n  months/NNS\n  ;/:\n  95/CD\n  %/NN\n  CI/NNP\n  ,/,\n  10.4\u201313.4/CD\n  ;/:\n  P=/NNP\n  0.00002/CD\n  )/)\n  [/VBD\n  103/CD\n  ]/NN\n  ./.\n  However/RB\n  ,/,\n  more/RBR\n  recently/RB\n  ,/,\n  in/IN\n  a/DT\n  large/JJ\n  study/NN\n  of/IN\n  approx-/NN\n  imately/JJ\n  5900/CD\n  patients/NNS\n  across/IN\n  6/CD\n  placebo-controlled/JJ\n  ,/,\n  (ORGANIZATION phaseIII/JJ)\n  studies/NNS\n  of/IN\n  bevacizumab/NN\n  ,/,\n  hypertension/NN\n  that/IN\n  arose/JJ\n  duringtreatment/NN\n  did/VBD\n  not/RB\n  predict/JJ\n  improvement/NN\n  in/IN\n  (ORGANIZATION PFS/NNP)\n  or/CC\n  OS/NNP\n  [/VBP\n  104/CD\n  ]/NNP\n  ./.\n  6/CD\n  ./.\n  Conclusions/NNPS\n  The/DT\n  development/NN\n  of/IN\n  bevacizumab/NN\n  represents/VBZ\n  a/DT\n  step/NN\n  toward/IN\n  the/DT\n  use/NN\n  of/IN\n  targeted/JJ\n  antiangiogenic/JJ\n  agents/NNS\n  in/IN\n  the/DT\n  (ORGANIZATION clinicalA/NN)\n  ./.\n  (PERSON Wozniak/NNP)\n  //NNP\n  Critical/NNP\n  Reviews/NNP\n  in/IN\n  Oncology/Hematology/NNP\n  82/CD\n  (/(\n  2012/CD\n  )/)\n  200\u2013212/CD\n  209/CD\n  management/NN\n  of/IN\n  patients/NNS\n  with/IN\n  (ORGANIZATION NSCLC/NNP)\n  ./.\n  However/RB\n  ,/,\n  because/IN\n  of/IN\n  limitations/NNS\n  of/IN\n  currently/RB\n  available/JJ\n  antiangiogenic/JJ\n  therapy/NN\n  withrespect/NN\n  to/TO\n  ef\ufb01cacy/NN\n  and/CC\n  safety/NN\n  ,/,\n  new/JJ\n  antiangiogenic/JJ\n  agents/NNS\n  havebeen/JJ\n  developed/VBD\n  that/DT\n  may/MD\n  further/RB\n  improve/VB\n  outcomes/NNS\n  in/IN\n  thesepatients/NNS\n  ./.\n  The/DT\n  challenge/NN\n  remains/VBZ\n  to/TO\n  de\ufb01ne/VB\n  the/DT\n  optimal/JJ\n  roleand/NN\n  appropriate/JJ\n  sequence/NN\n  of/IN\n  these/DT\n  agents/NNS\n  in/IN\n  the/DT\n  treatmentparadigm/NN\n  for/IN\n  (ORGANIZATION NSCLC/NNP)\n  ,/,\n  particularly/RB\n  with/IN\n  respect/NN\n  to/TO\n  risk/VB\n  ofserious/JJ\n  adverse/JJ\n  events/NNS\n  in/IN\n  patient/JJ\n  subpopulations/NNS\n  or/CC\n  amongpatients/NNS\n  with/IN\n  speci\ufb01c/JJ\n  tumor/NN\n  histologies/NNS\n  ./.\n  In/IN\n  addition/NN\n  ,/,\n  thereis/EX\n  currently/RB\n  no/DT\n  biomarker-driven/JJ\n  guidance/NN\n  for/IN\n  the/DT\n  use/NN\n  ofthese/JJ\n  agents/NNS\n  in/IN\n  patients/NNS\n  with/IN\n  (ORGANIZATION NSCLC/NNP)\n  ;/:\n  predictive/JJ\n  biomark-ers/NNS\n  or/CC\n  gene/NN\n  signatures/NNS\n  that/WDT\n  could/MD\n  identify/VB\n  patients/NNS\n  likely/JJ\n  toderive/JJ\n  bene\ufb01t/NN\n  from/IN\n  these/DT\n  agents/NNS\n  will/MD\n  be/VB\n  necessary/JJ\n  to/TO\n  trulypersonalize/VB\n  antiangiogenic/JJ\n  therapy/NN\n  ./.\n  Con\ufb02ict/NNP\n  of/IN\n  interest/NN\n  statement/NN\n  Dr./NNP\n  Wozniak/NNP\n  is/VBZ\n  a/DT\n  member/NN\n  of/IN\n  the/DT\n  speakers/NNS\n  bureau/VBP\n  at/IN\n  Genen-/NNP\n  tech/NN\n  and/CC\n  (PERSON Lilly/NNP Oncology/NNP)\n  ,/,\n  and/CC\n  is/VBZ\n  a/DT\n  member/NN\n  of/IN\n  the/DT\n  advisoryboard/NN\n  at/IN\n  (ORGANIZATION Genentech/NNP)\n  ,/,\n  (PERSON Boehringer/NNP Ingelheim/NNP)\n  ,/,\n  (PERSON Astra/NNP Zeneca/NNP)\n  ,/,\n  and/CC\n  (PERSON Lilly/NNP Oncology/NNP)\n  ./.\n  Dr./NNP\n  Wozniak/NNP\n  receives/VBZ\n  research/NN\n  fundingfrom/NN\n  (PERSON Lilly/NNP Oncology/NNP)\n  ./.\n  Reviewers/NNP\n  (PERSON Robert/NNP Pirker/NNP)\n  ,/,\n  (ORGANIZATION MD/NNP)\n  ,/,\n  (ORGANIZATION Medical/NNP University/NNP)\n  of/IN\n  (GSP Vienna/NNP)\n  ,/,\n  Divi-/NNP\n  sion/NN\n  of/IN\n  (GPE Oncology/NNP)\n  ,/,\n  (ORGANIZATION Department/NNP)\n  of/IN\n  (ORGANIZATION Internal/NNP)\n  Medicine/NNP\n  I/PRP\n  ,/,\n  (PERSON W\u00e4hringer/NNP G\u00fcrtel/NNP)\n  18-20/JJ\n  ,/,\n  A-1090/NNP\n  Vienna/NNP\n  ,/,\n  (GSP Austria/NNP)\n  ./.\n  (PERSON Niels/NNP Reinmuth/NNP)\n  ,/,\n  (ORGANIZATION MD/NNP)\n  ,/,\n  (ORGANIZATION University/NNP Clinik/NNP)\n  of/IN\n  (GPE Heidelberg/NNP)\n  ,/,\n  Thoraxklinik-Heidelberg/NNP\n  GmbH/NNP\n  ,/,\n  (ORGANIZATION Amalienstr/NNP)\n  ./.\n  5/CD\n  ,/,\n  D-69126Heidelberg/NNP\n  ,/,\n  (GPE Germany/NNP)\n  ./.\n  Acknowledgments/NNS\n  This/DT\n  work/NN\n  was/VBD\n  supported/VBN\n  by/IN\n  (PERSON Boehringer/NNP Ingelheim/NNP)\n  Phar-/NNP\n  maceuticals/NNS\n  ,/,\n  (GPE Inc./NNP)\n  (/(\n  (ORGANIZATION BIPI/NNP)\n  )/)\n  ./.\n  Writing/VBG\n  and/CC\n  editorial/JJ\n  assistance/NN\n  wasprovided/VBN\n  by/IN\n  (PERSON Staci/NNP Deaton/NNP)\n  ,/,\n  (ORGANIZATION PhD/NNP)\n  ,/,\n  of/IN\n  (ORGANIZATION MedErgy/NNP)\n  ,/,\n  which/WDT\n  wascontracted/VBN\n  by/IN\n  (ORGANIZATION BIPI/NNP)\n  for/IN\n  these/DT\n  services/NNS\n  ./.\n  The/DT\n  author/NN\n  meets/VBZ\n  cri-teria/NN\n  for/IN\n  authorship/NN\n  as/IN\n  recommended/VBN\n  by/IN\n  the/DT\n  (ORGANIZATION InternationalCommittee/NNP)\n  of/IN\n  (ORGANIZATION Medical/NNP Journal/NNP Editors/NNP)\n  (/(\n  (ORGANIZATION ICMJE/NNP)\n  )/)\n  ,/,\n  was/VBD\n  fullyresponsible/JJ\n  for/IN\n  all/DT\n  content/NN\n  and/CC\n  editorial/NN\n  decisions/NNS\n  ,/,\n  and/CC\n  wasinvolved/VBD\n  at/IN\n  all/DT\n  stages/NNS\n  of/IN\n  manuscript/NN\n  development/NN\n  ./.\n  The/DT\n  authorreceived/JJ\n  no/DT\n  compensation/NN\n  related/VBN\n  to/TO\n  the/DT\n  development/NN\n  of/IN\n  themanuscript/NN\n  ./.\n  References/NNS\n  [/VBD\n  1/CD\n  ]/NNP\n  World/NNP\n  Health/NNP\n  Organization/NNP\n  ./.\n  (PERSON Fact/NNP Sheet/NNP No/NNP)\n  ./.\n  310/CD\n  :/:\n  The/DT\n  top/JJ\n  ten/NN\n  causes/NNS\n  of/IN\n  death/NN\n  ./.\n  November/NNP\n  2008./CD\n  http/NN\n  :/:\n  //www.who.int/mediacentre//JJ\n  factsheets/fs310/NN\n  2008.pdf/CD\n  ./.\n  Accessed/VBN\n  October/NNP\n  8/CD\n  ;/:\n  2009/CD\n  ./.\n  [/VB\n  2/CD\n  ]/NNP\n  Jemal/NNP\n  A/NNP\n  ,/,\n  (PERSON Siegel/NNP R/NNP)\n  ,/,\n  (PERSON Xu/NNP J/NNP)\n  ,/,\n  (PERSON Ward/NNP E./NNP Cancer/NNP)\n  statistics/NNS\n  ,/,\n  2010/CD\n  ./.\n  CA/NNP\n  Cancer/NNP\n  J/NNP\n  Clin/NNP\n  2010/CD\n  ;/:\n  60:277\u2013300/CD\n  ./.\n  [/VB\n  3/CD\n  ]/JJ\n  (ORGANIZATION American/JJ Cancer/NNP Society/NNP)\n  ./.\n  (PERSON Cancer/NNP)\n  facts/VBZ\n  &/CC\n  \ufb01gures/NNS\n  ,/,\n  2009/CD\n  ./.\n  (PERSON Atlanta/NNP)\n  ,/,\n  GA/NNP\n  :/:\n  (ORGANIZATION American/JJ Cancer/NNP Society/NNP)\n  ,/,\n  (GPE Inc./NNP)\n  ;/:\n  2009/CD\n  ./.\n  [/VB\n  4/CD\n  ]/NNP\n  Ramalingam/NNP\n  S/NNP\n  ,/,\n  (PERSON Belani/NNP C./NNP Systemic/NNP)\n  chemotherapy/NN\n  for/IN\n  advanced/JJ\n  non-small/JJ\n  cell/NN\n  lung/NN\n  cancer/NN\n  :/:\n  recent/JJ\n  advances/NNS\n  and/CC\n  future/JJ\n  directions.Oncologist/NN\n  2008/CD\n  ;/:\n  13/CD\n  (/(\n  Suppl/NNP\n  ./.\n  1/CD\n  )/)\n  :5\u201313/NN\n  ./.\n  [/CC\n  5/CD\n  ]/JJ\n  (ORGANIZATION\n    National/NNP\n    Comprehensive/NNP\n    Cancer/NNP\n    Network/NNP)\n  ./.\n  (ORGANIZATION NCCN/NNP Clinical/NNP)\n  Practice/NNP\n  Guidelines/NNP\n  in/IN\n  (GPE Oncology/NNP)\n  TM/NNP\n  ./.\n  Non-Small/NN\n  (PERSON Cell/NNP Lung/NNP Cancer/NNP)\n  ./.\n  V/NNP\n  .2.2010./JJ\n  http/NN\n  :/:\n  //www.nccn.org/professionals/physician/JJ\n  gls/PDF/nscl.pdf/NN\n  ./.\n  Accessed/VBN\n  April/NNP\n  8/CD\n  ;/:\n  2010/CD\n  ./.\n  [/VB\n  6/CD\n  ]/NNP\n  Scagliotti/NNP\n  GV/NNP\n  ,/,\n  (PERSON Parikh/NNP P/NNP)\n  ,/,\n  von/NNP\n  Pawel/NNP\n  J/NNP\n  ,/,\n  et/VBZ\n  al/NN\n  ./.\n  study/NN\n  comparing/VBG\n  cisplatin/JJ\n  plus/CC\n  gemcitabine/JJ\n  with/IN\n  cisplatin/JJ\n  plus/CC\n  pemetrexed/JJ\n  in/IN\n  chemotherapy-naive/JJ\n  patients/NNS\n  with/IN\n  advanced-stage/JJ\n  non-small-cell/JJ\n  lung/NN\n  cancer/NN\n  ./.\n  J/NNP\n  ClinOncol/NNP\n  2008/CD\n  ;/:\n  26:3543\u201351/CD\n  ./.\n  [/VB\n  7/CD\n  ]/NNP\n  (PERSON Schiller/NNP JH/NNP)\n  ,/,\n  (PERSON Harrington/NNP D/NNP)\n  ,/,\n  (PERSON Belani/NNP CP/NNP)\n  ,/,\n  et/RB\n  al/NN\n  ./.\n  (ORGANIZATION Comparison/NNP)\n  of/IN\n  four/CD\n  chemotherapy/NN\n  regimens/NNS\n  for/IN\n  advanced/JJ\n  non-small-cell/JJ\n  lung/NN\n  cancer/NN\n  ./.\n  (ORGANIZATION NEngl/NNP)\n  J/NNP\n  Med/NNP\n  2002/CD\n  ;/:\n  346:92\u20138/CD\n  ./.\n  [/VB\n  8/CD\n  ]/NNP\n  Breathnach/NNP\n  OS/NNP\n  ,/,\n  (PERSON Freidlin/NNP B/NNP)\n  ,/,\n  (PERSON Conley/NNP B/NNP)\n  ,/,\n  et/NN\n  al/NN\n  ./.\n  Twenty-two/CD\n  years/NNS\n  of/IN\n  phase/NN\n  (ORGANIZATION III/NNP)\n  trials/NNS\n  for/IN\n  patients/NNS\n  with/IN\n  advanced/JJ\n  non-small-cell/JJ\n  lung/NN\n  cancer/NN\n  :/:\n  sobering/JJ\n  results/NNS\n  ./.\n  J/NNP\n  (PERSON Clin/NNP Oncol/NNP)\n  2001/CD\n  ;/:\n  19:1734\u201342/CD\n  ./.\n  [/VB\n  9/CD\n  ]/NNP\n  (PERSON Tarceva/NNP)\n  \u00ae/NNP\n  (/(\n  erlotinib/JJ\n  tablets/NNS\n  )/)\n  [/VBP\n  package/NN\n  insert/JJ\n  ]/NNP\n  ./.\n  (PERSON South/NNP San/NNP Franscisco/NNP)\n  ,/,\n  CA/NNP\n  :/:\n  Genentech/NNP\n  ,/,\n  (PERSON Inc./NNP)\n  [/VBD\n  10/CD\n  ]/JJ\n  (ORGANIZATION AstraZeneca/NNP)\n  ./.\n  (ORGANIZATION IRESSA/NNP)\n  (/(\n  (ORGANIZATION Ge\ufb01tinib/NNP)\n  )/)\n  Receives/VBZ\n  Marketing/VBG\n  Autho-/NNP\n  risation/NN\n  for/IN\n  the/DT\n  (ORGANIZATION Treatment/NNP)\n  of/IN\n  Non-Small/NNP\n  Cell/NNP\n  Lung/NNP\n  Cancer/NNP\n  inEurope/NN\n  ./.\n  http/NN\n  :/:\n  //www.astrazeneca.com/Media/Press-releases/Article//JJ\n  20090701\u2013IRESSA-Ge\ufb01tinib-Receives-Marketing-Authorisation-f/JJ\n  ./.\n  Accessed/VBN\n  April/NNP\n  8/CD\n  ;/:\n  2010/CD\n  ./.\n  [/VB\n  11/CD\n  ]/NNP\n  Kerbel/NNP\n  RS/NNP\n  ./.\n  (PERSON Antiangiogenic/NNP)\n  therapy/NN\n  :/:\n  a/DT\n  universal/JJ\n  chemosensitization/NN\n  strategy/NN\n  for/IN\n  cancer/NN\n  ?/.\n  Science/NN\n  2006/CD\n  ;/:\n  312:1171\u20135/CD\n  ./.\n  [/VB\n  12/CD\n  ]/NNP\n  (PERSON Carmeliet/NNP P./NNP Angiogenesis/NNP)\n  in/IN\n  life/NN\n  ,/,\n  disease/NN\n  and/CC\n  medicine/NN\n  ./.\n  Nature/NN\n  2005/CD\n  ;/:\n  438:932\u20136/CD\n  ./.\n  [/VB\n  13/CD\n  ]/NNP\n  (PERSON Ferrara/NNP N/NNP)\n  ,/,\n  (PERSON Gerber/NNP HP/NNP)\n  ,/,\n  (ORGANIZATION LeCouter/NNP J/NNP)\n  ./.\n  The/DT\n  biology/NN\n  of/IN\n  (ORGANIZATION VEGF/NNP)\n  and/CC\n  its/PRP$\n  receptors/NNS\n  ./.\n  (PERSON Nat/NNP Med/NNP)\n  2003/CD\n  ;/:\n  9:669\u201376/CD\n  ./.\n  [/VB\n  14/CD\n  ]/NNP\n  (PERSON Carmeliet/NNP P/NNP)\n  ,/,\n  (PERSON Jain/NNP RK/NNP)\n  ./.\n  Angiogenesis/NNP\n  in/IN\n  cancer/NN\n  and/CC\n  other/JJ\n  diseases/NNS\n  ./.\n  Nature/NN\n  2000/CD\n  ;/:\n  407:249\u201357/CD\n  ./.\n  [/VB\n  15/CD\n  ]/NNP\n  Folkman/NNP\n  J/NNP\n  ,/,\n  (PERSON Klagsbrun/NNP M./NNP Vascular/NNP)\n  physiology/NN\n  A/NNP\n  family/NN\n  of/IN\n  angiogenic/JJ\n  peptides/NNS\n  ./.\n  Nature/NN\n  1987/CD\n  ;/:\n  329:671\u20132/CD\n  ./.\n  [/VB\n  16/CD\n  ]/NNP\n  Folkman/NNP\n  J/NNP\n  ,/,\n  (PERSON Shing/NNP Y/NNP)\n  ./.\n  Angiogenesis/NNP\n  ./.\n  J/NNP\n  Biol/NNP\n  Chem/NNP\n  1992/CD\n  ;/:\n  267:10931\u20134/CD\n  ./.\n  [/VB\n  17/CD\n  ]/NNP\n  Fukumura/NNP\n  D/NNP\n  ,/,\n  (PERSON Xavier/NNP R/NNP)\n  ,/,\n  (PERSON Sugiura/NNP T/NNP)\n  ,/,\n  et/RB\n  al/NN\n  ./.\n  (PERSON Tumor/NNP)\n  induction/NN\n  of/IN\n  (ORGANIZATION VEGF/NNP)\n  promoter/NN\n  activity/NN\n  in/IN\n  stromal/JJ\n  cells/NNS\n  ./.\n  Cell/NNP\n  1998/CD\n  ;/:\n  94:715\u201325/CD\n  ./.\n  [/VB\n  18/CD\n  ]/JJ\n  Gerber/NNP\n  HP/NNP\n  ,/,\n  (PERSON Kowalski/NNP J/NNP)\n  ,/,\n  (PERSON Sherman/NNP D/NNP)\n  ,/,\n  (PERSON Eberhard/NNP DA/NNP)\n  ,/,\n  (PERSON Ferrara/NNP N./NNP Complete/NNP)\n  inhibition/NN\n  of/IN\n  rhabdomyosarcoma/NN\n  xenograft/NN\n  growthand/NN\n  neovascularization/NN\n  requires/VBZ\n  blockade/NN\n  of/IN\n  both/DT\n  tumor/NN\n  andhost/VBD\n  vascular/JJ\n  endothelial/JJ\n  growth/NN\n  factor/NN\n  ./.\n  (PERSON Cancer/NNP Res/NNP)\n  2000/CD\n  ;/:\n  60:6253\u20138/CD\n  ./.\n  [/VB\n  19/CD\n  ]/NNP\n  Toi/NNP\n  M/NNP\n  ,/,\n  (PERSON Matsumoto/NNP T/NNP)\n  ,/,\n  (PERSON Bando/NNP H./NNP Vascular/NNP)\n  endothelial/JJ\n  growth/NN\n  factor/NN\n  :/:\n  its/PRP$\n  prognostic/JJ\n  ,/,\n  predictive/JJ\n  ,/,\n  and/CC\n  therapeutic/JJ\n  implications/NNS\n  ./.\n  (PERSON Lancet/NNP Oncol2001/NNP)\n  ;/:\n  2:667\u201373/CD\n  ./.\n  [/VB\n  20/CD\n  ]/NNP\n  (PERSON Ferrara/NNP N/NNP)\n  ,/,\n  Davis-Smyth/NNP\n  T./NNP\n  The/DT\n  biology/NN\n  of/IN\n  vascular/JJ\n  endothelial/JJ\n  growth/NN\n  factor/NN\n  ./.\n  (PERSON Endocr/NNP Rev/NNP)\n  1997/CD\n  ;/:\n  18:4\u201325/CD\n  ./.\n  [/VB\n  21/CD\n  ]/NNP\n  (PERSON Kim/NNP KJ/NNP)\n  ,/,\n  (PERSON Li/NNP B/NNP)\n  ,/,\n  (PERSON Winer/NNP J/NNP)\n  ,/,\n  et/VBZ\n  al/NN\n  ./.\n  Inhibition/NN\n  of/IN\n  vascular/JJ\n  endothelial/JJ\n  growth/NN\n  factor-induced/JJ\n  angiogenesis/NN\n  suppresses/VBZ\n  tumour/JJ\n  growth/NN\n  invivo/NN\n  ./.\n  Nature/NN\n  1993/CD\n  ;/:\n  362:841\u20134/CD\n  ./.\n  [/VB\n  22/CD\n  ]/NNP\n  Sund/NNP\n  M/NNP\n  ,/,\n  (PERSON Hamano/NNP Y/NNP)\n  ,/,\n  (PERSON Sugimoto/NNP H/NNP)\n  ,/,\n  et/RB\n  al/NN\n  ./.\n  Function/NN\n  of/IN\n  endogenous/JJ\n  inhibitors/NNS\n  of/IN\n  angiogenesis/NN\n  as/IN\n  endothelium-speci\ufb01c/JJ\n  tumor/NN\n  suppressors.Proc/NN\n  (PERSON Natl/NNP Acad/NNP Sci/NNP)\n  USA/NNP\n  2005/CD\n  ;/:\n  102:2934\u20139/CD\n  ./.\n  [/VB\n  23/CD\n  ]/NNP\n  Yuan/NNP\n  A/NNP\n  ,/,\n  (PERSON Yu/NNP C-J/NNP)\n  ,/,\n  (PERSON Kuo/NNP S-H/NNP)\n  ,/,\n  et/VBZ\n  al/NN\n  ./.\n  Vascular/JJ\n  endothelial/JJ\n  growth/NN\n  factor/NN\n  189/CD\n  mRNA/NN\n  isoform/NN\n  expression/NN\n  speci\ufb01cally/RB\n  correlates/VBZ\n  with/IN\n  tumor/NN\n  angio-genesis/NN\n  ,/,\n  patient/JJ\n  survival/NN\n  ,/,\n  and/CC\n  postoperative/JJ\n  relapse/NN\n  in/IN\n  non-small-celllung/JJ\n  cancer/NN\n  ./.\n  J/NNP\n  (PERSON Clin/NNP Oncol/NNP)\n  2001/CD\n  ;/:\n  19:432\u201341/CD\n  ./.\n  [/VB\n  24/CD\n  ]/NNP\n  (PERSON Millauer/NNP B/NNP)\n  ,/,\n  (PERSON Longhi/NNP MP/NNP)\n  ,/,\n  (ORGANIZATION Plate/NNP)\n  KH/NNP\n  ,/,\n  et/RB\n  al/NN\n  ./.\n  Dominant-negative/JJ\n  inhibition/NN\n  of/IN\n  Flk-1/NNP\n  suppresses/VBZ\n  the/DT\n  growth/NN\n  of/IN\n  many/JJ\n  tumor/NN\n  types/NNS\n  in/IN\n  vivo/NN\n  ./.\n  CancerRes/NNP\n  1996/CD\n  ;/:\n  56:1615\u201320/CD\n  ./.\n  [/VB\n  25/CD\n  ]/NNP\n  (PERSON Alvarez/NNP RH/NNP)\n  ,/,\n  (PERSON Kantarjian/NNP HM/NNP)\n  ,/,\n  (PERSON Cortes/NNP JE/NNP)\n  ./.\n  (PERSON Biology/NNP)\n  of/IN\n  platelet-derived/JJ\n  growth/NN\n  factor/NN\n  and/CC\n  its/PRP$\n  involvement/NN\n  in/IN\n  disease/NN\n  ./.\n  (PERSON Mayo/NNP Clin/NNP Proc2006/NNP)\n  ;/:\n  81:1241\u201357/CD\n  ./.\n  [/VB\n  26/CD\n  ]/NNP\n  (PERSON Bergsten/NNP E/NNP)\n  ,/,\n  (PERSON Uutela/NNP M/NNP)\n  ,/,\n  (PERSON Li/NNP X/NNP)\n  ,/,\n  et/JJ\n  al/NN\n  ./.\n  PDGF-D/NNP\n  is/VBZ\n  a/DT\n  speci\ufb01c/NN\n  ,/,\n  protease-/JJ\n  activated/JJ\n  ligand/NN\n  for/IN\n  the/DT\n  (ORGANIZATION PDGF/NNP)\n  /H9252-receptor/NN\n  ./.\n  (PERSON Nat/NNP Cell/NNP)\n  Biol/NNP\n  2001/CD\n  ;/:\n  3:512\u20136.210/CD\n  A./NN\n  (PERSON Wozniak/NNP)\n  //NNP\n  Critical/NNP\n  Reviews/NNP\n  in/IN\n  Oncology/Hematology/NNP\n  82/CD\n  (/(\n  2012/CD\n  )/)\n  200\u2013212/CD\n  [/$\n  27/CD\n  ]/NNP\n  Wu/NNP\n  E/NNP\n  ,/,\n  (PERSON Palmer/NNP N/NNP)\n  ,/,\n  (PERSON Tian/NNP Z/NNP)\n  ,/,\n  et/RB\n  al/NN\n  ./.\n  Comprehensive/JJ\n  dissection/NN\n  of/IN\n  PDGF-/NNP\n  PDGFR/NNP\n  signaling/VBG\n  pathways/NNS\n  in/IN\n  (GPE PDGFR/NNP)\n  genetically/RB\n  de\ufb01ned/VBD\n  cells.PLoS/NN\n  One/CD\n  2008/CD\n  ;/:\n  3/CD\n  :/:\n  e3794/NN\n  ./.\n  [/CC\n  28/CD\n  ]/JJ\n  Levitzki/NNP\n  A./NN\n  (ORGANIZATION PDGF/NNP)\n  receptor/NN\n  kinase/NN\n  inhibitors/NNS\n  for/IN\n  the/DT\n  treatment/NN\n  of/IN\n  (ORGANIZATION PDGF/NNP)\n  driven/NN\n  diseases/NNS\n  ./.\n  (PERSON Cytokine/NNP Growth/NNP Factor/NNP)\n  Rev/NNP\n  2004/CD\n  ;/:\n  15:229\u201335/CD\n  ./.\n  [/VB\n  29/CD\n  ]/NNP\n  (PERSON Beitz/NNP JG/NNP)\n  ,/,\n  (PERSON Kim/NNP IS/NNP)\n  ,/,\n  (PERSON Calabresi/NNP P/NNP)\n  ,/,\n  (PERSON Frackelton/NNP ARJr/NNP)\n  ./.\n  (PERSON Human/NNP)\n  microvascular/JJ\n  endothelial/NN\n  cells/NNS\n  express/JJ\n  receptors/NNS\n  for/IN\n  platelet-derived/JJ\n  growth/NN\n  factor.Proc/NN\n  (PERSON Natl/NNP Acad/NNP Sci/NNP)\n  USA/NNP\n  1991/CD\n  ;/:\n  88:2021\u20135/CD\n  ./.\n  [/VB\n  30/CD\n  ]/NNP\n  (PERSON Pietras/NNP K/NNP)\n  ,/,\n  (PERSON Rubin/NNP K/NNP)\n  ,/,\n  (PERSON Sjoblom/NNP T/NNP)\n  ,/,\n  et/RB\n  al/NN\n  ./.\n  Inhibition/NN\n  of/IN\n  (ORGANIZATION PDGF/NNP)\n  receptor/NN\n  signaling/VBG\n  in/IN\n  tumor/NN\n  stroma/NN\n  enhances/VBZ\n  antitumor/JJ\n  effect/NN\n  of/IN\n  chemotherapy.Cancer/NN\n  Res/NNP\n  2002/CD\n  ;/:\n  62:5476\u201384/CD\n  ./.\n  [/VB\n  31/CD\n  ]/NNP\n  (PERSON Lindahl/NNP P/NNP)\n  ,/,\n  (PERSON Johansson/NNP BR/NNP)\n  ,/,\n  (PERSON Leveen/NNP P/NNP)\n  ,/,\n  (PERSON Betsholtz/NNP C./NNP Pericyte/NNP)\n  loss/NN\n  and/CC\n  microaneurysm/JJ\n  formation/NN\n  in/IN\n  PDGF-B-de\ufb01cient/NNP\n  mice/NN\n  ./.\n  (GPE Science1997/NNP)\n  ;/:\n  277:242\u20135/CD\n  ./.\n  [/VB\n  32/CD\n  ]/NN\n  (PERSON Hellstrom/NNP M/NNP)\n  ,/,\n  (PERSON Gerhardt/NNP H/NNP)\n  ,/,\n  (PERSON Kalen/NNP M/NNP)\n  ,/,\n  et/RB\n  al/NN\n  ./.\n  Lack/NNP\n  of/IN\n  pericytes/NNS\n  leads/NNS\n  to/TO\n  endothelial/JJ\n  hyperplasia/NN\n  and/CC\n  abnormal/JJ\n  vascular/JJ\n  morphogenesis/NN\n  ./.\n  J/NNP\n  CellBiol/NNP\n  2001/CD\n  ;/:\n  153:543\u201353/CD\n  ./.\n  [/VB\n  33/CD\n  ]/NNP\n  (PERSON Abramsson/NNP A/NNP)\n  ,/,\n  (PERSON Lindblom/NNP P/NNP)\n  ,/,\n  (PERSON Betsholtz/NNP C./NNP Endothelial/NNP)\n  and/CC\n  nonendothe-/JJ\n  lial/JJ\n  sources/NNS\n  of/IN\n  PDGF-B/NNP\n  regulate/NN\n  pericyte/NN\n  recruitment/NN\n  and/CC\n  in\ufb02uencevascular/JJ\n  pattern/NN\n  formation/NN\n  in/IN\n  tumors/NNS\n  ./.\n  J/NNP\n  (PERSON Clin/NNP Invest/NNP)\n  2003/CD\n  ;/:\n  112:1142\u201351/CD\n  ./.\n  [/VB\n  34/CD\n  ]/NN\n  (PERSON Hellstrom/NNP M/NNP)\n  ,/,\n  (PERSON Kalen/NNP M/NNP)\n  ,/,\n  (PERSON Lindahl/NNP P/NNP)\n  ,/,\n  (PERSON Abramsson/NNP A/NNP)\n  ,/,\n  (PERSON Betsholtz/NNP C./NNP Role/NNP)\n  of/IN\n  PDGF-B/NNP\n  and/CC\n  PDGFR-beta/NNP\n  in/IN\n  recruitment/NN\n  of/IN\n  vascular/JJ\n  smooth/NN\n  musclecells/NNS\n  and/CC\n  pericytes/NNS\n  during/IN\n  embryonic/JJ\n  blood/NN\n  vessel/NN\n  formation/NN\n  in/IN\n  themouse/NN\n  ./.\n  Development/NNP\n  1999/CD\n  ;/:\n  126:3047\u201355/CD\n  ./.\n  [/VB\n  35/CD\n  ]/NNP\n  Jain/NNP\n  RK/NNP\n  ,/,\n  (PERSON Booth/NNP MF/NNP)\n  ./.\n  What/WP\n  brings/VBZ\n  pericytes/NNS\n  to/TO\n  tumor/VB\n  vessels/NNS\n  ?/.\n  J/NNP\n  (PERSON Clin/NNP Invest/NNP)\n  2003/CD\n  ;/:\n  112:1134\u20136/CD\n  ./.\n  [/VB\n  36/CD\n  ]/NNP\n  Dong/NNP\n  J/NNP\n  ,/,\n  (PERSON Grunstein/NNP J/NNP)\n  ,/,\n  (PERSON Tejada/NNP M/NNP)\n  ,/,\n  et/RB\n  al/NN\n  ./.\n  VEGF-null/JJ\n  cells/NNS\n  require/VBP\n  (ORGANIZATION PDGFR/NNP)\n  alpha/JJ\n  signaling-mediated/JJ\n  stromal/JJ\n  \ufb01broblast/NN\n  recruitment/NN\n  for/IN\n  tumori-genesis/NN\n  ./.\n  (ORGANIZATION EMBO/NNP)\n  J/NNP\n  2004/CD\n  ;/:\n  23:2800\u201310/CD\n  ./.\n  [/VB\n  37/CD\n  ]/JJ\n  (ORGANIZATION Bergers/NNP G/NNP)\n  ,/,\n  (PERSON Song/NNP S/NNP)\n  ,/,\n  Meyer-Morse/NNP\n  N/NNP\n  ,/,\n  (PERSON Bergsland/NNP E/NNP)\n  ,/,\n  (PERSON Hanahan/NNP D./NNP Bene\ufb01ts/NNP)\n  of/IN\n  targeting/VBG\n  both/DT\n  pericytes/NNS\n  and/CC\n  endothelial/JJ\n  cells/NNS\n  in/IN\n  thetumor/NN\n  vasculature/NN\n  with/IN\n  kinase/NN\n  inhibitors/NNS\n  ./.\n  J/NNP\n  (PERSON Clin/NNP Invest/NNP)\n  2003/CD\n  ;/:\n  111:1287\u201395/CD\n  ./.\n  [/VB\n  38/CD\n  ]/JJ\n  Erber/NNP\n  R/NNP\n  ,/,\n  (PERSON Thurnher/NNP A/NNP)\n  ,/,\n  (PERSON Katsen/NNP AD/NNP)\n  ,/,\n  et/VBZ\n  al/NN\n  ./.\n  Combined/VBN\n  inhibition/NN\n  of/IN\n  (ORGANIZATION VEGF/NNP)\n  and/CC\n  (ORGANIZATION PDGF/NNP)\n  signaling/VBG\n  enforces/NNS\n  tumor/JJ\n  vessel/JJ\n  regression/NN\n  by/IN\n  interferingwith/JJ\n  pericyte-mediated/JJ\n  endothelial/NN\n  cell/NN\n  survival/JJ\n  mechanisms/NN\n  ./.\n  FASEBJ/NNP\n  2004/CD\n  ;/:\n  18:338\u201340/CD\n  ./.\n  [/VB\n  39/CD\n  ]/NNP\n  Cabebe/NNP\n  E/NNP\n  ,/,\n  (PERSON Wakelee/NNP H./NNP Role/NNP)\n  of/IN\n  anti-angiogenesis/JJ\n  agents/NNS\n  in/IN\n  treat-/JJ\n  ing/NN\n  NSCLC/NNP\n  :/:\n  focus/NN\n  on/IN\n  bevacizumab/NN\n  and/CC\n  (ORGANIZATION VEGFR/NNP)\n  tyrosine/NN\n  kinaseinhibitors/NNS\n  ./.\n  (PERSON Curr/NNP Treat/NNP)\n  Options/NNPS\n  Oncol/NNP\n  2007/CD\n  ;/:\n  8:15\u201327/CD\n  ./.\n  [/VB\n  40/CD\n  ]/NNP\n  Murakami/NNP\n  M/NNP\n  ,/,\n  (PERSON Zheng/NNP Y/NNP)\n  ,/,\n  (PERSON Hirashima/NNP M/NNP)\n  ,/,\n  et/RB\n  al/NN\n  ./.\n  (ORGANIZATION VEGFR1/NNP)\n  tyrosine/JJ\n  kinase/NN\n  signaling/VBG\n  promotes/NNS\n  lymphangiogenesis/NN\n  as/RB\n  well/RB\n  as/IN\n  angiogenesis/NN\n  indi-rectly/RB\n  via/IN\n  macrophage/NN\n  recruitment/NN\n  ./.\n  (PERSON Arterioscler/NNP Thromb/NNP Vasc/NNP Biol2008/NNP)\n  ;/:\n  28:658\u201364/CD\n  ./.\n  [/VB\n  41/CD\n  ]/NNP\n  Presta/NNP\n  M/NNP\n  ,/,\n  (ORGANIZATION Dell/NNP)\n  \u2019/NNP\n  Era/NNP\n  P/NNP\n  ,/,\n  (PERSON Mitola/NNP S/NNP)\n  ,/,\n  (PERSON Moroni/NNP E/NNP)\n  ,/,\n  (PERSON Ronca/NNP R/NNP)\n  ,/,\n  (PERSON Rusnati/NNP M./NNP Fibroblast/NNP)\n  growth/NN\n  factor/\ufb01broblast/NN\n  growth/NN\n  factor/NN\n  receptor/NN\n  system/NN\n  inangiogenesis/NN\n  ./.\n  (PERSON Cytokine/NNP Growth/NNP Factor/NNP)\n  Rev/NNP\n  2005/CD\n  ;/:\n  16:159\u201378/CD\n  ./.\n  [/VB\n  42/CD\n  ]/NNP\n  Rusnati/NNP\n  M/NNP\n  ,/,\n  (PERSON Presta/NNP M./NNP Fibroblast/NNP)\n  growth/NN\n  factors/\ufb01broblast/NN\n  growth/NN\n  factor/NN\n  receptors/NNS\n  as/IN\n  targets/NNS\n  for/IN\n  the/DT\n  development/NN\n  of/IN\n  anti-angiogenesisstrategies/NNS\n  ./.\n  (PERSON Curr/NNP Pharm/NNP)\n  Des/NNP\n  2007/CD\n  ;/:\n  13:2025\u201344/CD\n  ./.\n  [/VB\n  43/CD\n  ]/NNP\n  Casanovas/NNP\n  O/NNP\n  ,/,\n  (PERSON Hicklin/NNP DJ/NNP)\n  ,/,\n  (PERSON Bergers/NNP G/NNP)\n  ,/,\n  (PERSON Hanahan/NNP D./NNP Drug/NNP)\n  resistance/NN\n  by/IN\n  evasion/NN\n  of/IN\n  antiangiogenic/JJ\n  targeting/NN\n  of/IN\n  (ORGANIZATION VEGF/NNP)\n  signaling/VBG\n  in/IN\n  late-stagepancreatic/JJ\n  islet/NN\n  tumors/NNS\n  ./.\n  (PERSON Cancer/NNP Cell/NNP)\n  2005/CD\n  ;/:\n  8:299\u2013309/CD\n  ./.\n  [/VB\n  44/CD\n  ]/JJ\n  Kano/NNP\n  MR/NNP\n  ,/,\n  (PERSON Morishita/NNP Y/NNP)\n  ,/,\n  (PERSON Iwata/NNP C/NNP)\n  ,/,\n  et/RB\n  al/NN\n  ./.\n  VEGF-A/JJ\n  and/CC\n  FGF-2/JJ\n  synergisti-/JJ\n  cally/RB\n  promote/JJ\n  neoangiogenesis/NN\n  through/IN\n  enhancement/NN\n  of/IN\n  endogenousPDGF-B-PDGFRbeta/JJ\n  signaling/NN\n  ./.\n  J/NNP\n  Cell/NNP\n  Sci/NNP\n  2005/CD\n  ;/:\n  118:3759\u201368/CD\n  ./.\n  [/VB\n  45/CD\n  ]/NNP\n  Nissen/NNP\n  LJ/NNP\n  ,/,\n  (PERSON Cao/NNP R/NNP)\n  ,/,\n  (PERSON Hedlund/NNP EM/NNP)\n  ,/,\n  et/RB\n  al/NN\n  ./.\n  Angiogenic/JJ\n  factors/NNS\n  (ORGANIZATION FGF2/NNP)\n  and/CC\n  PDGF-BB/NNP\n  synergistically/RB\n  promote/VBP\n  murine/JJ\n  tumor/NN\n  neovascularizationand/NN\n  metastasis/NN\n  ./.\n  J/NNP\n  (PERSON Clin/NNP Invest/NNP)\n  2007/CD\n  ;/:\n  117:2766\u201377/CD\n  ./.\n  [/VB\n  46/CD\n  ]/NNP\n  (PERSON Avastin/NNP)\n  \u00ae/NNP\n  (/(\n  bevacizumab/NN\n  )/)\n  [/NN\n  package/NN\n  insert/JJ\n  ]/NNP\n  ./.\n  (PERSON South/NNP San/NNP Francisco/NNP)\n  ,/,\n  CA/NNP\n  :/:\n  Genentech/NNP\n  ,/,\n  (GPE Inc./NNP)\n  ;/:\n  2009/CD\n  ./.\n  [/VB\n  47/CD\n  ]/NNP\n  (PERSON Reynolds/NNP S./NNP National/NNP Cancer/NNP Institute/NNP)\n  ./.\n  (ORGANIZATION FDA/NNP Advisory/NNP Committee/NNP Recommends/NNP)\n  against/IN\n  (GPE Bevacizumab/NNP)\n  for/IN\n  (ORGANIZATION Metastatic/NNP Breast/NNP)\n  Cancer.http/NNP\n  :/:\n  //www.cancer.gov/ncicancerbulletin/072710/page2/NN\n  ./.\n  (PERSON Accessed/JJ)\n  September/NNP\n  9/CD\n  ;/:\n  2010/CD\n  ./.\n  [/VB\n  48/CD\n  ]/NNP\n  Genentech/NNP\n  ./.\n  (PERSON Genentech/NNP)\n  provides/VBZ\n  update/JJ\n  on/IN\n  (PERSON Avastin/NNP)\n  for/IN\n  metastatic/JJ\n  breast/NN\n  cancer/NN\n  following/VBG\n  reviews/NNS\n  in/IN\n  (GPE Europe/NNP)\n  and/CC\n  the/DT\n  (ORGANIZATION UnitedStates/NNP)\n  ./.\n  http/NN\n  :/:\n  //www.gene.com/gene/news/press-releases/display.do/JJ\n  ?/.\n  method=detail/NN\n  &/CC\n  id=13127/NN\n  ./.\n  (PERSON Accessed/JJ)\n  December/NNP\n  16/CD\n  ;/:\n  2010/CD\n  ./.\n  [/VB\n  49/CD\n  ]/NNP\n  (PERSON Johnson/NNP DH/NNP)\n  ,/,\n  (PERSON Fehrenbacher/NNP L/NNP)\n  ,/,\n  (PERSON Novotny/NNP WF/NNP)\n  ,/,\n  et/RB\n  al/NN\n  ./.\n  (PERSON Randomized/NNP)\n  phase/NN\n  II/NNP\n  trial/NN\n  comparing/VBG\n  bevacizumab/JJ\n  plus/CC\n  carboplatin/JJ\n  and/CC\n  pacli-taxel/JJ\n  with/IN\n  carboplatin/NN\n  and/CC\n  paclitaxel/VB\n  alone/RB\n  in/IN\n  previously/RB\n  untreatedlocally/RB\n  advanced/JJ\n  or/CC\n  metastatic/JJ\n  non-small-cell/JJ\n  lung/NN\n  cancer/NN\n  ./.\n  J/NNP\n  ClinOncol/NNP\n  2004/CD\n  ;/:\n  22:2184\u201391/CD\n  ./.\n  [/VB\n  50/CD\n  ]/NNP\n  (PERSON Sandler/NNP A/NNP)\n  ,/,\n  (PERSON Gray/NNP R/NNP)\n  ,/,\n  (PERSON Perry/NNP MC/NNP)\n  ,/,\n  et/RB\n  al/NN\n  ./.\n  Paclitaxel-carboplatin/JJ\n  alone/NN\n  or/CC\n  with/IN\n  bevacizumab/NN\n  for/IN\n  non-small-cell/JJ\n  lung/NN\n  cancer/NN\n  ./.\n  N/NNP\n  Engl/NNP\n  J/NNP\n  Med2006/NNP\n  ;/:\n  355:2542\u201350/CD\n  ./.\n  [/VB\n  51/CD\n  ]/NNP\n  Reck/NNP\n  M/NNP\n  ,/,\n  von/NNP\n  Pawel/NNP\n  J/NNP\n  ,/,\n  (PERSON Zatloukal/NNP P/NNP)\n  ,/,\n  et/RB\n  al/NN\n  ./.\n  Overall/JJ\n  survival/NN\n  with/IN\n  cisplatin-/JJ\n  gemcitabine/NN\n  and/CC\n  bevacizumab/NN\n  or/CC\n  placebo/NN\n  as/IN\n  \ufb01rst-line/JJ\n  therapy/NN\n  fornonsquamous/JJ\n  non-small-cell/JJ\n  lung/NN\n  cancer/NN\n  :/:\n  results/NNS\n  from/IN\n  a/DT\n  randomisedphase/NN\n  (ORGANIZATION III/NNP)\n  trial/NN\n  (/(\n  A/DT\n  V/NNP\n  AiL/NNP\n  )/)\n  ./.\n  (PERSON Ann/NNP Oncol/NNP)\n  2010/CD\n  ;/:\n  21:1804\u20139/CD\n  ./.\n  [/VB\n  52/CD\n  ]/NNP\n  Reck/NNP\n  M/NNP\n  ,/,\n  von/NNP\n  Pawel/NNP\n  J/NNP\n  ,/,\n  (PERSON Zatloukal/NNP P/NNP)\n  ,/,\n  et/RB\n  al/NN\n  ./.\n  (PERSON Phase/NNP III/NNP)\n  trial/NN\n  of/IN\n  cisplatin/NN\n  plus/CC\n  gemcitabine/NN\n  with/IN\n  either/DT\n  placebo/NN\n  or/CC\n  bevacizumab/NN\n  as/IN\n  \ufb01rst-line/JJ\n  therapyfor/JJ\n  nonsquamous/JJ\n  non-small-cell/JJ\n  lung/NN\n  cancer/NN\n  :/:\n  A/DT\n  V/NNP\n  AiL/NNP\n  ./.\n  J/NNP\n  (PERSON Clin/NNP Oncol2009/NNP)\n  ;/:\n  27:1227\u201334/CD\n  ./.\n  [/VB\n  53/CD\n  ]/NNP\n  (ORGANIZATION Genentech/NNP Inc./NNP Synopsis/NNP)\n  of/IN\n  (PERSON Clinical/NNP Study/NNP Report/NNP)\n  ./.\n  A/NNP\n  pilot/NN\n  study/NN\n  of/IN\n  the/DT\n  bevacizumab/NN\n  plus/CC\n  carboplatin/NN\n  and/CC\n  paclitaxel/NN\n  in/IN\n  subjects/NNS\n  withadvanced/VBN\n  ,/,\n  previously/RB\n  untreated/VBN\n  ,/,\n  squamous/JJ\n  non-small/JJ\n  cell/NN\n  lung/NN\n  cancer/NN\n  ;/:\n  2010/CD\n  ./.\n  [/VB\n  54/CD\n  ]/NNP\n  (PERSON Socinski/NNP MA/NNP)\n  ,/,\n  (PERSON Langer/NNP CJ/NNP)\n  ,/,\n  (PERSON Huang/NNP JE/NNP)\n  ,/,\n  et/RB\n  al/NN\n  ./.\n  Safety/NN\n  of/IN\n  bevacizumab/NN\n  in/IN\n  patients/NNS\n  with/IN\n  non-small-cell/JJ\n  lung/NN\n  cancer/NN\n  and/CC\n  brain/NN\n  metastases/NNS\n  ./.\n  J/NNP\n  ClinOncol/NNP\n  2009/CD\n  ;/:\n  27:5255\u201361/CD\n  ./.\n  [/VB\n  55/CD\n  ]/NNP\n  (PERSON Herbst/NNP RS/NNP)\n  ./.\n  Toxicities/NNS\n  of/IN\n  antiangiogenic/JJ\n  therapy/NN\n  in/IN\n  non-small-cell/JJ\n  lung/NN\n  cancer/NN\n  ./.\n  (PERSON Clin/NNP Lung/NNP)\n  Cancer/NNP\n  2006/CD\n  ;/:\n  8/CD\n  :/:\n  S23\u201330/NN\n  ./.\n  [/CC\n  56/CD\n  ]/JJ\n  Fischbach/NNP\n  NA/NNP\n  ,/,\n  (PERSON Spigel/NNP D/NNP)\n  ,/,\n  (PERSON Brahmer/NNP J/NNP)\n  ,/,\n  et/VBZ\n  al/NN\n  ./.\n  Preliminary/JJ\n  safety/NN\n  and/CC\n  effectiveness/NN\n  of/IN\n  bevacizumab/NN\n  (/(\n  BV/NNP\n  )/)\n  based/VBN\n  treatment/NN\n  in/IN\n  subpopulationsof/NN\n  patients/NNS\n  (/(\n  pts/NNS\n  )/)\n  with/IN\n  non-small/JJ\n  cell/NN\n  lung/NN\n  cancer/NN\n  (/(\n  (ORGANIZATION NSCLC/NNP)\n  )/)\n  from/IN\n  theARIES/NN\n  study/NN\n  :/:\n  a/DT\n  bevacizumab/NN\n  (/(\n  BV/NNP\n  )/)\n  treatment/NN\n  observational/JJ\n  cohortstudy/NN\n  (/(\n  (ORGANIZATION OCS/NNP)\n  )/)\n  ./.\n  J/NNP\n  (PERSON Clin/NNP Oncol/NNP)\n  2009/CD\n  ;/:\n  27/CD\n  [/CD\n  abstract/JJ\n  8040/CD\n  ]/NN\n  ./.\n  [/CC\n  57/CD\n  ]/JJ\n  (PERSON Wozniak/NNP AJ/NNP)\n  ,/,\n  (PERSON Garst/NNP J/NNP)\n  ,/,\n  (PERSON Jahanzeb/NNP M/NNP)\n  ,/,\n  et/RB\n  al/NN\n  ./.\n  (PERSON Clinical/JJ)\n  outcomes/NNS\n  (/(\n  CO/NNP\n  )/)\n  for/IN\n  special/JJ\n  populations/NNS\n  of/IN\n  patients/NNS\n  (/(\n  pts/NNS\n  )/)\n  with/IN\n  advanced/JJ\n  non-small/JJ\n  celllung/NN\n  cancer/NN\n  (/(\n  (ORGANIZATION NSCLC/NNP)\n  )/)\n  :/:\n  results/NNS\n  from/IN\n  (ORGANIZATION ARIES/NNP)\n  ,/,\n  a/DT\n  bevacizumab/NN\n  (/(\n  BV/NNP\n  )/)\n  observational/JJ\n  cohort/NN\n  study/NN\n  (/(\n  (ORGANIZATION OCS/NNP)\n  )/)\n  ./.\n  J/NNP\n  (PERSON Clin/NNP Oncol/NNP)\n  2010/CD\n  ;/:\n  28/CD\n  [/NN\n  abstract7618/NN\n  ]/NNP\n  ./.\n  [/CC\n  58/CD\n  ]/JJ\n  (ORGANIZATION Ramalingam/NNP)\n  SS/NNP\n  ,/,\n  (PERSON Dahlberg/NNP SE/NNP)\n  ,/,\n  (PERSON Langer/NNP CJ/NNP)\n  ,/,\n  et/RB\n  al/NN\n  ./.\n  Outcomes/CC\n  for/IN\n  elderly/JJ\n  ,/,\n  advanced-stage/JJ\n  non/NN\n  small-cell/NN\n  lung/NN\n  cancer/NN\n  patients/NNS\n  treated/VBN\n  with/IN\n  beva-cizumab/NN\n  in/IN\n  combination/NN\n  with/IN\n  carboplatin/NN\n  and/CC\n  paclitaxel/NN\n  :/:\n  analysisof/JJ\n  (LOCATION Eastern/NNP Cooperative/NNP)\n  (ORGANIZATION Oncology/NNP Group/NNP)\n  Trial/NNP\n  4599/CD\n  ./.\n  J/NNP\n  (PERSON Clin/NNP Oncol2008/NNP)\n  ;/:\n  26:60\u20135/CD\n  ./.\n  [/VB\n  59/CD\n  ]/NNP\n  (PERSON Leighl/NNP NB/NNP)\n  ,/,\n  (PERSON Zatloukal/NNP P/NNP)\n  ,/,\n  (PERSON Mezger/NNP J/NNP)\n  ,/,\n  et/VBZ\n  al/NN\n  ./.\n  (PERSON Ef\ufb01cacy/NN)\n  and/CC\n  safety/NN\n  of/IN\n  bevacizumab-based/JJ\n  therapy/NN\n  in/IN\n  elderly/JJ\n  patients/NNS\n  with/IN\n  advanced/JJ\n  orrecurrent/JJ\n  nonsquamous/JJ\n  non-small/NN\n  cell/NN\n  lung/NN\n  cancer/NN\n  in/IN\n  the/DT\n  phase/NN\n  (ORGANIZATION IIIBO17704/NNP)\n  study/NN\n  (/(\n  A/NNP\n  V/NNP\n  AiL/NNP\n  )/)\n  ./.\n  J/NNP\n  (PERSON Thorac/NNP Oncol/NNP)\n  2010/CD\n  ;/:\n  5:1970\u20136/CD\n  ./.\n  [/VB\n  60/CD\n  ]/NNP\n  (PERSON Miller/NNP V/NNP A/NNP)\n  ,/,\n  (PERSON O/NNP)\n  \u2019/NNP\n  Conner/NNP\n  P/NNP\n  ,/,\n  (PERSON Soh/NNP C/NNP)\n  ,/,\n  (PERSON Kabbinavar/NNP)\n  F./NNP\n  A/NNP\n  randomized/JJ\n  ,/,\n  double-blind/JJ\n  ,/,\n  placebo-controlled/JJ\n  ,/,\n  phase/JJ\n  (ORGANIZATION IIIb/NNP)\n  trial/NN\n  (/(\n  (ORGANIZATION ATLAS/NNP)\n  )/)\n  compar-ing/NN\n  bevacizumab/NN\n  (/(\n  B/NNP\n  )/)\n  therapy/NN\n  with/IN\n  or/CC\n  without/IN\n  erlotinib/NN\n  (/(\n  E/NNP\n  )/)\n  aftercompletion/NN\n  of/IN\n  chemotherapy/NN\n  with/IN\n  B/NNP\n  for/IN\n  \ufb01rst-line/JJ\n  treatment/NN\n  oflocally/RB\n  advanced/VBD\n  ,/,\n  recurrent/NN\n  ,/,\n  or/CC\n  metastatic/JJ\n  non-small/JJ\n  cell/NN\n  lung/NN\n  cancer/NN\n  (/(\n  (ORGANIZATION NSCLC/NNP)\n  )/)\n  ./.\n  J/NNP\n  (PERSON Clin/NNP Oncol/NNP)\n  2009/CD\n  ;/:\n  27/CD\n  :/:\n  LBA8002/NNP\n  ./.\n  [/CC\n  61/CD\n  ]/JJ\n  (ORGANIZATION Kabbinavar/NNP)\n  FF/NNP\n  ,/,\n  (PERSON Miller/NNP V/NNP A/NNP)\n  ,/,\n  (PERSON Johnson/NNP BE/NNP)\n  ,/,\n  (PERSON O/NNP)\n  \u2019/NNP\n  Connor/NNP\n  PG/NNP\n  ,/,\n  (PERSON Soh/NNP C/NNP)\n  ,/,\n  (PERSON Tlas/NNP)\n  I/PRP\n  ./.\n  Overall/JJ\n  survival/NN\n  (/(\n  OS/NNP\n  )/)\n  in/IN\n  (GPE ATLAS/NNP)\n  ,/,\n  a/DT\n  phase/NN\n  (ORGANIZATION IIIb/NNP)\n  trial/NN\n  comparingbevacizumab/NN\n  (/(\n  B/NNP\n  )/)\n  therapy/NN\n  with/IN\n  or/CC\n  without/IN\n  erlotinib/NN\n  (/(\n  E/NNP\n  )/)\n  after/IN\n  com-pletion/NN\n  of/IN\n  chemotherapy/NN\n  (/(\n  chemo/NN\n  )/)\n  with/IN\n  B/NNP\n  for/IN\n  \ufb01rst-line/JJ\n  treatment/NN\n  oflocally/RB\n  advanced/VBD\n  ,/,\n  recurrent/NN\n  ,/,\n  or/CC\n  metastatic/JJ\n  non-small/JJ\n  cell/NN\n  lung/NN\n  cancer/NN\n  (/(\n  (ORGANIZATION NSCLC/NNP)\n  )/)\n  ./.\n  J/NNP\n  (PERSON Clin/NNP Oncol/NNP)\n  2010/CD\n  ;/:\n  28/CD\n  [/CD\n  abstract/JJ\n  7526/CD\n  ]/NN\n  ./.\n  [/CC\n  62/CD\n  ]/JJ\n  (ORGANIZATION Hainsworth/NNP J/NNP)\n  ,/,\n  (PERSON Herbst/NNP)\n  R./NNP\n  A/NNP\n  phase/NN\n  (ORGANIZATION III/NNP)\n  ,/,\n  multicenter/NN\n  ,/,\n  placebo-controlled/JJ\n  ,/,\n  double-blind/JJ\n  ,/,\n  randomized/JJ\n  clinical/JJ\n  trial/NN\n  to/TO\n  evaluate/VB\n  the/DT\n  ef\ufb01cacy/NN\n  ofbevacizumab/NN\n  (/(\n  (PERSON Avastin/NNP)\n  \u00ae/NNP\n  )/)\n  in/IN\n  combination/NN\n  with/IN\n  erlotinib/NN\n  (/(\n  Tarceva\u00ae/NNP\n  )/)\n  compared/VBN\n  with/IN\n  erlotinib/NN\n  alone/RB\n  for/IN\n  treatment/NN\n  of/IN\n  advanced/JJ\n  non-smallcell/JJ\n  lung/NN\n  cancer/NN\n  after/IN\n  failure/NN\n  of/IN\n  standard/JJ\n  \ufb01rst-line/JJ\n  chemotherapy/NN\n  (/(\n  (ORGANIZATION BETA/NNP)\n  )/)\n  [/VBP\n  plenary/JJ\n  abstract/NN\n  ]/NNP\n  ./.\n  J/NNP\n  (PERSON Thorac/NNP Oncol/NNP)\n  2008/CD\n  ;/:\n  3/CD\n  :/:\n  (PERSON S302/NNP)\n  [/NNP\n  abstract189/NN\n  ]/NNP\n  ./.\n  [/CC\n  63/CD\n  ]/JJ\n  (PERSON Patel/NNP JD/NNP)\n  ,/,\n  (PERSON Bonomi/NNP P/NNP)\n  ,/,\n  (PERSON Socinski/NNP MA/NNP)\n  ,/,\n  et/RB\n  al/NN\n  ./.\n  Treatment/NNP\n  ratio-/JJ\n  nale/NN\n  and/CC\n  study/NN\n  design/NN\n  for/IN\n  the/DT\n  pointbreak/NN\n  study/NN\n  :/:\n  a/DT\n  randomized/VBN\n  ,/,\n  A/DT\n  ./.\n  (PERSON Wozniak/NNP)\n  //NNP\n  Critical/NNP\n  Reviews/NNP\n  in/IN\n  Oncology/Hematology/NNP\n  82/CD\n  (/(\n  2012/CD\n  )/)\n  200\u2013212/CD\n  211/CD\n  open-label/JJ\n  phase/NN\n  (ORGANIZATION III/NNP)\n  study/NN\n  of/IN\n  pemetrexed/carboplatin/bevacizumab/NN\n  followed/VBN\n  by/IN\n  maintenance/NN\n  pemetrexed/bevacizumab/NN\n  versus/IN\n  pacli-taxel/carboplatin/bevacizumab/NN\n  followed/VBN\n  by/IN\n  maintenance/NN\n  beva-cizumab/NN\n  in/IN\n  patients/NNS\n  with/IN\n  stage/NN\n  (ORGANIZATION IIIB/NNP)\n  or/CC\n  IV/NNP\n  nonsquamous/JJ\n  non-small-celllung/JJ\n  cancer/NN\n  ./.\n  (PERSON Clin/NNP Lung/NNP)\n  Cancer/NNP\n  2009/CD\n  ;/:\n  10:252\u20136/CD\n  ./.\n  [/VB\n  64/CD\n  ]/NNP\n  Ellis/NNP\n  LM/NNP\n  ,/,\n  (PERSON Hicklin/NNP DJ/NNP)\n  ./.\n  (PERSON Pathways/NNP)\n  mediating/VBG\n  resistance/NN\n  to/TO\n  vascu-/JJ\n  lar/JJ\n  endothelial/JJ\n  growth/NN\n  factor-targeted/JJ\n  therapy/NN\n  ./.\n  (PERSON Clin/NNP Cancer/NNP Res2008/NNP)\n  ;/:\n  14:6371\u20135/CD\n  ./.\n  [/VB\n  65/CD\n  ]/NNP\n  Ellis/NNP\n  LM/NNP\n  ,/,\n  (PERSON Hicklin/NNP DJ/NNP)\n  ./.\n  Resistance/NN\n  to/TO\n  targeted/VBN\n  therapies/NNS\n  :/:\n  re\ufb01ning/VBG\n  anti-/JJ\n  cancer/NN\n  therapy/NN\n  in/IN\n  the/DT\n  era/NN\n  of/IN\n  molecular/JJ\n  oncology/NN\n  ./.\n  (PERSON Clin/NNP Cancer/NNP Res2009/NNP)\n  ;/:\n  15:7471\u20138/CD\n  ./.\n  [/VB\n  66/CD\n  ]/NNP\n  Lockhart/NNP\n  AC/NNP\n  ,/,\n  (PERSON Rothenberg/NNP ML/NNP)\n  ,/,\n  (PERSON Dupont/NNP J/NNP)\n  ,/,\n  et/VBZ\n  al/NN\n  ./.\n  Phase/NNP\n  I/PRP\n  study/VBP\n  of/IN\n  intra-/JJ\n  venous/JJ\n  vascular/JJ\n  endothelial/JJ\n  growth/NN\n  factor/NN\n  trap/NN\n  ,/,\n  a\ufb02ibercept/NN\n  ,/,\n  in/IN\n  patientswith/NN\n  advanced/VBD\n  solid/JJ\n  tumors/NNS\n  ./.\n  J/NNP\n  (PERSON Clin/NNP Oncol/NNP)\n  2010/CD\n  ;/:\n  28:207\u201314/CD\n  ./.\n  [/VB\n  67/CD\n  ]/NNP\n  (PERSON Leighl/NNP NB/NNP)\n  ,/,\n  (PERSON Raez/NNP LE/NNP)\n  ,/,\n  (PERSON Besse/NNP B/NNP)\n  ,/,\n  et/NN\n  al/NN\n  ./.\n  A/DT\n  multicenter/NN\n  ,/,\n  phase/NN\n  2/CD\n  study/NN\n  of/IN\n  vascular/JJ\n  endothelial/JJ\n  growth/NN\n  factor/NN\n  trap/NN\n  (/(\n  (ORGANIZATION A\ufb02ibercept/NNP)\n  )/)\n  in/IN\n  platinum-and/JJ\n  erlotinib-resistant/JJ\n  adenocarcinoma/NN\n  of/IN\n  the/DT\n  lung/NN\n  ./.\n  J/NNP\n  (PERSON Thorac/NNP Oncol2010/NNP)\n  ;/:\n  5:1054\u20139/CD\n  ./.\n  [/VB\n  68/CD\n  ]/NNP\n  (PERSON Wilhelm/NNP SM/NNP)\n  ,/,\n  (PERSON Carter/NNP C/NNP)\n  ,/,\n  (PERSON Tang/NNP L/NNP)\n  ,/,\n  et/RB\n  al/NN\n  ./.\n  (ORGANIZATION BAY/NNP)\n  43-9006/JJ\n  exhibits/NNS\n  broad/JJ\n  spectrum/JJ\n  oral/JJ\n  antitumor/NN\n  activity/NN\n  and/CC\n  targets/VBZ\n  the/DT\n  RAF/MEK/ERK/NNP\n  path-way/NN\n  and/CC\n  receptor/NN\n  tyrosine/NN\n  kinases/VBZ\n  involved/VBN\n  in/IN\n  tumor/NN\n  progression/NN\n  andangiogenesis/NN\n  ./.\n  (PERSON Cancer/NNP Res/NNP)\n  2004/CD\n  ;/:\n  64:7099\u2013109/CD\n  ./.\n  [/VB\n  69/CD\n  ]/NNP\n  NEXA/NNP\n  V/NNP\n  AR/NNP\n  (/(\n  sorafenib/NN\n  )/)\n  tablets/NNS\n  ,/,\n  oral/JJ\n  [/NNP\n  package/NN\n  insert/NN\n  ]/NNP\n  ./.\n  (PERSON Wayne/NNP)\n  ,/,\n  NJ/NNP\n  :/:\n  (PERSON Bayer/NNP)\n  (ORGANIZATION HealthCare/NNP Pharmaceuticals/NNP Inc./NNP)\n  ;/:\n  2009/CD\n  ./.\n  [/VB\n  70/CD\n  ]/NNP\n  (PERSON Schiller/NNP JH/NNP)\n  ,/,\n  (PERSON Lee/NNP JW/NNP)\n  ,/,\n  (PERSON Hanna/NNP NH/NNP)\n  ,/,\n  (PERSON Traynor/NNP AM/NNP)\n  ,/,\n  (PERSON Carbone/NNP DP/NNP)\n  ./.\n  A/DT\n  ran-/JJ\n  domized/JJ\n  discontinuation/NN\n  phase/NN\n  II/NNP\n  study/NN\n  of/IN\n  sorafenib/JJ\n  versus/NN\n  placebo/NN\n  inpatients/NNS\n  with/IN\n  non-small/JJ\n  cell/NN\n  lung/NN\n  cancer/NN\n  who/WP\n  have/VBP\n  failed/VBN\n  at/IN\n  least/JJS\n  twoprior/JJ\n  chemotherapy/NN\n  regimens/NNS\n  :/:\n  E2501/NNP\n  ./.\n  J/NNP\n  (PERSON Clin/NNP Oncol/NNP)\n  2008/CD\n  ;/:\n  26/CD\n  [/NN\n  abstract8014/NN\n  ]/NNP\n  ./.\n  [/CC\n  71/CD\n  ]/JJ\n  (ORGANIZATION Scagliotti/NNP G/NNP)\n  ,/,\n  (PERSON Novello/NNP S/NNP)\n  ,/,\n  von/NNP\n  Pawel/NNP\n  J/NNP\n  ,/,\n  et/VBZ\n  al/NN\n  ./.\n  (PERSON Phase/NNP III/NNP)\n  study/NN\n  of/IN\n  carboplatin/NN\n  and/CC\n  paclitaxel/VB\n  alone/RB\n  or/CC\n  with/IN\n  sorafenib/NN\n  in/IN\n  advanced/JJ\n  non-small-cell/JJ\n  lung/NN\n  cancer/NN\n  ./.\n  J/NNP\n  (PERSON Clin/NNP Oncol/NNP)\n  2010/CD\n  ;/:\n  28:1835\u201342/CD\n  ./.\n  [/VB\n  72/CD\n  ]/NNP\n  Bayer/NNP\n  Healthcare/NNP\n  Pharmaceuticals/NNP\n  Inc./NNP\n  ,/,\n  (PERSON Onyx/NNP)\n  Pharmaceuti-/NNP\n  cals/NNS\n  Inc/NNP\n  ./.\n  Phase/NNP\n  3/CD\n  Trial/NNP\n  of/IN\n  (GPE Nexavar/NNP)\n  in/IN\n  First-Line/NNP\n  AdvancedNon-Small/NNP\n  Cell/NNP\n  Lung/NNP\n  Cancer/NNP\n  Does/NNP\n  Not/RB\n  (PERSON Meet/NNP Primary/NNP)\n  End-point/NNP\n  of/IN\n  (ORGANIZATION Overall/NNP Survival/NNP)\n  ./.\n  Press/NNP\n  release/NN\n  ./.\n  June/NNP\n  14/CD\n  ;/:\n  2010.http/CD\n  :/:\n  //www.onyx-pharm.com/view.cfm/685/Phase-3-Trial-of-Nexavar-in-First-Line-Advanced-Non-Small-Cell-Lung-Cancer-Does-Not-Meet-Primary-Endpoint-of-Overall-Survival/JJ\n  ./.\n  Accessed/VBN\n  July/NNP\n  27/CD\n  ;/:\n  2010/CD\n  ./.\n  [/VB\n  73/CD\n  ]/NNP\n  Sun/NNP\n  L/NNP\n  ,/,\n  (PERSON Liang/NNP C/NNP)\n  ,/,\n  (PERSON Shirazian/NNP S/NNP)\n  ,/,\n  et/RB\n  al/NN\n  ./.\n  Discovery/NNP\n  of/IN\n  5-/JJ\n  [/JJ\n  5-\ufb02uoro-2-oxo-1,2-dihydroindol-/JJ\n  (/(\n  3Z/CD\n  )/)\n  -ylidenemethyl/NN\n  ]/NNP\n  -2,4-dimethyl-1H-pyrrole-3-carboxylic/NNP\n  acid/NN\n  (/(\n  2-diethylaminoethyl/JJ\n  )/)\n  amide/NN\n  ,/,\n  a/DT\n  novel/JJ\n  tyrosine/NN\n  kinase/NN\n  inhibitor/NN\n  targeting/VBG\n  vascular/JJ\n  endothelial/JJ\n  andplatelet-derived/JJ\n  growth/NN\n  factor/NN\n  receptor/NN\n  tyrosine/JJ\n  kinase/NN\n  ./.\n  J/NNP\n  Med/NNP\n  (GPE Chem2003/NNP)\n  ;/:\n  46:1116\u20139/CD\n  ./.\n  [/VB\n  74/CD\n  ]/JJ\n  (ORGANIZATION SUTENT/NNP)\n  \u00ae/NNP\n  (/(\n  sunitinib/JJ\n  malate/NN\n  )/)\n  capsules/NNS\n  ,/,\n  oral/JJ\n  [/NNP\n  package/NN\n  insert/NN\n  ]/NNP\n  ./.\n  (GPE New/NNP York/NNP)\n  ,/,\n  NY/NNP\n  :/:\n  (PERSON P\ufb01zer/NNP Inc./NNP)\n  ;/:\n  2010/CD\n  ./.\n  [/VB\n  75/CD\n  ]/NNP\n  (PERSON Socinski/NNP MA/NNP)\n  ,/,\n  (PERSON Novello/NNP S/NNP)\n  ,/,\n  (PERSON Brahmer/NNP JR/NNP)\n  ,/,\n  et/RB\n  al/NN\n  ./.\n  Multicenter/NNP\n  ,/,\n  phase/NN\n  II/NNP\n  trial/NN\n  of/IN\n  sunitinib/NN\n  in/IN\n  previously/RB\n  treated/VBN\n  ,/,\n  advanced/VBD\n  non-small-cell/JJ\n  lungcancer/NN\n  ./.\n  J/NNP\n  (PERSON Clin/NNP Oncol/NNP)\n  2008/CD\n  ;/:\n  26:650\u20136/CD\n  ./.\n  [/VB\n  76/CD\n  ]/NNP\n  Novello/NNP\n  S/NNP\n  ,/,\n  (PERSON Scagliotti/NNP GV/NNP)\n  ,/,\n  (PERSON Rosell/NNP R/NNP)\n  ,/,\n  et/RB\n  al/NN\n  ./.\n  (PERSON Phase/NNP II/NNP)\n  study/NN\n  of/IN\n  continuous/JJ\n  daily/JJ\n  sunitinib/NN\n  dosing/NN\n  in/IN\n  patients/NNS\n  with/IN\n  previously/RB\n  treated/VBN\n  advancednon-small/NN\n  cell/NN\n  lung/NN\n  cancer/NN\n  ./.\n  Br/NNP\n  J/NNP\n  Cancer/NNP\n  2009/CD\n  ;/:\n  101:1543\u20138/CD\n  ./.\n  [/VB\n  77/CD\n  ]/NNP\n  Roth/NNP\n  GJ/NNP\n  ,/,\n  (PERSON Heckel/NNP A/NNP)\n  ,/,\n  (PERSON Colbatzky/NNP F/NNP)\n  ,/,\n  et/VBZ\n  al/NN\n  ./.\n  Design/NNP\n  ,/,\n  synthesis/NN\n  ,/,\n  and/CC\n  evalua-/JJ\n  tion/NN\n  of/IN\n  indolinones/NNS\n  as/IN\n  triple/JJ\n  angiokinase/NN\n  inhibitors/NNS\n  and/CC\n  the/DT\n  discoveryof/NN\n  a/DT\n  highly/RB\n  speci\ufb01c/JJ\n  6-methoxycarbonyl-substituted/JJ\n  indolinone/NN\n  (/(\n  (ORGANIZATION BIBF1120/NNP)\n  )/)\n  ./.\n  J/NNP\n  Med/NNP\n  Chem/NNP\n  2009/CD\n  ;/:\n  52:4466\u201380/CD\n  ./.\n  [/VB\n  78/CD\n  ]/NNP\n  (PERSON Hilberg/NNP F/NNP)\n  ,/,\n  (PERSON Roth/NNP GJ/NNP)\n  ,/,\n  (PERSON Krssak/NNP M/NNP)\n  ,/,\n  et/RB\n  al/NN\n  ./.\n  BIBF/NNP\n  1120/CD\n  triple/NN\n  angiokinase/NN\n  inhibitor/NN\n  with/IN\n  sustained/JJ\n  receptor/NN\n  blockade/NN\n  and/CC\n  good/JJ\n  antitumor/NN\n  ef\ufb01-cacy/NN\n  ./.\n  (PERSON Cancer/NNP Res/NNP)\n  2008/CD\n  ;/:\n  68:4774\u201382/CD\n  ./.\n  [/VB\n  79/CD\n  ]/NNP\n  Ellis/NNP\n  PM/NNP\n  ,/,\n  (PERSON Kaiser/NNP R/NNP)\n  ,/,\n  (PERSON Zhao/NNP Y/NNP)\n  ,/,\n  (PERSON Stopfer/NNP P/NNP)\n  ,/,\n  (PERSON Gyorffy/NNP S/NNP)\n  ,/,\n  (PERSON Hanna/NNP N./NNP)\n  Phase/NNP\n  I/PRP\n  open-label/VBP\n  study/NN\n  of/IN\n  continuous/JJ\n  treatment/NN\n  with/IN\n  (ORGANIZATION BIBF/NNP)\n  1120/CD\n  ,/,\n  a/DT\n  tripleangiokinase/NN\n  inhibitor/NN\n  ,/,\n  and/CC\n  pemetrexed/NN\n  in/IN\n  pretreated/JJ\n  non-small/JJ\n  celllung/NN\n  cancer/NN\n  patients/NNS\n  ./.\n  (PERSON Clin/NNP Cancer/NNP)\n  Res/NNP\n  2010/CD\n  ;/:\n  16:2881\u20139/CD\n  ./.\n  [/VB\n  80/CD\n  ]/NNP\n  Reck/NNP\n  M/NNP\n  ,/,\n  (PERSON Kaiser/NNP R/NNP)\n  ,/,\n  (PERSON Eschbach/NNP C/NNP)\n  ,/,\n  et/RB\n  al/NN\n  ./.\n  A/DT\n  phase/NN\n  II/NNP\n  double-blind/NN\n  study/NN\n  to/TO\n  investigate/VB\n  ef\ufb01cacy/NN\n  and/CC\n  safety/NN\n  of/IN\n  two/CD\n  doses/NNS\n  of/IN\n  the/DT\n  triple/JJ\n  angiokinaseinhibitor/NN\n  BIBF/NNP\n  1120/CD\n  in/IN\n  patients/NNS\n  with/IN\n  relapsed/JJ\n  advanced/JJ\n  non-small-cell/JJ\n  lung/NN\n  cancer/NN\n  ./.\n  (PERSON Ann/NNP Oncol/NNP)\n  2011/CD\n  [/NNP\n  Epub/NNP\n  ,/,\n  January/NNP\n  6/CD\n  ]/NNP\n  ./.\n  [/CC\n  81/CD\n  ]/JJ\n  (PERSON Schiller/NNP JH/NNP)\n  ,/,\n  (PERSON Larson/NNP T/NNP)\n  ,/,\n  (PERSON Ou/NNP SH/NNP)\n  ,/,\n  et/RB\n  al/NN\n  ./.\n  (PERSON Ef\ufb01cacy/NN)\n  and/CC\n  safety/NN\n  of/IN\n  axitinib/NN\n  in/IN\n  patients/NNS\n  with/IN\n  advanced/JJ\n  non-small-cell/JJ\n  lung/NN\n  cancer/NN\n  :/:\n  results/NNS\n  from/IN\n  aphase/JJ\n  II/NNP\n  study/NN\n  ./.\n  J/NNP\n  (PERSON Clin/NNP Oncol/NNP)\n  2009/CD\n  ;/:\n  27:3836\u201341/CD\n  ./.\n  [/VB\n  82/CD\n  ]/NNP\n  (PERSON Goss/NNP GD/NNP)\n  ,/,\n  (ORGANIZATION Arnold/NNP)\n  A/NNP\n  ,/,\n  (ORGANIZATION Shepherd/NNP)\n  FA/NNP\n  ,/,\n  et/RB\n  al/NN\n  ./.\n  Randomized/VBN\n  ,/,\n  double-blind/JJ\n  trial/NN\n  of/IN\n  carboplatin/NN\n  and/CC\n  paclitaxel/NN\n  with/IN\n  either/DT\n  daily/JJ\n  oral/JJ\n  cediranib/NN\n  orplacebo/NN\n  in/IN\n  advanced/JJ\n  non-small-cell/JJ\n  lung/NN\n  cancer/NN\n  :/:\n  (ORGANIZATION NCIC/NNP Clinical/NNP)\n  TrialsGroup/NNP\n  BR24/NNP\n  study/NN\n  ./.\n  J/NNP\n  (PERSON Clin/NNP Oncol/NNP)\n  2010/CD\n  ;/:\n  28:49\u201355/CD\n  ./.\n  [/VB\n  83/CD\n  ]/NNP\n  Wedge/NNP\n  SR/NNP\n  ,/,\n  (PERSON Kendrew/NNP J/NNP)\n  ,/,\n  (PERSON Hennequin/NNP LF/NNP)\n  ,/,\n  et/RB\n  al/NN\n  ./.\n  AZD2171/NN\n  :/:\n  a/DT\n  highly/RB\n  potent/JJ\n  ,/,\n  orally/RB\n  bioavailable/JJ\n  ,/,\n  vascular/JJ\n  endothelial/JJ\n  growth/NN\n  factorreceptor-2/JJ\n  tyrosine/NN\n  kinase/NN\n  inhibitor/NN\n  for/IN\n  the/DT\n  treatment/NN\n  of/IN\n  cancer/NN\n  ./.\n  CancerRes/NNP\n  2005/CD\n  ;/:\n  65:4389\u2013400/CD\n  ./.\n  [/VB\n  84/CD\n  ]/NNP\n  Polverino/NNP\n  A/NNP\n  ,/,\n  (PERSON Coxon/NNP A/NNP)\n  ,/,\n  (PERSON Starnes/NNP C/NNP)\n  ,/,\n  et/RB\n  al/NN\n  ./.\n  AMG/NNP\n  706/CD\n  ,/,\n  an/DT\n  oral/JJ\n  ,/,\n  multikinase/JJ\n  inhibitor/NN\n  that/WDT\n  selectively/RB\n  targets/VBZ\n  vascular/JJ\n  endothelial/JJ\n  growth/NN\n  factor/NN\n  ,/,\n  platelet-derived/JJ\n  growth/NN\n  factor/NN\n  ,/,\n  and/CC\n  kit/NN\n  receptors/NNS\n  ,/,\n  potently/RB\n  inhibitsangiogenesis/NN\n  and/CC\n  induces/NNS\n  regression/NN\n  in/IN\n  tumor/NN\n  xenografts/NNS\n  ./.\n  (PERSON Cancer/NNP Res2006/NNP)\n  ;/:\n  66:8715\u201321/CD\n  ./.\n  [/VB\n  85/CD\n  ]/NNP\n  Amgen/NNP\n  ./.\n  Independent/NNP\n  Data/NNP\n  Monitoring/NNP\n  Committee/NNP\n  Recommends/NNP\n  Resuming/NNP\n  Enrollment/NNP\n  of/IN\n  Non-squamous/NNP\n  (ORGANIZATION NSCLC/NNP Patients/NNPS)\n  in/IN\n  theMotesanib/JJ\n  (ORGANIZATION MONET1/NNP Trial/NNP)\n  ./.\n  http/NN\n  :/:\n  //www.amgen.com/media/media/NN\n  prdetail.jsp/NN\n  ?/.\n  year=2009/NN\n  &/CC\n  releaseID=1255738/NN\n  ./.\n  Accessed/VBN\n  May/NNP\n  12/CD\n  ;/:\n  2010/CD\n  ./.\n  [/VB\n  86/CD\n  ]/NNP\n  Choueiri/NNP\n  TK/NNP\n  ./.\n  (PERSON Axitinib/NNP)\n  ,/,\n  a/DT\n  novel/JJ\n  anti-angiogenic/JJ\n  drug/NN\n  with/IN\n  promis-/JJ\n  ing/NN\n  activity/NN\n  in/IN\n  various/JJ\n  solid/JJ\n  tumors/NNS\n  ./.\n  (PERSON Curr/NNP Opin/NNP Investig/NNP Drugs2008/NNP)\n  ;/:\n  9:658\u201371/CD\n  ./.\n  [/VB\n  87/CD\n  ]/NNP\n  (PERSON Kumar/NNP R/NNP)\n  ,/,\n  (PERSON Knick/NNP VB/NNP)\n  ,/,\n  (PERSON Rudolph/NNP SK/NNP)\n  ,/,\n  et/RB\n  al/NN\n  ./.\n  Pharmacokinetic-/JJ\n  pharmacodynamic/JJ\n  correlation/NN\n  from/IN\n  mouse/NN\n  to/TO\n  human/JJ\n  with/IN\n  pazopanib/NN\n  ,/,\n  a/DT\n  multikinase/NN\n  angiogenesis/NN\n  inhibitor/NN\n  with/IN\n  potent/JJ\n  antitumor/NN\n  and/CC\n  antian-giogenic/JJ\n  activity/NN\n  ./.\n  (PERSON Mol/NNP Cancer/NNP)\n  Ther/NNP\n  2007/CD\n  ;/:\n  6:2012\u201321/CD\n  ./.\n  [/VB\n  88/CD\n  ]/NNP\n  Podar/NNP\n  K/NNP\n  ,/,\n  (PERSON Tonon/NNP G/NNP)\n  ,/,\n  (PERSON Sattler/NNP M/NNP)\n  ,/,\n  et/RB\n  al/NN\n  ./.\n  The/DT\n  small-molecule/JJ\n  (ORGANIZATION VEGF/NNP)\n  receptor/NN\n  inhibitor/NN\n  pazopanib/NN\n  (/(\n  (ORGANIZATION GW786034B/NNP)\n  )/)\n  targets/VBZ\n  both/DT\n  tumor/JJ\n  andendothelial/JJ\n  cells/NNS\n  in/IN\n  multiple/JJ\n  myeloma/NN\n  ./.\n  (PERSON Proc/NNP Natl/NNP Acad/NNP Sci/NNP USA2006/NNP)\n  ;/:\n  103:19478\u201383/CD\n  ./.\n  [/VB\n  89/CD\n  ]/NNP\n  Altorki/NNP\n  N/NNP\n  ,/,\n  (PERSON Lane/NNP ME/NNP)\n  ,/,\n  (PERSON Bauer/NNP T/NNP)\n  ,/,\n  et/RB\n  al/NN\n  ./.\n  (PERSON Phase/NNP II/NNP)\n  proof-of-concept/NN\n  study/NN\n  of/IN\n  pazopanib/NN\n  monotherapy/NN\n  in/IN\n  treatment-naive/JJ\n  patients/NNS\n  with/IN\n  stageI/II/JJ\n  resectable/JJ\n  non-small-cell/JJ\n  lung/NN\n  cancer/NN\n  ./.\n  J/NNP\n  (PERSON Clin/NNP Oncol/NNP)\n  2010/CD\n  ;/:\n  28:3131\u20137/CD\n  ./.\n  [/VB\n  90/CD\n  ]/NNP\n  Wedge/NNP\n  SR/NNP\n  ,/,\n  (PERSON Ogilvie/NNP DJ/NNP)\n  ,/,\n  (PERSON Dukes/NNP M/NNP)\n  ,/,\n  et/RB\n  al/NN\n  ./.\n  (ORGANIZATION ZD6474/NNP)\n  inhibits/VBZ\n  vascular/JJ\n  endothelial/JJ\n  growth/NN\n  factor/NN\n  signaling/VBG\n  ,/,\n  angiogenesis/NN\n  ,/,\n  and/CC\n  tumor/NN\n  growthfollowing/VBG\n  oral/JJ\n  administration/NN\n  ./.\n  (PERSON Cancer/NNP Res/NNP)\n  2002/CD\n  ;/:\n  62:4645\u201355/CD\n  ./.\n  [/VB\n  91/CD\n  ]/NNP\n  (PERSON Natale/NNP RB/NNP)\n  ,/,\n  (PERSON Thongprasert/NNP S/NNP)\n  ,/,\n  (PERSON Greco/NNP FA/NNP)\n  ,/,\n  et/RB\n  al/NN\n  ./.\n  (PERSON Phase/NNP III/NNP Trial/NNP)\n  of/IN\n  van-/JJ\n  detanib/NNS\n  compared/VBN\n  with/IN\n  erlotinib/NN\n  in/IN\n  patients/NNS\n  with/IN\n  previously/RB\n  treatedadvanced/VBN\n  non-small-cell/JJ\n  lung/NN\n  cancer/NN\n  ./.\n  J/NNP\n  (PERSON Clin/NNP Oncol/NNP)\n  2011/CD\n  [/NNP\n  Epub/NNP\n  ,/,\n  January/NNP\n  31/CD\n  ]/NNP\n  ./.\n  [/CC\n  92/CD\n  ]/NN\n  (PERSON De/NNP Boer/NNP RH/NNP)\n  ,/,\n  (PERSON Arrieta/NNP O/NNP)\n  ,/,\n  (PERSON Yang/NNP CH/NNP)\n  ,/,\n  et/RB\n  al/NN\n  ./.\n  (PERSON Vandetanib/NNP)\n  plus/CC\n  pemetrexed/VBN\n  for/IN\n  the/DT\n  second-line/JJ\n  treatment/NN\n  of/IN\n  advanced/JJ\n  non-small-cell/JJ\n  lung/NN\n  cancer/NN\n  :/:\n  a/DT\n  randomized/JJ\n  ,/,\n  double-blind/JJ\n  phase/NN\n  (ORGANIZATION III/NNP)\n  trial/NN\n  ./.\n  J/NNP\n  (PERSON Clin/NNP Oncol/NNP)\n  2011/CD\n  [/NNP\n  Epub/NNP\n  ,/,\n  January/NNP\n  31/CD\n  ]/NNP\n  ./.\n  [/CC\n  93/CD\n  ]/JJ\n  (PERSON Herbst/NNP RS/NNP)\n  ,/,\n  (ORGANIZATION Sun/NNP Y/NNP)\n  ,/,\n  (PERSON Eberhardt/NNP WE/NNP)\n  ,/,\n  et/VBD\n  al/NN\n  ./.\n  (PERSON Vandetanib/NNP)\n  plus/CC\n  docetaxel/JJ\n  versus/NN\n  docetaxel/NN\n  as/IN\n  second-line/JJ\n  treatment/NN\n  for/IN\n  patients/NNS\n  with/IN\n  advancednon-small-cell/JJ\n  lung/NN\n  cancer/NN\n  (/(\n  (ORGANIZATION ZODIAC/NNP)\n  )/)\n  :/:\n  a/DT\n  double-blind/NN\n  ,/,\n  randomised/VBN\n  ,/,\n  phase/VB\n  3/CD\n  trial/NN\n  ./.\n  (PERSON Lancet/NNP Oncol/NNP)\n  2010/CD\n  ;/:\n  11:619\u201326/CD\n  ./.\n  [/VB\n  94/CD\n  ]/NNP\n  (PERSON Lee/NNP J/NNP)\n  ,/,\n  (PERSON Hirsh/NNP V/NNP)\n  ,/,\n  (PERSON Park/NNP K/NNP)\n  ,/,\n  et/VBZ\n  al/NN\n  ./.\n  (PERSON Vandetanib/NNP)\n  versus/NN\n  placebo/NN\n  in/IN\n  patients/NNS\n  with/IN\n  advanced/JJ\n  non-small/JJ\n  cell/NN\n  lung/NN\n  cancer/NN\n  (/(\n  (ORGANIZATION NSCLC/NNP)\n  )/)\n  after/IN\n  prior/JJ\n  therapy/NN\n  withan/NN\n  (ORGANIZATION EGFR/NNP)\n  tyrosine/NN\n  kinase/NN\n  inhibitor/NN\n  (/(\n  (ORGANIZATION TKI/NNP)\n  )/)\n  :/:\n  a/DT\n  randomized/JJ\n  ,/,\n  double-blindphase/JJ\n  (ORGANIZATION III/NNP)\n  trial/NN\n  (/(\n  (ORGANIZATION ZEPHYR/NNP)\n  )/)\n  ./.\n  J/NNP\n  (PERSON Clin/NNP Oncol/NNP)\n  2010/CD\n  ;/:\n  28/CD\n  [/CD\n  abstract/JJ\n  7525/CD\n  ]/NN\n  ./.\n  [/CC\n  95/CD\n  ]/NN\n  (PERSON Dowlati/NNP A/NNP)\n  ,/,\n  (PERSON Gray/NNP R/NNP)\n  ,/,\n  (PERSON Sandler/NNP AB/NNP)\n  ,/,\n  (PERSON Schiller/NNP JH/NNP)\n  ,/,\n  (PERSON Johnson/NNP DH/NNP)\n  ./.\n  (PERSON Cell/NNP)\n  adhesion/NN\n  molecules/NNS\n  ,/,\n  vascular/JJ\n  endothelial/JJ\n  growth/NN\n  factor/NN\n  ,/,\n  and/CC\n  basic\ufb01broblast/JJS\n  growth/NN\n  factor/NN\n  in/IN\n  patients/NNS\n  with/IN\n  non-small/JJ\n  cell/NN\n  lung/NN\n  can-cer/NN\n  treated/VBN\n  with/IN\n  chemotherapy/NN\n  with/IN\n  or/CC\n  without/IN\n  bevacizumab\u2014anEastern/JJ\n  Cooperative/NNP\n  Oncology/NNP\n  Group/NNP\n  Study/NNP\n  ./.\n  (PERSON Clin/NNP Cancer/NNP Res2008/NNP)\n  ;/:\n  14:1407\u201312/CD\n  ./.\n  [/VB\n  96/CD\n  ]/NNP\n  Hanrahan/NNP\n  EO/NNP\n  ,/,\n  (PERSON Ryan/NNP AJ/NNP)\n  ,/,\n  (PERSON Mann/NNP H/NNP)\n  ,/,\n  et/RB\n  al/NN\n  ./.\n  (PERSON Baseline/NNP)\n  vascular/JJ\n  endothelial/JJ\n  growth/NN\n  factor/NN\n  concentration/NN\n  as/IN\n  a/DT\n  potential/JJ\n  predictive/JJ\n  marker/NN\n  of/IN\n  ben-e\ufb01t/NN\n  from/IN\n  vandetanib/NN\n  in/IN\n  non-small/JJ\n  cell/NN\n  lung/NN\n  cancer/NN\n  ./.\n  (PERSON Clin/NNP Cancer/NNP Res2009/NNP)\n  ;/:\n  15:3600\u20139.212/CD\n  A./NN\n  (PERSON Wozniak/NNP)\n  //NNP\n  Critical/NNP\n  Reviews/NNP\n  in/IN\n  Oncology/Hematology/NNP\n  82/CD\n  (/(\n  2012/CD\n  )/)\n  200\u2013212/CD\n  [/$\n  97/CD\n  ]/NNP\n  Hanrahan/NNP\n  EO/NNP\n  ,/,\n  (PERSON Lin/NNP HY/NNP)\n  ,/,\n  (PERSON Kim/NNP ES/NNP)\n  ,/,\n  et/RB\n  al/NN\n  ./.\n  Distinct/NNP\n  patterns/NNS\n  of/IN\n  cytokine/NN\n  and/CC\n  angiogenic/JJ\n  factor/NN\n  modulation/NN\n  and/CC\n  markers/NNS\n  of/IN\n  bene\ufb01t/NN\n  for/IN\n  vandetaniband/or/NN\n  chemotherapy/NN\n  in/IN\n  patients/NNS\n  with/IN\n  non-small-cell/JJ\n  lung/NN\n  cancer/NN\n  ./.\n  (ORGANIZATION JClin/NNP)\n  Oncol/NNP\n  2010/CD\n  ;/:\n  28:193\u2013201/CD\n  ./.\n  [/VB\n  98/CD\n  ]/NNP\n  Faivre/NNP\n  S/NNP\n  ,/,\n  (PERSON Delbaldo/NNP C/NNP)\n  ,/,\n  (PERSON Vera/NNP K/NNP)\n  ,/,\n  et/VBZ\n  al/NN\n  ./.\n  (PERSON Safety/NNP)\n  ,/,\n  pharmacokinetic/JJ\n  ,/,\n  and/CC\n  antitumor/JJ\n  activity/NN\n  of/IN\n  (ORGANIZATION SU11248/NNP)\n  ,/,\n  a/DT\n  novel/JJ\n  oral/JJ\n  multitarget/NN\n  tyrosine/NN\n  kinaseinhibitor/NN\n  ,/,\n  in/IN\n  patients/NNS\n  with/IN\n  cancer/NN\n  ./.\n  J/NNP\n  (PERSON Clin/NNP Oncol/NNP)\n  2006/CD\n  ;/:\n  24:25\u201335/CD\n  ./.\n  [/VB\n  99/CD\n  ]/NNP\n  Motzer/NNP\n  RJ/NNP\n  ,/,\n  (PERSON Michaelson/NNP MD/NNP)\n  ,/,\n  (PERSON Redman/NNP BG/NNP)\n  ,/,\n  et/RB\n  al/JJ\n  ./.\n  Activity/NN\n  of/IN\n  (ORGANIZATION SU11248/NNP)\n  ,/,\n  a/DT\n  multitargeted/JJ\n  inhibitor/NN\n  of/IN\n  vascular/JJ\n  endothelial/JJ\n  growth/NN\n  factor/NN\n  receptorand/VBP\n  platelet-derived/JJ\n  growth/NN\n  factor/NN\n  receptor/NN\n  ,/,\n  in/IN\n  patients/NNS\n  with/IN\n  metastaticrenal/JJ\n  cell/NN\n  carcinoma/NN\n  ./.\n  J/NNP\n  (PERSON Clin/NNP Oncol/NNP)\n  2006/CD\n  ;/:\n  24:16\u201324/CD\n  ./.\n  [/VB\n  100/CD\n  ]/NNP\n  Ebos/NNP\n  JM/NNP\n  ,/,\n  (PERSON Lee/NNP CR/NNP)\n  ,/,\n  (PERSON Christensen/NNP JG/NNP)\n  ,/,\n  (ORGANIZATION Mutsaers/NNP)\n  AJ/NNP\n  ,/,\n  (PERSON Kerbel/NNP RS/NNP)\n  ./.\n  Multi-/NNP\n  ple/JJ\n  circulating/VBG\n  proangiogenic/JJ\n  factors/NNS\n  induced/VBN\n  by/IN\n  sunitinib/JJ\n  malate/JJ\n  aretumor-independent/NN\n  and/CC\n  correlate/NN\n  with/IN\n  antitumor/NN\n  ef\ufb01cacy/NN\n  ./.\n  (PERSON Proc/NNP NatlAcad/NNP Sci/NNP)\n  USA/NNP\n  2007/CD\n  ;/:\n  104:17069\u201374/CD\n  ./.\n  [/VB\n  101/CD\n  ]/NNP\n  (PERSON Kim/NNP ES/NNP)\n  ,/,\n  (PERSON Herbst/NNP RS/NNP)\n  ,/,\n  (PERSON Lee/NNP JJ/NNP)\n  ,/,\n  et/RB\n  al/NN\n  ./.\n  The/DT\n  (ORGANIZATION BATTLE/NNP)\n  trial/NN\n  (/(\n  biomarker-/JJ\n  integrated/VBN\n  approaches/NNS\n  of/IN\n  targeted/JJ\n  therapy/NN\n  for/IN\n  lung/NN\n  cancer/NN\n  elimination/NN\n  )/)\n  :/:\n  personalizing/NN\n  therapy/NN\n  for/IN\n  lung/NN\n  cancer/NN\n  ./.\n  In/IN\n  :/:\n  Presented/VBN\n  at/IN\n  :/:\n  the/DT\n  101stannual/CD\n  meeting/NN\n  of/IN\n  the/DT\n  (ORGANIZATION American/NNP Association/NNP)\n  for/IN\n  cancer/NN\n  research.2010/NN\n  ./.\n  [/CC\n  102/CD\n  ]/JJ\n  (PERSON Herbst/NNP RS/NNP)\n  ,/,\n  (PERSON Blumenschein/NNP Jr/NNP GR/NNP)\n  ,/,\n  (PERSON Kim/NNP ES/NNP)\n  ,/,\n  et/RB\n  al/NN\n  ./.\n  (PERSON Sorafenib/NNP)\n  treat-/JJ\n  ment/NN\n  ef\ufb01cacy/NN\n  and/CC\n  (ORGANIZATION KRAS/NNP)\n  biomarker/NN\n  status/NN\n  in/IN\n  the/DT\n  Biomarker-IntegratedApproaches/NNP\n  of/IN\n  (ORGANIZATION Targeted/NNP)\n  Therapy/NNP\n  for/IN\n  (PERSON Lung/NNP Cancer/NNP Elimination/NNP)\n  (/(\n  BAT-TLE/NNP\n  )/)\n  trial/NN\n  ./.\n  J/NNP\n  (PERSON Clin/NNP Oncol/NNP)\n  (/(\n  Meeting/NNP\n  Abstracts/NNP\n  )/)\n  2010/CD\n  ;/:\n  28:7609/CD\n  ./.\n  [/VB\n  103/CD\n  ]/NNP\n  Dahlberg/NNP\n  SE/NNP\n  ,/,\n  (PERSON Sandler/NNP AB/NNP)\n  ,/,\n  (PERSON Brahmer/NNP JR/NNP)\n  ,/,\n  (PERSON Schiller/NNP JH/NNP)\n  ,/,\n  (PERSON Johnson/NNP DH/NNP)\n  ./.\n  (PERSON Clinical/JJ)\n  course/NN\n  of/IN\n  advanced/JJ\n  non-small-cell/JJ\n  lung/NN\n  cancer/NN\n  patientsexperiencing/VBG\n  hypertension/NN\n  during/IN\n  treatment/NN\n  with/IN\n  bevacizumab/JJ\n  incombination/NN\n  with/IN\n  carboplatin/NN\n  and/CC\n  paclitaxel/NN\n  on/IN\n  ECOG/NNP\n  4599/CD\n  ./.\n  J/NNP\n  ClinOncol/NNP\n  2010/CD\n  ;/:\n  28:949\u201354/CD\n  ./.\n  [/VB\n  104/CD\n  ]/NNP\n  (PERSON Hurwitz/NNP H/NNP)\n  ,/,\n  (PERSON Douglas/NNP PS/NNP)\n  ,/,\n  (PERSON Middleton/NNP JP/NNP)\n  ,/,\n  et/RB\n  al/NN\n  ./.\n  Analysis/NN\n  of/IN\n  early/JJ\n  hyper-/JJ\n  tension/NN\n  (/(\n  (ORGANIZATION HTN/NNP)\n  )/)\n  and/CC\n  clinical/JJ\n  outcome/NN\n  with/IN\n  bevacizumab/NN\n  (/(\n  BV/NNP\n  )/)\n  ./.\n  J/NNP\n  ClinOncol/NNP\n  2010/CD\n  ;/:\n  28/CD\n  [/CD\n  abstract/JJ\n  3039/CD\n  ]/NN\n  ./.\n  (PERSON Biography/NNP Antoinette/NNP Wozniak/NNP)\n  is/VBZ\n  a/DT\n  Professor/NNP\n  of/IN\n  (GPE Oncology/NNP)\n  and/CC\n  (PERSON Medicine/NNP)\n  at/IN\n  the/DT\n  (ORGANIZATION Karmanos/NNP Cancer/NNP Institute/NNP)\n  ,/,\n  a/DT\n  (ORGANIZATION National/NNP)\n  Can-cer/NNP\n  Institute/NNP\n  (/(\n  (ORGANIZATION NCI/NNP)\n  )/)\n  designated/VBD\n  comprehensive/JJ\n  cancer/NN\n  centerin/NN\n  (PERSON Detroit/NNP)\n  ,/,\n  (PERSON Michigan/NNP)\n  ./.\n  She/PRP\n  obtained/VBD\n  her/PRP\n  medical/JJ\n  degree/NN\n  fromthe/NN\n  (ORGANIZATION State/NNP University/NNP)\n  of/IN\n  (GPE New/NNP York/NNP)\n  at/IN\n  (ORGANIZATION Buffalo/NNP)\n  and/CC\n  completedher/PRP$\n  residency/NN\n  in/IN\n  (ORGANIZATION Internal/NNP Medicine/NNP)\n  at/IN\n  the/DT\n  (ORGANIZATION SUNY/NNP)\n  Af\ufb01liatedHospitals/NNPS\n  ./.\n  She/PRP\n  completed/VBD\n  a/DT\n  fellowship/NN\n  in/IN\n  (GPE Hematology/NNP)\n  andOncology/NN\n  at/IN\n  the/DT\n  (ORGANIZATION University/NNP)\n  of/IN\n  (GPE Florida/NNP)\n  and/CC\n  is/VBZ\n  boarded/VBN\n  in/IN\n  bothsubspecialities/NNS\n  ./.\n  For/IN\n  many/JJ\n  years/NNS\n  she/PRP\n  headed/VBD\n  the/DT\n  Multidisci-plinary/NNP\n  Thoracic/NNP\n  Team/NNP\n  at/IN\n  the/DT\n  (ORGANIZATION Cancer/NNP Center/NNP)\n  ./.\n  Dr./NNP\n  (PERSON Wozniak/NNP)\n  \u2019/NNP\n  sclinical/JJ\n  research/NN\n  focus/NN\n  has/VBZ\n  been/VBN\n  in/IN\n  the/DT\n  area/NN\n  of/IN\n  thoracic/JJ\n  malig-nancies/NNS\n  and/CC\n  investigational/JJ\n  drugs/NNS\n  ./.\n  She/PRP\n  has/VBZ\n  been/VBN\n  involved/VBN\n  inmultiple/JJ\n  clinical/JJ\n  trials/NNS\n  from/IN\n  the/DT\n  (LOCATION Southwest/NNP Oncology/NNP Group/NNP)\n  ,/,\n  (ORGANIZATION NCI/NNP)\n  sponsored/VBD\n  studies/NNS\n  ,/,\n  and/CC\n  pharmaceutical/JJ\n  trials/NNS\n  ./.\n  She/PRP\n  hasmultiple/JJ\n  publications/NNS\n  and/CC\n  continues/VBZ\n  to/TO\n  be/VB\n  active/JJ\n  in/IN\n  clinicalresearch/NN\n  ./.)"
}